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1 Introduction 
1.1 Biological lipids 
As one of the four main classes of biological molecules, lipids besides carbohydrates, 
proteins and nucleic acids are of crucial importance for cellular integrity and survival. 
Among a plethora of biological functions, they are essential constituents of cellular 
membranes, serve energy storage and are involved in multiple signaling pathways 
regulating cellular functions. Lipids can be defined as hydrophobic or amphiphatic 
molecules originating from carbanion-based condensations of thioesters and/or 
carbocation-based condensation of isoprene units (Fahy et al., 2009). Based on this 
definition lipids can be subdivided into eight categories i.e. fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids and 
polyketides (Fahy et al., 2005, 2009). 
 
The most fundamental lipid category is represented by fatty acyls. The category 
includes several subclasses e.g. eicosanoids, which comprise a huge number of lipid 
hormones (Marion-Letellier et al., 2015) or fatty acids. Fatty acids, besides being a 
major source of energy, which can be released in a degradation process termed 
ß-oxidation, are important building blocks for a large number of biological lipids. Fatty 
acids are synthesized through successive attachment of malonyl-CoA to an acetyl-
CoA primer (propionyl-CoA for odd-numbered fatty acids) and differ in chain length 
and degree of saturation. 
 
Glycerolipids are based on the trihydric sugar alcohol glycerol. Step-wise 
esterification of the hydroxy groups at C1 and C2 (per definition depicted as sn1 and 
sn2) with fatty acyl-CoAs produces monoacylglycerol and diacylglycerol (DAG), a 
universal intermediate of glycerolipid synthesis. Further esterification with a fatty acyl-
CoA at C3 (sn3) produces triacylglycerol (TAG). While TAGs primarily serve storage 
of metabolic energy, DAGs can also act as membrane bound second messengers. 
 
Glycerophospholipids are directly derived from glycerolipids, with DAG being the 
backbone of most glycerophospholipids. The most common representatives, 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) 
and phosphatidylinositol (PI) are presented in Figure 1.1 A. The synthesis of PC is 
mainly accomplished through the Kennedy pathway in which CDP-choline originating 
from sequential conversion of choline in the cytoplasm, reacts with DAG in the 
endoplasmic reticulum (ER)(Gibellini & Smith, 2010). The synthesis of PE is 
analogous to this. While PC and PE can be converted to PS in a base-exchange 
reaction in the ER, PE can also be produced by decarboxylation of PS in 
mitochondria (Vance & Tasseva, 2013). In an alternative pathway of 
glycerophospholipid synthesis, phosphatidic acid, a phosphorylated derivative of 
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DAG, is activated with CTP. The resulting CDP-diacylglycerol can be converted to PI. 
PI is the basic structure of a specific class of membrane-bound second messengers, 
summed up as phosphoinositides. They regulate a wide array of biological processes 
including lipid distribution and metabolism, or vesicular trafficking (Balla, 2013). PC, 
PE, PS and PI represent the vast majority of phospholipids in eukaryotic cell 
membranes. 
 
Another category of lipids are the sphingolipids. The backbone of all higher order 
sphingolipids is ceramide, the central intermediate of the sphingolipid metabolic 
pathway. Sphingolipids and especially ceramides are of central importance in the 
course of this thesis and a more detailed introduction is given in chapter 1.3. The 
most abundant sphingolipid is sphingomyelin (SM). SM structurally resembles 
glycerophospholipids, sharing a similar backbone of two hydrophobic acyl tails and a 
phosphate containing hydrophilic head group (Figure 1.1 B). Together these lipids 
can be referred to as phospholipids. Phospholipids, together with glycosphingolipids 
and cholesterol, represent the main constituents of eucaryotic membranes. While 
only PC and PE account for more than 50 % of all phospholipids in eucaryotic cell 
membranes, sphingolipids account for 10-20 % (Holthuis et al., 2001).  
 
A very prominent lipid is the sterol cholesterol (Figure 1.1 C). Together with higher 
sterols e.g. ergosterol, it represents 20-40 mol % of lipids in eukaryotic membranes 
and is an essential regulator of membrane fluidity (Mouritsen & Zuckermann, 2004). 
Due to its biophysical properties it increases lipid order and establishes low 
permeability barriers by specifically interacting with certain phospholipids in cellular 
lipid-bilayers (Ohvo-Rekilä et al., 2002; Mouritsen & Zuckermann, 2004). 
Introduction 
3 
 
 
Figure 1.1 - Representative structures for the most common glycerophospholipids, 
sphingolipids and sterols. (A) Structural formula of the glycerophospholipid 
phosphatidylcholine with myristic acid at sn1 and palmitoleic acid at sn2 (C14:0/C16:1 cis-9). 
Substitution of the choline head group (in brackets) with the below depicted head groups 
leads to representative structural formulas of phosphatidylethanolamine, phosphatidylserine 
and phosphatidylinositol. Substitution of the phosphocholine group at sn3 with a hydroxy 
group leads to the structural formula of diacylglycerol, the precursor of the most abundant 
glycerophospholipids. The glycerol backbone is depicted in red. The acyl chains at sn1 and 
sn2 can differ in chain length and degree of saturation. (B) Structural formula of the 
sphingolipid sphingomyelin with N-acylated palmitic acid (d18:1/C16:0). The sphingoid 
backbone (sphingosine) is depicted in red. Substitution of the phosphocholine group at C3 
with a hydroxy group leads to the structural formula of ceramide, the precursor of all higher 
order sphingolipids. The N-acyl chain can differ in chain length and degree of saturation. (C) 
Structural formula of the steroid cholesterol. Red boxes highlight hydrophobic backbones, 
blue boxes highlight hydrophilic head groups. Fatty acyl chains are depicted in green, 
hydrophilic head groups in blue. Molecule structures were created and modified according to 
the LIPID MAPS Lipidomics Gateway (http://www.lipidmaps.org/) using ChemDraw Prime 15 
software (Perkin Elmer). 
 
1.2 Eucaryotic membranes 
Eukaryotic membranes are characterized by a number of functions that are vital for 
cellular survival and integrity. Besides the surrounding cell membrane, which 
provides mechanical stability and represents a protective barrier between the interior 
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and the outside of the cell, each cell contains specialized membranes that surround 
organelles to establish separated reaction spaces. For instance, mitochondrial 
membranes that provide the basis for oxidative phosphorylation or membranes of the 
ER that facilitate lipid synthesis. Despite different function, all of these membranes 
share a similar structure consisting of a selectively-permeable lipid bilayer with 
associated proteins (Figure 1.2). The basic architecture of cellular lipid bilayers is 
established by amphipathic phospholipids (Figure 1.1 A, B). In an aqueous 
environment these lipids tend to organize in a thermodynamically favorable 
arrangement. While the non-polar acyl chains establish a hydrophobic core, the 
phosphate containing hydrophilic head groups build up the inner and outer surface of 
the bilayer. The protein portion comprises a large subset of structurally and 
functionally diverse proteins that for instance mediate cell to cell communication and 
transport of metabolites, or confer mechanical stability by connecting the cell 
membrane to the cytoskeleton. 
 
 
Figure 1.2 - Schematic drawing of the eukaryotic cell membrane. The picture illustrates 
the typical organization with the semi-permeable phospholipid bilayer and inserted 
cholesterol as an essential regulator of membrane fluidity. Carbohydrate moieties of 
glycolipids and glycosylated proteins are exclusively directed to the extracellular space. 
Proteins are subdivided in peripheral proteins on the surface of the bilayer and integral 
proteins inserted into the bilayer. (Modified and adopted from https://upload.wikimedia.org/ 
wikipedia/en/9/9c/Cell_membrane_detailed_diagram_edit2.svg) 
 
According to the fluid mosaic model, lipid bilayers represent a fluid continuum, 
allowing lateral diffusion and free rotation of lipids and proteins around an axis 
perpendicular to the membrane (Singer & Nicolson, 1972). In contrast, transbilayer 
movement (also known as flip-flop) is thermodynamically unfavorable and rather rare. 
This leads to asymmetric distribution of phospholipids in cellular lipid bilayers by 
specialized transbilayer transporters, which is of fundamental importance for cellular 
function and integrity (Daleke, 2007). The outer monolayer of the cell membrane 
mainly consists of PC, SM and glycosylated sphingolipids, whereas PE, PI and PS 
mainly occur in the inner monolayer. PS is almost exclusively found in the inner 
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monolayer, its exposure in the outer monolayer due to increased transbilayer 
movement during early stages of apoptosis represents a signal for phagocytosis 
(Vance & Tasseva, 2013). 
 
According to function and needs of different cell types, the lipid (and protein) 
composition of cell and organelle membranes can strongly differ from each other, 
especially with respect to incorporated fatty acids. Nevertheless, the vast majority of 
the glycerophospholipids in eukaryotic lipid bilayers are composed of a saturated 
fatty acid at position sn1 and an unsaturated fatty acid at sn2 (Zarringhalam et al., 
2012). The cis-configured double bonds of unsaturated fatty acyl chains prevent tight 
packing of individual lipid molecules, which is mainly responsible for the fluidity of 
eukaryotic membranes. In contrast, the structure of sphingolipids allows tighter 
packing. As a consequence they preferentially assemble with each other and with 
cholesterol, and establish highly ordered membrane domains (Pike, 2009). Several 
studies indicated that such lipid microdomains, originally termed lipid rafts, 
compartmentalize cellular processes by facilitating local clustering of proteins 
involved in the execution and control of cellular signaling (Pike, 2009; van Meer & 
Hoetzl, 2010). The existence of lipid microdomains in vivo is subject of a 
controversial debate, for instance, because detection in living cells is restricted by the 
resolution limit of optical microscopy (Fan et al., 2010). Stimulated emission depletion 
(STED) far-field fluorescence nanoscopy allows to detect single diffusing (lipid) 
molecules in nanosized membrane areas (Eggeling et al., 2009). Using this 
technique it was demonstrated that cholesterol-mediated molecular complexes 
(<20 nm in diameter) of sphingolipids and glycosylphosphatidylinositol (GPI)-
anchored proteins transiently exist (~10–20 ms) in plasma membranes of living 
mammalian cells (Eggeling et al., 2009). According to the general consensus lipid 
microdomains are rather small (10-200 nm), heterogeneous, highly dynamic and can 
be stabilized to larger platforms (Pike, 2009). Several of the studies focusing on lipid 
microdomain function in the control of cellular signaling made use of detergent-
resistant membranes (DRMs), but it is questionable whether these actually resemble 
lipid microdomains that exist in vivo or are artifacts resulting from the isolation 
procedure (Brown & London, 1997; Rodgers et al., 2005). 
 
1.3 Sphingolipids 
Emerging evidence in the last decades highlighted the importance of sphingolipids in 
several cellular processes. As major constituents of eukaryotic membranes they 
provide mechanical stability and mediate molecular sorting, cell recognition or signal 
transduction (Holthuis et al., 2001; Lopez & Schnaar, 2009; Breslow & Weissman, 
2010). In their function as signaling molecules they cover a wide array of cellular 
processes including cell growth, death, senescence, adhesion, migration, 
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inflammation, angiogenesis or intracellular trafficking (Hannun & Obeid, 2008; 
Lingwood & Simons, 2010). 
 
1.3.1 Sphingolipid metabolic pathway 
The central intermediate of the sphingolipid metabolic pathway (Figure 1.3) is 
ceramide (Figure 1.3 E). Ceramides were shown to be potent mediators of cellular 
stress responses, cell cycle arrest and apoptosis (Merrill, 2002; Hannun & Obeid, 
2008; Morad & Cabot, 2013) and are the precursors for all higher order sphingolipids. 
Ceramide originates either from a „de novo pathway‟ or from a recycling pathway, 
referred to as „salvage pathway‟. The backbones of ceramides are sphingoid long 
chain bases (LCBs). The basic LCB of the de novo synthesis is sphinganine (Figure 
1.3 C). The most common LCB, sphingosine (Figure 1.3 F), is a sphinganine analog 
containing a 4, 5-trans double bond. The less common sphingadiene contains an 
additional double bond of varying position (Zhang et al., 2015). Another less common 
LCB in mammals is phytosphingosine, which harbors an additional hydroxy group at 
C4. It is the predominant LCB in plants and yeast (Mizutani et al., 2004). 
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Figure 1.3 - Schematic drawing of the sphingolipid metabolic pathway. The central 
intermediate of the sphingolipid biosynthetic pathway is ceramide. It can either be produced 
through de novo synthesis starting with the condensation of palmitoyl-CoA and L-serine or 
through recycling of sphingolipids in the salvage pathway. The only exit point from the 
sphingolipid metabolic pathway is the degradation of sphingosine-1-phosphate to 
hexadecenal and phosphoethanolamine. The upper part depicts common intermediates and 
corresponding enzyme families of the sphingolipid metabolism (dashed lines refer to 
synthesis pathways involving multiple enzymes). The lower part depicts representative 
structures occurring during the de novo synthesis (A-D), the salvage pathway (E-J), or the 
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degradation pathway (K). Red structures depict sphingoid backbones including precursor (A) 
and degradation products (K), green structures depict N-acyl chains with n referring to any 
fatty acid (usually ranging from C14 to C36) and blue structures depict hydrophilic head 
groups. Abbreviations: Cer, ceramide; C1P, ceramide-1-phosphate; Sph, sphingosine; S1P, 
sphingosine-1-phosphate; SMase, sphingomyelinase; SMS, sphingomyelin synthase; SMSr, 
sphingomyelin synthase related protein. Molecule structures were created and modified 
according to the LIPID MAPS Lipidomics Gateway (http://www.lipidmaps.org/) using 
ChemDraw Prime 15 software (Perkin Elmer). 
 
1.3.1.1 De novo sphingolipid biosynthesis 
The de novo synthesis of ceramide (Figure 1.3, upper left part) exclusively takes 
place in the cytoplasmic leaflet of the ER (Tidhar & Futerman, 2013). The first and 
rate limiting step is the condensation of palmitoyl-CoA and L-serine (Figure 1.3 A) 
catalyzed by the enzyme serine palmitoyltransferase (SPT), resulting in the formation 
of 3-ketosphinganine (3-ketodihydrosphingosine; Figure 1.3 B) (Hanada, 2003). 
Alternatively, SPT can metabolize non-canonical substrates including acyl-CoAs 
ranging from C12 to C18, as well as L-alanine or glycine (Wei et al., 2014). 
Moreover, alternative use of L-alanine or glycine leads to the generation of 
neurotoxic 1-deoxyspingolipids, which can neither be metabolized to higher order 
sphingolipids nor being degraded by the canonical catabolic pathway (Wei et al., 
2014). In the second step of the de novo ceramide synthesis 3-ketosphinganine is 
reduced to sphinganine (Figure 1.3 C) catalyzed by 3-ketosphinganine reductase 
(Kihara & Igarashi, 2004). By the action of (dihydro)-ceramide synthases (CerS), the 
primary amino group of sphinganine can be N-acylated with different fatty acids 
leading to the formation of dihydroceramide (Figure 1.3 D)(Levy & Futerman, 2010). 
Mammals express six different CerS isoforms (CerS1-6; see chapter 1.3.2), which 
are characterized by different specificities towards fatty acyl-CoAs of varying chain 
length (ranging from C14 to C36). The fatty acyl chains can also differ in the degree 
of saturation (usually saturated and less often monounsaturated) or hydroxylation. In 
the last step, dihydroceramide is converted to ceramide (Figure 1.3 E) by the action 
of dihydroceramide reductase (Fabrias et al., 2012). The insertion of the 4, 5-trans-
double bond is also the initial step in the production of sphingosine, which can be 
liberated by deacylation of ceramide as part of the salvage pathway. 
 
1.3.1.2 The ceramide transfer protein 
Synthesis of higher order sphingolipids mainly occurs at the Golgi. Therefore, newly 
synthesized ceramide is constantly removed from the cytosolic leaflet of the ER and 
transported to the Golgi. While part of the ceramide is moved by vesicular transport  
to the cis-medial-Golgi for glycosphingolipid synthesis (van Meer & Holthuis, 2000), 
most of the ceramide is specifically transported to the site of SM synthesis at the 
trans-Golgi by the cytosolic ceramide transfer protein (CERT)(Hanada et al., 2003). 
CERT contains a FFAT (two phenylalanines in an acidic tract) domain, which can 
interact with ER resident VAP (vesicle-associated membrane protein (VAMP)-
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associated protein) proteins (Loewen et al., 2003) and an N-terminal PH (pleckstrin 
homology) domain, which allows the binding of phosphatidylinositol-4-phosphate 
(PI4P) at trans-Golgi acceptor membranes (Levine & Munro, 2002). Ceramide 
binding is facilitated by the C-terminal START (steroidogenic acute regulatory 
protein-related lipid transfer) domain (Hanada et al., 2003). The domain preferentially 
binds ceramide species with acyl chain length ranging from C14 to C20, whereas the 
transfer of C22 and C24 species is less efficient (Kumagai et al., 2005).  
 
1.3.1.3 Biosynthesis of complex sphingolipids 
The biosynthesis of higher order sphingolipids is depicted in Figure 1.3. Synthesis of 
the most abundant sphingolipid in mammalian cells, SM (Figure 1.3 G), is mediated 
by a family of phosphatidylcholine: ceramide choline phosphotransferases or SM 
synthases (SMS; see chapter 1.3.4), which catalyze head group transfer from PC to 
ceramide to produce SM and DAG at the Golgi and the plasma membrane (Villani et 
al., 2008; Ternes et al., 2009). Another member of the SMS family is the 
sphingomyelin synthase related protein (SMSr), which catalyzes synthesis of the SM 
analog ceramide phosphoethanolamine (CPE; Figure 1.3 H) in the luminal leaflet of 
the ER. SMSr is of central importance in the course of this thesis and will be 
discussed in detail in chapter 1.3.4.2. 
 
Cerebrosides are monohexosylceramides in which either glucose or galactose is 
attached to ceramide via a β-glycosidic bond. Glucosylceramide (Figure 1.3 I) is 
synthesized by the enzyme glucosylceramide synthase (GCS) at the cytosolic 
surface of the cis-Golgi. Galactosylceramide (Figure 1.3 J) is produced by ceramide 
galactosyltransferase (CGT) in the luminal leaflet of the ER (Gault et al., 2010). 
Glucosylceramide is the obligatory precursor for the synthesis of complex 
glycosphingolipids (GSLs) and its synthesis is essential for mouse development, as 
GCS deficient mice show embryonic lethality already on embryonic day 6.5 to 7.5. 
The vast majority of newly synthesized glucosylceramide at the cytoplasmic surface 
of cis- and medial-Golgi compartments is constantly extracted and transported to the 
trans-Golgi for GSL synthesis by the cytosolic lipid transfer protein FAPP2 (four 
phosphate adaptor protein)(D‟Angelo et al., 2007).  
 
The precursor for the synthesis of complex GSLs is lactosylceramide, which is 
generated by attachment of a galactose residue to the glucose moiety of 
glucosylceramide catalyzed by β4-galactosyltransferases (Kumagai et al., 2010). 
Complex GSLs are synthesized by a diverse set of glycotransferases that transfer a 
specific carbohydrate to the glycan structure of lactosylceramide (D‟Angelo et al., 
2013). At least 12 different carbohydrate moieties can be used to produce more than 
400 different glycan structures in vertebrates (Sud et al., 2007). The glycan 
structures can contain up to 20 highly-branched sugar residues (D‟Angelo et al., 
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2013). Common residues, besides glucose and galactose, are 
N-acteylgalactosamine (GalNAc) or sialic acids e.g. N-acetylneuraminic acid (NANA). 
Globosides are characterized by GalNAc residues and like cerebrosides are neutral 
GSLs. Gangliosides due to integration of sialic acid moieties are acidic GSLs. GSLs 
together with other sphingolipids and cholesterol contribute to the establishment of 
membrane lipid microdomains (Simons & Sampaio, 2011). 
 
An important intermediate in the sphingolipid metabolic pathway is sphingosine-1-
phosphate (S1P). S1P is a second messenger with essential functions in cellular 
proliferation and growth and acts as a suppressor of ceramide induced apoptosis 
(Cuvillier et al., 1996). The counteracting functions and the interconvertibility of 
ceramide and S1P with the intermediate sphingosine are commonly referred to as 
the „sphingolipid rheostat‟, a concept of fundamental importance in cancer 
development (Cuvillier et al., 1996; Newton et al., 2015). Mammalian cells consist of 
two sphingosine kinases, namely SK1 and SK2, which phosphorylate the hydroxy 
group at C1 of free sphingosine or sphinganine. Both are cytosolic proteins, which 
localize to the nucleus and the plasma membrane (Wattenberg, 2010). SK function 
depends on peripheral membrane association in response to stimulation by various 
agonists e.g. growth factors (Gault et al., 2010). Such stimuli can induce SK1 
translocation to the plasma membrane through a PKC (protein kinase C)-dependent 
mechanism, leading to extracellular release of S1P (Johnson et al., 2002). 
 
Another signaling molecule that can be produced by phosphorylation of ceramide is 
ceramide-1-phosphate (C1P). C1P is produced by the action of ceramide kinase 
(CERK) in the trans-Golgi, where it enhances release of arachidonic acid, an 
important mediator of immune responses (Lamour et al., 2007). 
 
1.3.1.4 Sphingolipid degradation and the salvage pathway 
The sphingolipid salvage pathway (Figure 1.3) represents an independent source for 
the generation of ceramide and is essential to prevent toxic accumulation of 
particular sphingolipid species. Mammalian cells have evolved counteracting 
catabolizing enzymes for all sphingolipid generating enzymes. Usually, most of the 
ceramides used for synthesis of higher order sphingolipids originate from the salvage 
pathway (Kitatani et al., 2008). Degradation of complex sphingolipids mainly occurs 
in lysosomes and is strongly dependent on sphingolipid activator proteins (SAPs) at 
the luminal surface of intralysosomal vesicles (Schulze & Sandhoff, 2014). Several 
lysosomal storage diseases result from genetic defects of SAPs or sphingolipid-
degrading enzymes and are known as sphingolipidoses. 
 
GSLs are degraded by stepwise removal of monosaccharide units from the non-
reducing end. According to the high complexity, a large variety of lysosomal enzymes 
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(glycosidases) are involved in this process. The degradation of GSLs is of special 
interest, as inherited defects of several enzymes are linked to sphingolipidoses 
(Schulze & Sandhoff, 2014). The most common sphingolipidosis is Gaucher disease, 
which originates from a defect in the gene for glucocerebrosidase 1 (GBA1) and is 
characterized by accumulation of glucosylceramide and glucosylsphingosine (Nilsson 
& Svennerholm, 1982). The most severe variant, Gaucher Type II is characterized by 
hepatosplenomegaly, neurological and skeletal disorders and premature death 
(Schulze & Sandhoff, 2014). 
 
The major source for rapid ceramide generation is SM. Hydrolysis of the 
phosphocholine head group of SM is catalyzed by a family of sphingomyelinases 
(SMases). Based on their pH optimum these enzymes are subdivided into acid-, 
alkaline- and neutral SMases. Alkaline SMase has an exclusive function in digesting 
dietary SM in intestine and liver (Gault et al., 2010). In contrast, acid SMase 
(aSMase) and neutral SMase (nSMase) are ubiquitously expressed. aSMase is 
predominantly localized to lysosomes, where it metabolizes SM from endosomal 
membranes (Gault et al., 2010). Alternatively, aSMase can be secreted into the 
extracellular space, where it mediates the hydrolysis of SM in lipoproteins (Schissel 
et al., 1996). Complete absence of functional aSMase causes the sphingolipidosis 
Niemann Pick Disease, which is characterized by neurodegeneration, 
hepatosplenomegaly, impaired lung function and premature death (Brady et al., 
1966). 
 
Another catabolic reaction that leads to the generation of ceramide is the degradation 
of C1P mediated by C1P phosphatases at the plasma membrane (Gault et al., 2010). 
Deacylation of ceramide to sphingosine is mediated by ceramidases, which are 
classified according to their pH optimum. Acid ceramidase (AC) is localized to 
lysosomes and catabolizes ceramide species originating from degradation of plasma 
membrane sphingolipids (Gault et al., 2010). AC dysfunction leads to the 
sphingolipidosis Farber disease, which is characterized by early onset arthritis, 
swollen lymph nodes, psychomotor difficulties and vocal cord pathology (Park & 
Schuchman, 2006). Alkaline ceramidases (ACER1-3) localize to the ER and the 
Golgi (Gault et al., 2010). Neutral ceramidase (NC) is a plasma 
membrane-associated protein that contributes to degradation of dietary ceramides in 
intestinal epithelial cells (Gault et al., 2010).  
 
Degradation of cytosolic S1P is mediated by ER-resident S1P phosphatases (SPPs). 
SPP1 was suggested to regulate the re-introduction of LCBs into ceramide at the ER 
(Le Stunff et al., 2002). An alternative pathway of S1P degradation and at the same 
time the final step in sphingolipid degradation is the conversion to hexadecenal and 
phosphoethanolamine (Figure 1.3 K) catalyzed by S1P lyase in the cytosolic leaflet of 
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the ER (Ikeda et al., 2004). The enzyme is also capable of catabolizing the other 
mammalian LCB-phosphates. 
 
1.3.2 Ceramide synthases 
The first ceramide synthase homologs were found in yeast, where it was shown that 
Lag1 and Lac1 are required for ceramide synthesis (Guillas et al., 2001). Meanwhile, 
it was shown that ceramide synthase homologs exist throughout the whole animal 
kingdom including mammals and the model organisms Caenorhabditis elegans, 
Drosophila melanogaster and Danio rerio (Voelzmann & Bauer, 2010). The first 
mammalian ceramide synthase (CerS1) was identified based on its homology to the 
yeast Lag1 (Venkataraman et al., 2002), further research revealed additional 
paralogs in mammals (Riebeling et al., 2003). Since Lag1 (longevity assurance 
gene 1) was identified in a screen for longevity-related genes (D‟mello et al., 1994), 
the mammalian paralogs were originally termed longevity assurance homolog of 
yeast lag1 (Lass), but according to their biochemical function were renamed 
ceramide synthases (CerS). 
 
The single CerS in Drosophila is called schlank. Schlank mutants show delayed 
growth, remain slim and die during larval stages (Bauer et al., 2009). This is 
accompanied by a reduction of TAG storage in the fat body. It was shown that 
schlank negatively regulates expression of lipases and hence lipolysis, whereas it 
promotes lipogenesis through activation of SREBP (sterol-responsive element 
binding protein), indicating a role of CerS in the regulation of body fat metabolism. 
 
The mammalian CerS family consists of six different members (CerS1-6). All 
members are ER-resident, multi-pass transmembrane proteins, most likely with six 
predicted transmembrane domains and both termini facing the ER lumen (Figure 
1.4)(Tidhar et al., 2012). CerS were also found in mitochondria and mitochondria-
associated membranes (Bionda et al., 2004; Siskind, 2005). 
 
All members of the CerS family share a TLC (TRAM-Lag-CLN8) domain of  
approximately 200 amino acid residues, named according to its similarity to TRAM1 
(translocating chain associating membrane protein) and CLN8 (ceroid-lipofuscinosis 
neuronal 8) proteins (Winter & Ponting, 2002). The main distinctive feature is the 
highly conserved 52 amino acid residues long LAG1p motif, which is essential for 
ceramide synthase activity (Spassieva et al., 2006). Especially important are two 
conserved histidine residues at the cytosolic face of transmembrane domain 4. 
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Figure 1.4 - Schematic drawing of the putative topology of CerS. Mammalian CerS most 
likely consist of six transmembrane domains with both termini facing the ER lumen. The Hox-
like domain, present in CerS2-6, is located in the cytoplasm and followed by the TLC domain, 
which comprises five transmembrane domains. The Lag1p domain is located in 
transmembrane domain 4 with the two conserved active site histidine residues (area in the 
box) facing the cytoplasm. The violet part of the TLC domain refers to the 150 amino acid 
residues that are essential for CerS specificity. (Adopted and modified from Tidhar et al., 
2012) 
 
All CerS, except for CerS1, contain a homeobox (Hox)-like domain in the first 
cytoplasmic loop (Venkataraman & Futerman, 2002). Classical Hox-domains are 
composed of 60 amino acid residues and share a typical helix-turn-helix motif of 
three alpha-helices that is capable of binding specific DNA sequences. Hox-domain 
containing proteins act as transcription factors with essential regulatory functions in 
the development of bilaterian animals (Gehring et al., 1994). The term Hox-like 
domain refers to the fact that the first 15 amino acid residues of classical Hox-
domains, including a key asparagine residue that is involved in DNA binding, are 
missing. Therefore, it is controversly discussed whether Hox-like domains in CerS de 
facto have DNA binding capacity. However, a more recent study reported that the 
Drosophila CerS, Schlank, gets imported into the nucleus, depending on two nuclear 
localization signals in the Hox-like domain (Voelzmann et al., 2016). Moreover, 
expression of catalytically inactive Schlank rescued the fat metabolism phenotype of 
Schlank mutant larvae. Although this points to a role of the Hox-like domain in lipid 
metabolism, it remains to be established whether Hox-like domains in mammalian 
CerS exhibit comparable functions. Furthermore, it was shown that a highly 
conserved region of 12 amino acid residues located C-terminally of the Hox-like 
domain, right before the TLC domain is essential for the catalytic activity of CerS5 
and CerS6 (Mesika et al., 2007). 
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1.3.2.1 Ceramide synthase expression pattern and substrate specificity 
The first studies focusing on CerS expression in mice (Mizutani et al., 2005, 2006; 
Laviad et al., 2008) and humans (Levy & Futerman, 2010) were based on the 
analyses of mRNA levels. An overview of CerS mRNA expression in mice is 
presented in Figure 1.5. CerS2 shows the strongest expression of all CerS and is 
ubiquitously expressed with high levels in liver and kidney. CerS1 is virtually absent 
from most tissues, but shows strong expression in brain and skeletal muscle. CerS3 
is exclusively expressed in skin and testis. CerS4-6 are ubiquitously expressed. 
CerS4 is strongly expressed in skin, heart, leucocytes and liver. The lowest 
expression levels were observed for CerS5 and CerS6. CerS5 shows the strongest 
expression in skeletal muscle and testis and CerS6 is strongly expressed in intestine 
and kidney. By the help of reporter proteins, expressed in CerS deficient mice and 
specific antibodies raised against most CerS proteins, the mRNA analyses were 
complemented. The corresponding studies revealed only minor deviations to the 
existing expression data and provided additional information concerning tissue 
specific expression (Ginkel et al., 2012; Ebel et al., 2013, 2014; Kremser et al., 2013; 
Gosejacob et al., 2016). For instance, CerS2 was shown to be highly expressed in 
lung and CerS4 besides skin, was highly expressed in spleen and lung. 
 
All mammalian CerS have a similar KM (Michaelis constant), and hence binding 
affinity, towards sphinganine (Lahiri et al., 2007). In contrast, they show distinct, 
specificity for the acyl-CoAs used for the N-acylation of LCBs. According to the 
incorporated fatty acids, ceramides are subdivided into long chain- (C14-C20), very 
long chain- (C22/C24) and ultra long chain (≥C26) ceramides. CerS5 and CerS6 
exhibit a specificity towards the use of C14 and C16 acyl-CoAs, additionally CerS5 
was suggested to be capable of using C18 acyl-CoAs (Mizutani et al., 2005; Ebel et 
al., 2013; Gosejacob et al., 2016). CerS1 exclusively uses C18 acyl-CoAs (Mizutani 
et al., 2005; Ginkel et al., 2012). The specificity of CerS4 ranges from C18-C22 acyl-
CoAs (Mizutani et al., 2005; Ebel et al., 2014). CerS2 has a specificity towards C20-
C26 acyl-CoAs (Mizutani et al., 2005; Kremser et al., 2013). CerS3 is capable of 
using very long chain and ultra long chain fatty acyl-CoAs ranging from C22-C36 
(Mizutani et al., 2006; Jennemann et al., 2012). 
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Figure 1.5 - Quantitative Real Time-PCR analysis of CerS mRNA expression in mouse 
tissues. CerS1 shows high expression levels in brain and skeletal muscle and is virtually 
absent in other tissues. CerS3 is strongly expressed in skin and testis. CerS2, 4, 5 and 6 are 
ubiquitously expressed. CerS2 shows the strongest expression in liver and kidney. CerS4 is 
predominantly expressed in skin, leucocytes, heart and liver. The highest levels of CerS5 are 
detected in skeletal muscle and testis. CerS6 is strongly expressed in intestine and kidney. 
(adopted and modified from Laviad et al., 2008) 
 
1.3.2.2 Chain length-specific functions of ceramides 
Several studies in the past have shown that ceramides with different acyl-chain 
length are implicated in different cellular processes, often with opposing functions 
(Grösch et al., 2012). An overview of chain length-specific actions of ceramides in 
cellular processes and diseases is presented in Figure 1.6. Studies of cultured cell 
lines led to the general consensus that elevated levels of C16 ceramide play a 
decisive role in the induction of apoptosis (Eto et al., 2003; Osawa et al., 2005; 
White-Gilbertson et al., 2009). However, in human head and neck squamous cell 
carcinomas (HNSCCs) the levels of CerS6 mRNA and C16 ceramides are increased 
(Karahatay et al., 2007) and the CerS6-mediated production of C16 ceramide in 
cultured HNSCC cells prevented ER-stress induced apoptosis (Senkal et al., 2010). 
In addition to an increase in C16 ceramide, some studies reported an increase in 
C24 ceramide following induction of apoptosis (Siskind et al., 2002, 2010; Seumois et 
al., 2007; Mesicek et al., 2010). Nevertheless, overexpression of CerS2 in HeLa cells 
reduced radiation-induced apoptosis by approximately 50 % and overexpression of 
CerS5 promoted apoptosis (Mesicek et al., 2010). Similar to that, overexpression of 
CerS4 and CerS6 induced apoptosis in human breast and colon cancer cell lines, 
which was attenuated by overexpression of CerS2 (Hartmann et al., 2013). It 
appears that with minor exceptions long chain ceramides have anti-survival function, 
whereas very long chain ceramides have pro-survival function. 
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Attributing cellular functions to specific ceramide species is complicated, since it is 
often not clear whether changes in the ceramide composition are the cause or the 
consequence of an observed effect. This is further complicated by the fact that 
ceramides can be metabolized to complex sphingolipids or sphingosine. 
 
 
Figure 1.6 - Overview of cellular processes, (dys)functions and diseases associated 
with altered levels of ceramides of differing acyl-chain length. Several diseases have 
been shown to be associated with changes in the ceramide composition (red). For example, 
disease progression in patients with Alzheimer‟s disease is associated with elevated C18 
and C24 ceramide levels in the brain and C16 and C18 ceramide species are increased in 
the airway epithelium of patients suffering from cystic fibrosis. Several cancers are 
associated with elevation of C16 and very long chain ceramides, while C18 ceramides are 
decreased in HNSCC. In addition, several cellular dysfunctions have been shown to be 
associated with altered ceramide levels (brown). Data from CerS2 deficient mice propose a 
role for C22 and C24 in myelin sheath formation and motorneuron activity. Very long chain 
ceramides are also decreased during autophagy, while C14 and C16 ceramides and several 
dihydroceramide (dh) species are elevated. Experiments with cultured cells suggest pro-
apoptotic and anti-proliferative roles of C16 and C18 ceramide, while C24 ceramides were 
shown to be rather pro-proliferative (green). It was shown that elevated levels of C16 
ceramide increase membrane fluidity, while very long chain ceramides have opposing 
effects. C16 and C18 ceramides may specifically regulate the function of protein phosphates 
and kinases (blue). (adopted and modified from Grösch et al., 2012). 
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1.3.2.3 Ceramide synthase deficient mice 
To investigate the in vivo function of CerS, different mouse mutants for all members 
of the CerS family were generated and characterized in the last years. CerS1 
deficient mice suffer from cerebellar ataxia and foliation defects, as well as from 
Purkinje cell degeneration (Zhao et al., 2011; Ginkel et al., 2012). The effects are 
associated with decreased levels of gangliosides and myelin-associated glycoprotein 
(MAG) in the brain. Studies on CerS2 deficient mice reported several severe 
phenotypes including reduced body size, myelin sheath defects, age-related 
hepatocarcinomas or hepatic insulin resistance associated with depletion of very long 
chain ceramides and increases in C16 ceramides (Imgrund et al., 2009; Pewzner-
Jung et al., 2010a; b; Park et al., 2013a). CerS3 deficient mice show defects in the 
transepidermal water barrier of the skin, resulting from the loss of ultra long chain 
ceramides, and die shortly after birth (Jennemann et al., 2012). CerS5 deficient mice 
are viable and fertile and show no obvious phenotypic alterations under non-
challenging conditions (Gosejacob et al., 2016). Analyses of steady state sphingolipid 
levels and ceramide synthase activity revealed decreases in C16 ceramide 
production in lung, spleen, muscle, liver and white adipose tissue. Also for CerS6 
deficient mice, no severe phenotypic alterations were observed (Ebel et al., 2013). 
The mice exhibited a clasping phenotype of the hind limbs and behavioral analyses 
revealed a habituation deficit. It was shown that CerS6 significantly contributes to the 
generation of C16-containing sphingolipids in kidney and small intestine. CerS2, 
CerS5 and CerS6 deficient mice were also investigated in the context of diet-induced 
obesity, the results of these studies are discussed in chapter 1.3.3.5. 
 
1.3.2.4 Ceramide synthase 4 
The mouse cers4 gene is encoded on chromosome 8 and comprises 11 exons with 
the first harboring the 5‟ untranslated region. The CerS4 protein consists of 393 
amino acid residues and has a molecular mass of 39.3 kDa. The enzyme exhibits a 
specificity towards the use of acyl-CoAs ranging from C18-C22 and shows a broad 
tissue distribution with the highest mRNA and protein levels in skin (Mizutani et al., 
2005; Ebel et al., 2014). 
 
First insights for a specific function of CerS4 came from the analysis of a pancreatic 
β-cell line. It was suggested that CerS4-dependent increases in C18 and C22 
ceramides contribute to glucolipotoxicity-induced apoptosis (Véret et al., 2011). 
Similar to that, a study focusing on light stress-induced photoreceptor apoptosis in 
rats, reported increased levels of C14-C26 ceramides that were associated by an 
increase in CerS4, but not CerS2 mRNA levels (Chen et al., 2013a). In contrast, a 
more recent study reported an increase in CerS4 mRNA levels in human breast 
cancer tissue, which was accompanied by estrogen-dependent proliferation (Wegner 
et al., 2014). In the same line CerS4 mRNA levels were shown to be increased in 
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endometrial and colon cancer cells and induction of apoptosis decreased these 
levels (Mojakgomo et al., 2015).  
 
To investigate the in vivo functions of CerS4 and corresponding ceramide species, 
Dr. Silke Imgrund in our group generated CerS4 deficient mice. These mice were 
characterized by Dr. Philipp Ebel. In line with the high expression level of CerS4 in 
the skin, the mice displayed an age-related, progressive hair loss, altered sebum 
composition (including decreased levels of wax diesters) and a general decrease in 
C18 and C20-containing sphingolipids in the skin (Ebel et al., 2014). Using newly 
generated, specific antibodies against CerS4, it was shown that the protein is 
strongly expressed in suprabasal layers of the epidermis and sebum producing 
sebaceous glands, which are part of the hair follicle (HF). It was shown that the 
sebum of CerS4 deficient mice has a significantly higher melting temperature, which 
might at least partially be explained by a strong decrease in the levels of 1, 2-alkane 
diols and wax diesters. The sebum usually supports hair growth by greasing the hair 
canals. Therefore, it was suggested that the solidification of the sebum leads to 
physical blocking of hair canals and consequently to the observed hair loss. 
 
Later on, Peters et al. generated a mouse line for the conditional depletion of CerS4. 
Consistent with the previous findings, ubiquitous-, as well as epidermis-specific 
depletion of CerS4 led to age-related, progressive hair loss (Peters et al., 2015). 
While HFs are characterized by constant renewal through continuous phases of 
growth (anagen), regression (catagen) and resting (telogen), CerS4 deficient HFs 
persisted in an anagen-like state at postnatal day 51 (P51) due to precocious entry of 
HF stem cells into growth phase. Entry into telogen and quiescence of stem cells is 
depending on bone morphogenetic protein (BMP), which was strongly decreased in 
CerS4 deficient HFs at P47. Moreover, Wnt signaling, which promotes entry into 
anagen was increased. The precocious activation of growth phase in HF stem cells 
resulted in exhaustion over time, which is probably responsible for hair loss in older 
mice. The study provided another example for a presumably anti-proliferative 
function of CerS4 and corresponding ceramide species. 
 
Although CerS4 was shown to be broadly expressed with high levels in spleen, liver, 
pancreas, heart, lung and brain (Ebel et al., 2014), deficient mice are fertile, show no 
obvious phenotypic alterations, aside from the observed skin phenotype, and have a 
normal life-expectancy (Ebel et al., 2014; Peters et al., 2015). Whether CerS4 and 
the corresponding ceramide species exhibit other specific functions in mice remains 
to be established. 
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1.3.2.5 Regulation of ceramide synthase activity 
The mRNA expression of CerS in several tissues does not always correlate with the 
ceramide acyl-chain composition (Laviad et al., 2008). While the ceramide 
composition certainly depends on substrate availability and metabolizing enzymes, it 
is likely that posttranscriptional mechanisms regulate protein levels or activity of 
CerS. A possible mechanism for the regulation of CerS activity could include 
dimerization of CerS. In human embryonic kidney (HEK) cells homo- and 
heterodimer formation of overexpressed, flag-tagged CerS was observed after cross-
linking and under non-denaturing conditions (Laviad et al., 2012). A more recent 
study showed co-immunoprecipitation of endogenous CerS1, CerS2 and CerS6 in 
isolated brain mitochondria (Novgorodov et al., 2015). It was suggested that such 
interactions modulate CerS activity, e.g. co-expression of CerS2 and CerS5 
increased the CerS2mediated production of C24 ceramides in HEK cells (Laviad et 
al., 2012). In a similar fashion, C24 ceramide production was increased in a human 
colon carcinoma cell line after co-expression of CerS2 with CerS4 or CerS6, whereas 
the CerS4dependent production of C20 ceramide was slightly decreased upon 
co-expression with CerS6 (Hartmann et al., 2013). Whether dimerization of CerS is 
relevant under physiological conditions is largely unexplored. Nevertheless, data 
from CerS deficient mice argue against dimer-dependent regulation of CerS activity 
in vivo. For instance, steady state levels and activity towards production of C24 
ceramides are unaltered in the lung of CerS5- or the kidney of CerS6 deficient mice, 
respectively (Ebel et al., 2013; Gosejacob et al., 2016). Moreover, using antibodies 
against different CerS it was not possible to detect putative dimers according to their 
expected molecular size under non-denaturing conditions in cultured mouse 
embryonic fibroblasts (MEFs) and human embryonic kidney (HEK) cells (personal 
communication with Christiane Kremser). 
 
Another mechanism could include acetylation of CerS. Studies with cerebral 
mitochondria revealed that CerS1, CerS2 and CerS6, but not CerS4 are acetylated 
and that deacetylation mediated by SIRT3 (sirtuin 3) activates ceramide synthesis 
(Novgorodov et al., 2015). This regulatory mechanism seems to be specific to 
mitochondria and the physiological relevance remains to be investigated. A more 
recent study reported several phosphorylation sites in the C-terminal regions of 
CerS2-6 (Sassa et al., 2016). In vitro activity assays using either membrane fractions 
from HEK cells overexpressing HA-tagged CerS or from mouse brain revealed that 
phosphorylation of these sites is casein kinase 2 (CK2) dependent and increases 
activity of the respective CerS, whereas phosphatase treatment reduces activity. 
Additionally, CerS2, CerS4, CerS5 and CerS6 have been shown to be N-terminally 
glycosylated (Mizutani et al., 2005; Sassa et al., 2016). The function of this 
glycosylation is not yet understood, but it was shown that at least the glycosylation of 
CerS6 is dispensable for its activity (Mizutani et al., 2005).  
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1.3.3 Ceramides in metabolic disease 
Detailed analyses of obese humans revealed that obese tissues including liver, 
skeletal muscle and adipose tissue are characterized by increased sphingolipid 
contents (Adams et al., 2004; Kotronen et al., 2010). Several studies investigated the 
correlation between sphingolipids and obesity and especially highlighted the 
implication of ceramides in obesity-associated metabolic diseases such as type 2 
diabetes, cardiomyopathy or atherosclerosis (Hla & Dannenberg, 2012; Russo et al., 
2013; Choi & Snider, 2015). 
 
1.3.3.1 Ceramides in the development of obesity and insulin resistance 
Free fatty acids (FFAs) originating from dietary intake are stored in adipose tissue 
and can be released in the fasting state (Hajer et al., 2008). Diet-induced obesity in 
humans and mice is characterized by an excess in FFAs, resulting from an overload 
of adipocytes (Russo et al., 2013). This leads to increased lipolysis and release of 
further FFAs, which consequently accumulate in peripheral tissues including liver, 
skeletal muscle or pancreas. As FFAs provide additional acyl-CoAs for ceramide 
synthesis, the obese state is characterized by a strong increase in sphingolipid 
levels. Accumulation of lipids in peripheral tissues is associated with several 
detrimental effects, referred to as lipotoxicity (Turpin et al., 2009). A direct cause is 
insulin resistance, a preliminary state in the development of type 2 diabetes and 
metabolic syndrome (Chavez & Summers, 2012). In skeletal muscle and adipose 
tissue, insulin stimulates uptake and storage of glucose, whereas in liver it inhibits 
glucose release and gluconeogenesis. Notably, ceramides antagonize insulin-
stimulated glucose uptake and anabolism and a block in synthesis is insulin 
sensitizing and prevents several pathologies associated with insulin resistance e.g. 
diabetes, atherosclerosis, hepatic steatosis or cardiomyopathy (Chavez & Summers, 
2012). 
 
Insulin signaling is initiated by extracellular binding of insulin to insulin receptors 
(IRs), receptor tyrosine kinases that subsequently phosphorylate intracellular insulin 
receptor substrates (IRSs), which in turn recruit and activate several effector 
enzymes (White, 1998). One of the most important effector kinases is PI3K 
(phosphoinositide 3 kinase) (Shepherd et al., 1998), which after activation mediates 
phosphorylation of specific phosphoinositides, as a prerequisite for the recruitment of 
Akt/PKB (protein kinase B) to the plasma membrane. Akt/PKB, the central mediator 
of anabolism is subsequently activated by PKD-mediated phosphorylation at two 
regulatory residues (T308 and S473) (Alessi & Cohen, 1998). 
 
It was shown that ceramide blocks Akt/PKB activation probably by activating PKCδ, 
leading to phosphorylation of Akt/PKB on a regulatory site (S34) in the enzymes PH 
domain (Bourbon et al., 2000), which prevents interaction with phosphoinositides and 
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hence translocation to the plasma membrane (Hajduch et al., 2001; Powell et al., 
2003). Additional studies suggested that ceramide might stabilize interactions 
between Akt/PKB and PKCδ by recruiting them to membrane lipid microdomains (Fox 
et al., 2007; Hajduch et al., 2008). Moreover, an alternative mechanism was 
proposed in which ceramide inhibits Akt/PKB activation by mediating 
dephosphorylation of the regulatory residues T308 and S473 through protein 
phosphatase 2A (PP2A) (Zinda et al., 2001; Chavez et al., 2003). 
 
Insulin resistance is often associated with mitochondrial dysfunction. Some studies 
suggested negative effects of ceramides or DAGs that might originate from impaired 
β-oxidation of fatty acids (Bruce et al., 2009), others suggested that mitochondrial 
overload leads to incomplete β-oxidation and subsequent impairments in glucose 
utilization (Koves et al., 2008). Interestingly, studies focusing on insulin resistance 
and mitochondrial dysfunction in high fat diet (HFD)-fed mice reported improved 
mitochondrial performance after depletion of ceramides by the SPT inhibitor myriocin 
(Schmitz-Peiffer, 2010; Ussher et al., 2010). 
 
1.3.3.2 Obesity-associated ceramide function in peripheral tissues 
It was shown that nutrient oversupply in the liver of mice and humans leads to a 
strong decrease in de novo ceramide production, but also to secretion of ceramides 
and transport to peripheral tissues, which might contribute to global development of 
insulin resistance (Watt et al., 2012). In line with that notion, a study focusing on 
HFD-induced obesity in mice suggested that hepatic ceramides may mediate brain 
insulin resistance and neurodegeneration in patients suffering from type 2 diabetes 
and steatohepatitis (Lyn-Cook et al., 2009). The sustained uptake of FFAs together 
with continuous synthesis of TAGs in the obese liver at some point leads to 
steatohepatosis (and perhaps steatohepatitis), which contributes to hepatic insulin 
resistance (Deevska et al., 2009). This is characterized by constitutive 
gluconeogenesis and consequently hyperglycemia (Bijl et al., 2009). Interestingly, 
TAG accumulation, hyperglycemia and insulin resistance were prevented in aSMase 
deficient mice, in which ceramide generation from SM is impaired (Deevska et al., 
2009), pointing to a role of ceramide in the development these pathologies. 
Hyperglycemia also results from skeletal muscle insulin resistance, under these 
conditions translocation of glucose transporter 4 (GluT4) to the plasma membrane 
and hence glucose uptake is impaired (Górski et al., 2002). Hyperglycemia 
consequently leads to hyperinsulinemia due to increased insulin production in 
pancreatic β-cells, which try to compensate increasing plasma glucose levels 
(Cavaghan et al., 2000; Bijl et al., 2009). At some point the pancreas loses its ability 
to produce insulin due to aberrant signaling and β-cell apoptosis (Hirose et al., 1996; 
Pick et al., 1998), leading to the development of type 2 diabetes. Interestingly, 
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palmitate-induced apoptosis in cultured β-cells can be prevented by a fumonisin B1- 
mediated block in de novo ceramide synthesis (Maedler et al., 2003). 
 
Besides liver, the most important tissue in the development of obesity and associated 
pathologies is adipose tissue. Aside from a decisive role in energy storage, it exhibits 
endocrine functions and thereby contributes to regulation of metabolic homeostasis. 
These regulatory functions are exerted through production and release of 
proinflammatory cytokines and chemokines collectively referred to as adipokines 
(Samad et al., 2011; Freitas Lima et al., 2015). One of the obesity-associated 
pathologies is adipose tissue inflammation, which is characterized by secretion of 
chemokines that mediate macrophage infiltration (Nishimura et al., 2009; Ouchi et al., 
2011). In a similar fashion adipokines seem to be involved in the development of 
atherosclerosis, which is also characterized by inflammation (Zhang et al., 2010). In 
the obese state exhausted capacity of adipocytes directly contributes to development 
of insulin resistance in peripheral tissues and it was suggested that adipokines are 
implicated in this process (Samad et al., 2011; Freitas Lima et al., 2015). Under 
normal conditions adipocytes secrete adiponectin, which is suggested to have 
insulin-sensitizing and cardioprotective functions, in contrast enlarged adipocytes 
secrete high levels of leptin and TNFα, which are associated with insulin resistance 
(Chavez & Summers, 2012). Leptin is usually secreted in response to dietary intake 
and regulates satiety. It has been shown that leptin treatment reduces ceramide 
levels in the hypothalamic arcuate nucleus of rats and that the decrease is important 
for leptins anorectic functions (Gao et al., 2011). TNFα was shown to mediate 
accumulation of the ganglioside GM3 in membrane lipid microdomains, thereby 
inhibiting IR clustering (Inokuchi, 2006; Kabayama et al., 2007). One of the effects of 
adiponectin includes activation of ceramidase activity, leading to depletion of 
ceramide and generation of the pro-survival factor S1P (Holland et al., 2011). 
 
1.3.3.3 Adipose tissue 
Adipose tissue can be divided into white adipose tissue (WAT) and brown adipose 
tissue (BAT). WAT is primarily responsible for energy storage in the form of TAGs in 
response to dietary intake and releases fatty acids for skeletal and cardiac muscles 
in the fasting state. In contrast, BAT is responsible for non-shivering thermogenesis 
and is abundant in small mammals and especially new borns to counteract heat loss 
due to small body volume to surface ratio (Saely et al., 2012). BAT is characterized 
by high expression levels of uncoupling protein 1 (UCP1), which is directly 
responsible for its thermogenic function. During oxidative phosphorylation a proton 
gradient across the inner mitochondrial membrane is established and the resulting 
intrinsic energy can be used to produce ATP as a universal carrier of free energy. In 
metabolically active BAT, UCP1 uncouples the proton gradient from ATP production, 
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dissipating the energy as heat, which goes along with higher oxygen consumption 
and an overall increase in energy expenditure (Saely et al., 2012). 
 
Originally, it was thought that white and brown adipocytes originate from a common 
precursor, but more recent studies suggested that brown adipocytes, similar to 
muscle cells, originate from Myf5 (Myogenic factor 5)-positive precursor cells (Warner 
& Mittag, 2015). White adipocytes are spherical, have low numbers of mitochondria 
and usually a single size determining lipid droplet filled with TAGs. In contrast, brown 
adipocytes are polygonal and similar to muscle cells characterized by a huge number 
of mitochondria. They rather catabolize lipids than storing them and display several 
small TAG containing vacuoles (Warner & Mittag, 2015). 
 
WAT can be found in several depots throughout the whole mammalian body 
including subcutaneous and visceral depots (Cinti, 2012). Subcutaneous adipose 
tissue underneath the skin provides minor insulation and includes anterior depots at 
the level of the scapulae and posterior depots in the lower ventral part of the body, 
e.g. inguinal WAT (igWAT). Visceral adipose tissue surrounds inner organs and is 
closely associated to the aorta and connected vessels, it can be found in the 
mediastinum and especially the abdomen. The main abdominal depot is gonadal 
WAT (gWAT). Different WAT depots are not homogenous, especially subcutaneous 
and visceral depots strongly differ in their biochemical profiles (Sackmann-Sala et al., 
2012) and it was shown that visceral adipose tissue is significantly stronger 
correlated with obesity comorbidities (Booth et al., 2014; Walker et al., 2014). 
 
BAT is mainly located in regions around neck and shoulders and in low amounts 
around kidneys, with the biggest depot being the interscapular BAT (iBAT) (Sidossis 
& Kajimura, 2015). While WAT continuously increases after birth, BAT already 
develops in midgestation, reaching its maximum size relative to body weight at birth 
(Gesta et al., 2007). It was originally discussed that in contrast to adult rodents, no 
functional BAT is anymore present in adult humans (Saely et al., 2012). However, 
meanwhile several studies reported generally high levels of functional BAT in adult 
humans (Nedergaard et al., 2007; Virtanen et al., 2009). BAT activity was shown to 
be induced by acute cold exposure, stimulated by the sympathetic nervous system 
and it negatively correlates with increased body weight (Nedergaard et al., 2007; van 
Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). 
 
Intriguingly, a lot of studies reported the occurrence of brown adipocytes aside from 
the typical BAT depots, interspersed in WAT depots, and notably, it was shown that 
these cells did not originate from Myf5-positive precursor cells (Seale et al., 2008). 
These brown-like adipocytes, referred to as beige (or brite) adipocytes could derive 
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from dormant precursor cells or from white to brown adipocyte transdifferentiation in 
a process commonly referred to as browning (Cinti, 2009; Warner & Mittag, 2015). 
 
Adipose tissue metabolism is tightly regulated by β-adrenoceptors (β-ARs) and 
strongly depends on catecholamines e.g. norepinephrine or epinephrine. Activation 
of β-ARs usually leads to a strong increase in intracellular cAMP levels and 
subsequently to activation of PKA, which finally results in the activation of 
transcriptional regulators of metabolism or development (Kajimura & Saito, 2014). 
Catecholamines can be released from the sympathetic nervous system in response 
to stress, cold exposure or diet and for example stimulate lipolysis and release of 
FFAs in WAT (Collins et al., 2014). They are also important mediators of BAT 
activation, they stimulate expression of UCP1 and oxidation of glucose and FFAs for 
thermogenesis and play a decisive role in browning of WAT (Warner & Mittag, 2015). 
 
Mechanisms leading to development and activation of brown and beige adipocytes to 
increase whole body energy expenditure have gained particular interest as a 
treatment for obesity (Kim & Plutzky, 2016). Several genes implicated in browning 
and a large number of „browning agents‟, including pharmacological substances and 
nutritional components, have already been identified (Bonet et al., 2013; Kim & 
Plutzky, 2016). Understanding the mechanisms by which browning agents act and 
further identification of genes and possible regulators would be valuable for the 
development of new strategies for obesity treatment.  
 
1.3.3.4 Ceramide in the development of diet-induced obesity in mice 
Most of the studies on ceramide dependent insulin resistance focused on 
manipulation of cultured skeletal muscle cells, isolated myotubes or hepatocytes with 
exogenous palmitate or ceramide (Chavez & Summers, 2012). Meanwhile, several 
studies addressed the question how ceramides affect obesity-associated pathologies 
in rodents and collectively reported increased ceramide levels in all investigated 
tissues including liver, skeletal and cardiac muscle, pancreas or adipose tissue 
(Chavez & Summers, 2012; Choi & Snider, 2015). 
 
Several of these studies used administration of the SPT inhibitor myriocin to block de 
novo ceramide synthesis and reported prevention of insulin resistance and diabetes 
(Frangioudakis et al., 2010; Ussher et al., 2010), atherosclerosis (Glaros et al., 2008; 
Park et al., 2008) and cardiomyopathy (Park et al., 2008). Interestingly, several 
studies reported increased levels of complex gangliosides in adipose tissue following 
HFD feeding (Chavez & Summers, 2012), and it was shown that depletion of GM3, 
the major ganglioside precursor, protects mice from diet-induced insulin resistance 
(Yamashita et al., 2003). Moreover, the use of glucosylceramide synthase inhibitors 
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in different mouse models for obesity improved insulin sensitivity and prevented from 
steatosis and adipose inflammation (Bijl et al., 2009; van Eijk et al., 2009). 
1.3.3.5 Diet-induced obesity in ceramide synthase deficient mice 
While the previously mentioned studies clearly indicated that ceramides and 
corresponding sphingolipids are involved in the pathogenesis of obesity, it remains 
unclear whether distinct pathologies result from a general increase or an increase in 
specific ceramide species. To shed more light on chain length-specific ceramide 
function in the development of obesity, different groups investigated diet-induced 
obesity in CerS deficient mice.  
 
The first study was published by Turpin et al., and focused on CerS6 deficient mice 
(Turpin et al., 2014). As a basis for their investigations, they reported increased 
levels of CerS6 mRNA and C16:0 ceramide in the adipose tissue of obese humans, 
in correlation with insulin resistance. CerS6 deficient mice displayed reduced levels 
of C16:0 ceramides in WAT, BAT and liver and were protected from HFD-induced 
obesity with higher insulin sensitivity and glucose tolerance. Reductions in body 
weight, fat content and adipocyte size correlated with increased energy expenditure 
and decreased leptin levels. CerS6 deficiency also prevented macrophage infiltration 
in WAT, but despite reduction in C16:0 ceramide levels in macrophages none of the 
beneficial effects upon HFD feeding were observed after conditional depletion of 
CerS6 in myeloid cells. Similar to ubiquitous depletion, conditional depletion of CerS6 
in BAT improved overall glucose tolerance and increased energy expenditure after 
HFD feeding, although weight gain and body fat reduction was only minor compared 
to wild type littermates. Moreover, isolated brown adipocytes exhibited reduced lipid 
accumulation and increased β-oxidative capacity. In the liver, HFD feeding led to a 
general increase in ceramide levels, but the levels of C14:0 and C16:0 ceramides 
were strongly decreased in CerS6 deficient mice. After HFD feeding, the liver of 
CerS6 deficient mice displayed reduced levels of the transcription factor peroxisome 
proliferator-activated receptor γ (PPARγ) and transcriptional targets, which control 
lipid uptake and storage. Isolated hepatocytes from these mice exhibited increased 
palmitate oxidation. Conditional depletion of CerS6 in liver significantly improved 
glucose tolerance, but not insulin sensitivity and weight gain was only slightly 
decreased compared to wild type mice upon HFD feeding. This study demonstrated 
that CerS6 in iBAT and liver contributes to diet-induced obesity and glucose 
intolerance in mice, at least partially by affecting β-oxidation. 
 
In line with the comparable substrate specificity, a more recent study published by 
Gosejacob et al., also reported protection from HFD-induced obesity in CerS5 
deficient mice (Gosejacob et al., 2016), including protection from glucose intolerance 
and insulin resistance. The study reported generally low levels of C16:0 ceramide in 
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liver and skeletal muscle. These levels were further decreased in CerS5 deficient 
mice, but not influenced by the HFD. A particular increase in C18:0 ceramide in 
skeletal muscle after HFD feeding was prevented in CerS5 deficient mice. In gonadal 
WAT (gWAT), HFD feeding led to a particular increase in C16:0 and C18:0 ceramide, 
which was prevented in CerS5 deficient mice. Changes in ceramide levels usually 
mirrored changes in SM levels, with the exception of gWAT, where no HFD-mediated 
increases in SM were detectable. HFD feeding revealed a strong reduction in weight 
gain, gWAT and adipocyte size, and circulating leptin levels of CerS5 deficient 
compared to wild type mice. The levels of TAGs and FFAs in the liver were 
decreased and signs of steatosis were only found in wild type mice fed a HFD. In line 
with that, several genes involved in fatty acid uptake were downregulated, whereas 
genes responsible for lipogenesis or oxidation were not affected. Morphological 
analyses of gWAT revealed crown-like structures in wild type, but not in CerS5 
deficient mice after HFD feeding, indicating protection from obesity-associated gWAT 
inflammation, which usually contributes to the development of insulin resistance. This 
was confirmed by reduced expression of the pro-inflammatory cytokines TNFα (tumor 
necrosis factor α) and IL1β (interleukin 1β). Further analyses revealed increased 
expression of genes responsible for lipogenesis, but also for lipolysis, in gWAT of 
CerS5 deficient mice after HFD feeding. Genes responsible for β-oxidation and 
acylcarnitine levels were largely unaffected. This study demonstrated that CerS5 in 
gWAT contributes to diet-induced obesity, glucose intolerance and insulin resistance 
in mice, probably by promoting lipid accumulation without affecting β-oxidation. 
 
Another study, published by Raichur at al., reported that haploinsufficiency in 
heterozygous CerS2gt mice increases susceptibility to HFD-induced obesity (Raichur 
et al., 2014). Heterozygous deficiency of CerS2 (CerS2gt/+) does not lead to obvious 
phenotypic alterations under normal conditions. However, HFD feeding did not alter 
weight gain, but did severely impair liver integrity in CerS2gt/+ compared to wild type 
mice. This was characterized by increased weight, elevated TAG levels, and 
increased macrophage infiltration. Morphological analyses and increased serum 
levels of ALT, AST and cholesterol clearly demonstrated liver damage in HFD-fed 
CerS2gt/+ mice. These mice displayed glucose intolerance and insulin resistance 
and the ratio of body fat to lean body mass was increased. No alteration of energy 
expenditure was detectable, but locomotor activity was decreased. Analyses of liver 
sphingolipid content after HFD feeding revealed only minor decreases in very long 
chain (C22-C24) ceramides, glucosylceramides and SMs, but a substantial 
compensatory increase in the corresponding C16:0 species in CerS2gt/+ compared 
to wild type mice. In line with that, total sphingolipid levels were not altered, but 
mRNA levels of CerS5 and CerS6 were increased. Pretreatment with the SPT 
inhibitor myriocin protected CerS2gt/+ mice from diet-induced phenotypes, indicating 
that the elevation in C16 ceramides, rather than decreases in very long chain 
Introduction 
27 
 
ceramides, is responsible for the detrimental effects observed in these mice after 
HFD feeding. Increased levels of certain acylcarnitine species indicated incomplete 
lipid oxidation and isolated hepatocytes from CerS2gt/+ mice exhibited impaired 
β-oxidation, as well as impaired activity of the respiratory chain complexes II and IV, 
which was associated with reduced ATP levels. Strikingly, overexpression of CerS6 
in wild type hepatocytes strongly increased C16 ceramide levels and was 
accompanied by TAG accumulation and disturbed insulin signaling and complex II 
activity. This indicated that lipid accumulation, impaired β-oxidation and steatosis in 
haploinsufficient CerS2gt/+ mice after HFD feeding is mediated by C16 ceramide. 
 
All of these studies consistently indicate an important role of C16 ceramide in the 
development of diet-induced obesity and highlight it as a potential therapeutical 
target for obesity treatment. It appears that depending on the tissue, C16 ceramide 
can contribute to different pathologies. It remains to be investigated how C16 
ceramide and possibly other ceramide species affect obesity-associated pathologies 
in different peripheral tissues. The involvement of three different CerS with distinct 
substrate specificity indicates that also other CerS could be involved in the 
development of diet-induced obesity. CerS3 is presumably not involved due to its 
specific expression in skin and testis, but according to its high expression in skeletal 
muscle, CerS1 could be involved. However, C18 ceramides in skeletal muscles were 
increased following HFD feeding, but the increase was probably mediated by CerS5 
(Gosejacob et al., 2016). This leaves CerS4, with its ubiquitous expression and broad 
substrate specificity (C18-C22), ranging between those of CerS5/6 and CerS2, as an 
interesting target. 
 
1.3.4 Sphingomyelin synthase family 
Biosynthesis of SM is catalyzed by a family of phosphatidylcholine: ceramide choline 
phosphotransferases or SM synthases (SMSs), which occurs throughout the whole 
animal kingdom (Tafesse et al., 2006). Mammalian cells express two isoforms of 
SMS, the first member SMS1 resides in the Golgi, whereas the second member 
SMS2 resides primarily in the plasma membrane, but also in the Golgi (Villani et al., 
2008; Ternes et al., 2009). A third member of this family is the ER-resident 
sphingomyelin synthase related protein (SMSr). All members share a similar 
membrane topology with the lipid phosphate phosphatase (LPP) superfamily  
including six transmembrane domains, exoplasmic N- and C-terminus and an active 
site facing the exoplasmic space (Figure 1.7) (Holthuis & Luberto, 2010). 
Responsible for the catalytic activity is a conserved domain build up by two histidine 
and one aspartate residues (Tafesse et al., 2006; Yeang et al., 2008). The 
conventional SMSs catalyze the transfer of a phosphocholine head group from PC to 
ceramide, generating SM (Figure 1.3 G) and DAG (Huitema et al., 2004). In contrast, 
SMSr catalyzes transfer of a phosphoethanolamine head group from PE to ceramide, 
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generating trace amounts of the SM analog ceramide phosphoethanolamine (CPE; 
Figure 1.3 H) and DAG (Vacaru et al., 2009). SMS2 shows a dual activity and is also 
capable of synthesizing CPE (Ternes et al., 2009). 
 
 
Figure 1.7 - Domain structure of the mammalian SMS family. SMS share a similar 
domain structure with six transmembrane domains, N-terminal SAM-domain and both termini 
and active side residues in transmembrane domains 4 and 6 directed to the exoplasmic 
space. (adopted and modified from Vacaru et al., 2009) 
 
An interesting feature shared by SMSr and SMS1 is the N-terminal sterile α motif 
(SAM)-domain. SAM-domains were found in a diverse set of proteins including 
scaffolding proteins, regulators of transcription/translation or in Tyr- and Ser/Thr-
kinases (Kim & Bowie, 2003). The SAM-domain of the Drosophila Smaug protein for 
example mediates RNA binding and is involved in post-transcriptional regulation of 
development (Aviv et al., 2003; Green et al., 2003). A broad analysis of human 
SAM-domains predicted a role for the SMSr SAM-domain in oligomerization (Knight 
et al., 2011). The SAM-domain of SMSr was shown to be essential for ER retention 
of the protein (Vacaru et al., 2009). In contrast, removal of the SAM-domain from 
SMS1 did not alter subcellular localization (Yeang et al., 2008). 
 
1.3.4.1 Sphingomyelin synthase 1 and 2 
SMS1 and SMS2 support cell growth in certain types of cultured cancer cells 
(Yamaoka et al., 2004; Tafesse et al., 2007). It was shown that SMS1-mediated 
ceramide generation at the plasma membrane is critical for Fas-clustering and Fas-
mediated-apoptosis (Miyaji et al., 2005) and depletion of SMS1 enhanced ceramide 
production and apoptosis after light-induced stress (Separovic et al., 2008). SMS1 
deficiency in mice causes moderate neonatal lethality, reduction of body weight and 
fat tissue mass, and affects WAT function associated with impaired insulin secretion 
(Yano et al., 2011, 2013). Depletion of SMS1 led to decreased SM and elevated 
glycosphingolipid levels in plasma, liver and macrophages, attenuated macrophage 
activation by NFκB (nuclear factor κ B) and MAPK (mitogen-activated protein kinase) 
in response to inflammatory stimuli, and transplantation of deficient macrophages to 
LDL (low density lipoprotein)-receptor deficient mice reduced atherosclerosis (Li et 
al., 2012). SMS2 deficient mice display decreased SM and increased apolipoprotein 
E (ApoE) levels in plasma, which was reversed in mice liver-specifically 
overexpressing SMS2 (Liu et al., 2009b). Interestingly, atherosclerotic lesions were 
also significantly reduced when transplanting SMS2 deficient macrophages to LDL-
receptor deficient mice (Liu et al., 2009a). Moreover, SMS2 deficiency increased 
insulin sensitivity and ameliorated HFD-induced obesity and liver steatosis (Li et al., 
2011; Mitsutake et al., 2011), as well as lipopolysaccharide-induced lung injury 
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(Gowda et al., 2011). Another study reported decreased expression and altered 
function of drug transporters in the brain of SMS2 deficient mice (Zhang et al., 2011). 
 
1.3.4.2 Sphingomyelin synthase related protein 
SMSr shares a similar reaction mechanism with conventional SMSs, but uses PE 
instead of PC for head group transfer to ceramide, and produces trace amounts of 
the SM analog CPE in the ER (Vacaru et al., 2009). SMSr is the best-conserved 
member of the SMS family and found in several organisms, e.g. Drosophila, which 
lacks SM and instead produces CPE as the major sphingolipid (Tafesse et al., 2014). 
Although SMSr is capable of synthesizing CPE in Drosophila, bulk production is 
mediated by a Golgi-resident CPE synthase that belongs to the CDP-alcohol 
phosphotransferase superfamily (Vacaru et al., 2013). In contrast, the levels of CPE 
in mammalian cells are rather low and approximately 300-fold lower than those of SM 
(Malgat et al., 1986, 1987; Vacaru et al., 2009).   
 
The mouse smsr gene, also known as samd8 (sterile alpha motif domain-containing 
protein 8) is located on chromosome 14 and consists of six exons. The encoded 
protein (mSMSr) includes 415 amino acid residues and consists of six 
transmembrane domains, with both termini facing the ER lumen. The N-terminal 
SAM-domain ranges from amino acid residues 12 to 78 and is located in the ER 
lumen, and the catalytically active amino acid residues are located in the 
transmembrane domains 4 (H301) and 6 (H344 and D348) at the luminal surface of 
the ER (Huitema et al., 2004; Tafesse et al., 2006). 
 
Remarkably, siRNA-mediated downregulation of SMSr in cultured HeLa- and 
Drosophila S2-cells caused a significant increase in ER ceramide levels and led to a 
structural collapse of ER exit sites and fragmentation of the Golgi (Vacaru et al., 
2009). Since SMSr is only capable of converting trace amounts of ceramide to CPE, 
the ceramide accumulation cannot be explained by missing conversion. In contrast to 
the endogenous SMSr, catalytically inactive SMSr was not able to rescue the 
observed phenotypes, pointing to an essential role of SMSr catalytic activity. Based 
on their observations, Vacaru et al., proposed a model for a possible ceramide 
sensor function of SMSr (Figure 1.8)(Vacaru et al., 2009). In a later study it was 
shown that the ceramide accumulation following acute disruption of SMSr triggers a 
mitochondrial pathway of apoptosis in various human carcinoma cell lines, including 
HeLa (Tafesse et al., 2014). This was characterized by proteolytic activation of 
caspase-3, PARP (Poly ADP ribose polymerase) cleavage, release of cytochrome c 
from mitochondria to the cytosol and subsequent activation of caspase-9, an initiator 
caspase of mitochondrial apoptosis. Interestingly, acute disruption of SMS1 or SMS2 
in HeLa cells, despite similar increases in ceramide levels did not lead to caspase 
and PARP cleavage, indicating that the site of ceramide accumulation is the 
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determining factor (Tafesse et al., 2007; Vacaru et al., 2009). In line with that, 
reduction of ER ceramide levels e.g. by targeting SMS1 to the ER or by inhibition of 
ceramide de novo synthesis prevented activation of the apoptotic machinery 
(Tafesse et al., 2014). Suppression of ceramide accumulation and apoptosis did not 
solely depend on SMSr catalytic activity, but also on its SAM-domain. 
Overexpression of a catalytically active SMSr variant lacking the SAM-domain was 
not able to rescue the phenotype, even when targeted to the ER using an alternative 
retention signal (Tafesse et al., 2014). Based on these results it was postulated that 
SMSr is essential in monitoring ER ceramide levels to prevent inappropriate cell 
death during sphingolipid synthesis (Vacaru et al., 2009; Tafesse et al., 2014). 
  
While it was shown that SMSr catalytic activity is essential to prevent ceramide 
accumulation and apoptosis in cultured HeLa cells, not much is known about the 
biological function of the product CPE. In Drosophila it is the major sphingolipid and 
an essential constituent of cellular membranes (Vacaru et al., 2013). It is known that 
at least two different enzymes are capable of producing CPE in mammals, but it 
remains to be established whether and how CPE influences cellular functions. 
 
 
Figure 1.8 - Hypothetical model for SMSr-mediated regulation of ceramide 
homeostasis in the ER. (A) In the normal situation newly synthesized ceramide is 
constantly extracted from the cytoplasmic leaflet of the ER and transported to the Golgi by 
CERT. (B) At some point CERT may not be able to cope with increasing ceramide levels and 
ceramides reaches the luminal leaflet of the ER by transbilayer movement. This allows 
binding to the active site of SMSr and conversion to CPE. Due to the high affinity of CPE to 
the active site it remains bound, leading to a conformational change of the protein. This might 
initiate signaling cascades that inhibit ceramide synthesis or stimulate degradation to restore 
ceramide homeostasis. cer, ceramide; sph, sphingosine. (adopted from Vacaru et al., 2009) 
 
1.4 The mouse as model organism 
While cultured cells and cell free systems allow rapid manipulation and investigation 
of gene, protein or lipid function, it is absolutely essential to test hypotheses resulting 
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from such investigations in vivo. A valuable tool for the analyses of physiological 
processes in mammals is the house mouse mus musculus. Mice facilitate 
understanding of complex biological processes in mammals and according to high 
similarities in structure, physiology and genetics allow comparative studies with 
humans. Despite complex physiology mice are easy to breed, display short 
generation times, high number of offspring and require less effort in housing. 
 
1.4.1 Transgenic mice 
The targeted manipulation of genes is an effective means for the investigation of 
gene function in mice. An effective method for genetic manipulation is blastocyst 
injection (Bradley et al., 1984). This method allows depletion of existing genes 
(„knock out‟) or introduction of modified genes („knock in‟). Specific sequences of the 
target gene can be manipulated by molecular cloning strategies to produce a 
specialized DNA plasmid that can be used as an exchange vector. The vector 
backbone harbors different antibiotic resistance genes for selection of bacteria and 
eucaryotic cells. The manipulated sequence is flanked by homology regions that 
allow exchange of the targeted genomic region by homologous recombination, 
following transfection of embryonic stem (ES) cells with the targeting vector. The 
manipulated region can also contain a reporter gene like eGFP (enhanced green 
fluorescent protein) or LacZ (β-galactosidase) to investigate expression of the target 
gene (Hadjantonakis et al., 1999; Serebriiskii & Golemis, 2000). The reporter gene 
can either completely exchange the target gene, be introduced in frame with the 
mutated gene to produce a fusion protein or be expressed from a bicistronic 
transcript under control of an IRES (internal ribosomal entry site)(Attal et al., 1999). 
Successful homologous recombination in ES cells is confirmed by PCR and Southern 
blot analyses. Positive ES cells are injected into isolated blastocysts at postnatal day 
3.5 (P3.5) and these are implanted into pseudopregnant surrogate mothers. As the 
ES cells are derived from agouti-colored SV/129 mice and the blastocysts from black 
C57BL/6 mice, successful blastocyst injection results in chimeric offspring with mixed 
fur color. Germ-line transmission of the transgenic allele is confirmed by subsequent 
backcrossing of chimeric mice with C57BL/6 mice and PCR analyses of agouti-
colored offspring. Resulting heterozygous carriers of the transgenic allele can then 
be used to generate homozygous animals for investigation. 
 
1.4.2 Conditional and non-conditional systems to manipulate gene function 
The easiest way to manipulate gene function is the non-conditional and hence 
ubiquitous depletion of a gene. However, depending on the function of the 
corresponding gene product this can lead to embryonic lethality or interfere with the 
investigation of tissue specific functions. To circumvent such problems, conditional 
approaches were established that allow development and cell type specific, as well 
as inducible modification of gene function (Rodríguez et al., 2000; Feil et al., 2009). 
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One possibility is the Cre/loxP system derived from the bacteriophage P1 (Plück, 
1996; Cvetkovic & Sigmund, 2000). The basis of this system are so-called loxP 
(locus of crossing over in P1) sites, specific recognition sites that consist of an 
asymmetric 8 bp long core element that determines direction and two terminal 13 bp 
long palindromic sequences. LoxP sites are specifically recognized by the Cre 
(Causes recombination) recombinase, which mediates site-specific recombination 
(Figure 1.9). If a DNA sequence is surrounded by two loxP sites in identical direction, 
recombination leads to deletion of this region and one loxP site remains. In contrast, 
opposite direction of loxP sites lead to inversion of the flanked region. An alternative 
is the Flp/frt system from the yeast Saccharomyces cerevisiae, which is based on the 
Flp (flippase) recombinase and frt (flippase recognition target) sites in a 
recombination mechanism analogous to the Cre/loxP system (Rodríguez et al., 
2000). To manipulate gene function in mice, target sequences on the exchange 
vector can be flanked by recognition sites and the respective recombinases can be 
expressed under control of specific promoters, which allows development or cell 
type-specific depletion of the target sequence. 
 
 
Figure 1.9 - Schematic illustration of the recombination mechanism mediated by Cre 
and Flp recombinase. Sequence deletion requires flanking of the targeted sequence by two 
loxP/frt sites in the same direction. Direction is determined by the 8 bp asymmetric core 
element and the terminal 13 bp palindromic sequences mediate binding of Cre/Flp 
recombinase monomers. The initial step requires dimerization at each loxP/frt site, before 
recombination is mediated by tetramer formation. The flanked sequence is irreversibly 
excised and released as a covalent ring structure and one loxP/frt site remains in the 
excision locus. (adopted and modified from Cvetkovic & Sigmund, 2000) 
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1.5 Aim of the study 
It was shown that acute depletion of SMSr function in cultured HeLa cells leads to 
ceramide accumulation in the ER and disruption of ER exit sites and Golgi stack 
morphology (Vacaru et al., 2009). Based on these results it was postulated that SMSr 
is an essential regulator of ceramide homeostasis (Vacaru et al., 2009). To test this 
hypothesis it was aimed to deplete SMSr catalytic activity in mice, as in contrast to 
functional SMSr, the catalytically inactive SMSrD348E failed to rescue the phenotype 
in HeLa cells (Vacaru et al., 2009). In the initial mouse line this was accomplished by 
introducing the SMSrD348E point mutation (Ginkel, 2013). In expectance of potential 
embryonic lethality a conditional mouse line was established for specific depletion of 
SMSr exon 6, encoding two catalytically essential amino acids (Bickert, 2011). As 
SMSrD348E mice were born in a Mendelian ratio, exon 6 was ubiquitously depleted. 
The SMSrdelEx6 mice express an SMSrNT-eGFP fusion protein and were used to 
verify the specificity of newly generated antibodies targeting the SMSr C-terminus. 
The antibodies were used to determine the tissue specific expression pattern of 
SMSr in mice. SMSrD348E mice were bred with SMS2gt mice (Liu et al., 2009b) and 
together with wild type and single mutant mice were subjected to mass spectrometric 
analyses to investigate the impact of SMSr and SMS2 on distribution and abundance 
of CPE (and SM) in ten different tissues. The analyses also included determination of 
ceramide and hexosylceramide contents to see whether depletion of SMSr catalytic 
activity affects ceramide metabolism. Moreover, integrity of brain, liver and kidney 
cells in SMSrD348E mice was investigated by electron microscopy. 
 
The implication of ceramides in the development of diet-induced obesity has long 
been proposed (Chavez & Summers, 2012). However, data from in vivo systems are 
scarce. Prior to starting this project, high fat diet-induced obesity was investigated in 
heterozygous CerS2gt and CerS6 deficient mice (Raichur et al., 2014; Turpin et al., 
2014), followed recently by CerS5 deficient mice (Gosejacob et al., 2016). Depletion 
of CerS5 and CerS6 protected from diet-induced obesity associated by increased 
β-oxidation in liver and iBAT, or by decreased lipid accumulation in WAT, 
respectively. In contrast, heterozygous depletion of CerS2 increased susceptibility, 
associated by disturbed β-oxidation in liver. The data suggest that C16 ceramide is 
responsible for the observed phenotypes, as it was decreased in the respective 
tissues of CerS5 and CerS6 deficient mice and increased in heterozygous CerS2gt 
mice. To investigate the function of CerS4 and the corresponding ceramide species, 
CerS4 deficient mice were fed a high fat diet for 16 weeks. Food intake and weight 
gain were measured once a week and glucose and insulin tolerance was determined 
before and after the experiment. After the experiment, the sphingolipid contents were 
quantified by mass spectrometry and CerS and insulin receptor expression was 
investigated in liver, pancreas and iBAT. In addition, energy expenditure and adipose 
tissue development were investigated in 5 week old CerS4 deficient mice. 
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2 Material 
Materials used for this thesis, including chemicals, buffers, media, accessories, 
supplies and devices, unless explicitly mentioned in this section were already 
described before (Bickert, 2011; Ginkel, 2013; Ebel, 2014). 
 
2.1 Antibodies 
Primary antibodies 
Antibodies Host Dilution Company/Reference 
anti-calnexin rabbit 1:200 Abcam 
anti-CerS2 rabbit 1:750 (Kremser et al., 2013) 
anti-CerS4 rabbit 1:300 (Ebel et al., 2014) 
anti-CerS5 sheep 1:2000 (Gosejacob et al., 2016) 
anti-CerS6 mouse 1:500 Santa Cruz Biotechnology 
anti-GAPDH mouse 1:10000 Millipore 
anti-IRβ mouse 1:500 Thermo scientific 
anti-SMSr rabbit 1:1000 (Ginkel, 2013; Bickert et al., 2015; this study) 
anti-V5 mouse 1:1000 Invitrogen 
 
Secondary antibodies 
Antibodies Host Dilution Company/Reference 
anti-mouse (HRP conjugated) goat 1:10000 Dianova 
anti-rabbit (HRP conjugated) goat 1:10000 Dianova 
anti-sheep (HRP conjugated) goat 1:20000 Dianova 
All antibodies were used in immunoblot analyses. HRP - horseradish peroxidase  
 
 
 
 
 
 
 
 
2.2 Primer 
All oligonucleotides were ordered from MWG Eurofins and diluted to 100 pmol/μl. 
Primer Sequence 5'→3' Binding region Application 
SMSr_1 
(forward) 
GAA ACT ACG ACG 
GGC ATT 
 
SMSr; exon 5 
 
SMSrD348E 
PCR 
 
SMSr_2b 
(forward) 
GGC TAA CTG AAA 
CAC GGA AGG 
SMSr; neomycin 
cassette in intron 5 
 
SMSr_3b 
(reverse) 
TTC AGC TCT GTC 
TCA TGT GGC 
SMSr; intron 5, 
downstream of 
neomycin cassette 
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SMSr_loxP_for  
(forward) 
AGC TCT GGT AAT 
TCT CTG GGC 
SMSr; intron 4, 
upstream of 5' loxP 
site 
SMSrdelEx6 
PCR 
SMSr_loxP_rev 
(reverse) 
TCT CAC TTC CTC 
CCT AGT TCC 
 
SMSr; intron 5 
SMSr_eGFP_rev 
(reverse) 
AAG TCG TGC TGC 
TTC ATG TGG 
 
SMSr; eGFP 
SMS2_WT_FP 
(forward) 
GTG GCG GAC AAT 
GGA TAT CA 
SMS2; exon 2, 
upstream of gene 
trap insertion site 
SMS2gt PCR 
SMS2_KO_FP 
(forward) 
GGT GGA TGT GGA 
ATG TGT GC 
 
SMS2; neomycin 
cassette in exon 2 
SMS2_WT&KO_RP 
(reverse) 
TAC GGA CAA AAG 
GTG GTG AG 
SMS2; exon 2, 
downstream of gene 
trap insertion site 
CerS4_E11_for 
(forward) 
CCA CAG CTG AAG 
AAT GGG ATG G 
 
CerS4; exon 11 
CerS4-/- PCR 
CerS4_LacZ_ 
3‟HR_for (forward) 
TCA GTA TCG GCG 
GAA TTC CAG C 
Cers4; LacZ 
upstream of 3‟ 
homology region 
CerS4_ 3‟HR_rev 
(reverse) 
CTC TGG CGC AGA 
GAA TTC ATC G 
 
CerS4; 3‟homology 
region 
Pgk1_for 
(forward) 
GCT GTT CTC CTC 
TTC CTC ATC TCC 
 
Pgk promoter 
PGK-Cre 
PCR 
Int-Cre_rev 
(reverse) 
TCC ATG AGT GAA 
CGA ACC TGG TCG 
 
Cre-recombinase 
coding region 
USP_Flp 
(forward) 
TAA GGT CCT GGT 
TCG TCA GTT TGT 
GG 
Flp-recombinase 
coding region 
Flp PCR 
DSP_Flp 
(reverse) 
GTG ATA TTA TCC 
CAT TCC ATG CGG 
GG 
Flp-recombinase 
coding region 
5' probe_for 
(forward) 
AGA GGT GAT GCA 
TTC CTT GG 
 
SMSr; upstream of 5' 
homology region 
External 
SMSrdelEx6 
5‟ probe 5' probe_rev 
(reverse) 
TGA ACT TCA CTA 
CGA CCT CG 
SMSr; upstream of 5' 
homology region 
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2.2.1 Primer Real Time-PCR 
Primer Sequence 5'→3' Target gene 
aP2 forward TGA AAG AAG TGG GAG TGG GCT TTG C 
aP2 
aP2 reverse CAC CAC CAG CTT GTC ACC ATC TCG T 
Cidea forward ATT TAA GAG ACG CGG CTT TGG GAC A 
CIDEA 
Cidea reverse TTT GGT TGC TTG CAG ACT GGG ACA T 
HPRT forward ACA TTG TGG CCC TCT GTG TGC TCA 
HPRT 
HPRT reverse CTG GCA ACA TCA ACA GGA CTC CTC GT 
PGC1α forward GCA CAC ACC GCA ATT CTC CCT TGT A 
PGC1α 
PGC1α reverse ACG CTG TCC CAT GAG GTA TTG ACC A 
PPARγ2 forward TCC GTA GAA GCC GTG CAA GAG ATC A 
PPARγ 
PPARγ2 reverse CAG CAG GTT GTC TTG GAT GTC CTC G 
UCP1 forward GGT GAA CCC GAC AAC TTC CGA AGT G 
UCP1 
UCP1 reverse GGG TCG TCC CTT TCC AAA GTG TTG A 
 
2.3 Southern blot probes 
Probe Description/Binding region 
External 
SMSrdelEx6  
5' probe 
513 bp PCR fragment amplified from BAC-DNA (see 2.4)/binds 
upstream of 5' homology region 
Internal 
SMSrdelEx6  
probe 
969 bp HincII/XbaI fragment from pDTA+Ex5+3'HR (Bickert, 
2011)/binds in 3' homology region 
 
2.4 Bacterial artificial chromosomes 
BAC Library Description Source 
BMQ-369P9 129S7Ab2.2 
comprises the genomic 
sequence of SMSr 
Sanger institute 
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2.5 Plasmids 
Plasmid Description Company 
pYES2.1/V5-His-TOPO yeast expression vector Invitrogen 
pADTrack-CMV 
shuttle vector for adenovirus 
generation 
Addgene 
pADEasy-1 adenoviral vector Addgene 
 
2.6 Adeno- and lentiviruses 
Virus Description Reference 
Ad. GFP adenovirus expressing GFP 
Dr. Rene 
Jacobs 
(Edmonton) 
Ad. PEMT 
adenovirus expressing 
phosphatidylethanolamine N-methyltransferase 
and GFP 
Dr. Rene 
Jacobs 
(Edmonton) 
rrl156-PGK-Tag 
lentivirus expressing the SV40 T large antigen 
for cell immortalization 
Prof. 
Alexander 
Pfeifer (Bonn) 
 
2.7 Primary and immortalized cells 
Cells Description Reference 
HM1 ES cells (wild 
type) 
mouse embryonic stem cells derived from 
mouse strain Sv129P2/OlaHsd 
(Magin et 
al., 1992) 
HM1 ES cells 
(SMSrD348E) 
HM1 cells heterozygous for SMSrD348E allele 
(Ginkel, 
2013) 
BMDM (wild type) 
bone marrow derived macrophages from 
C57BL/6 mice 
this thesis 
BMDM 
(SMSrdelEx6) 
bone marrow derived macrophages from 
SMSrdelEx6 mice 
this thesis 
MEF (wild type) 
mouse embryonic fibroblasts derived from 
embryos (ED 10.5) of C57BL/6 mice 
this thesis 
MEF (SMSrD348E) 
mouse embryonic fibroblasts derived from 
embryos (ED 10.5) of SMSrD348E mice 
this thesis 
MEF (SMSrdelEx6) 
mouse embryonic fibroblasts derived from 
embryos (ED 10.5) of SMSrdelEx6 mice 
this thesis 
IAY11 yeast cells S. cerevisiae yeast strain 
(Huitema et 
al., 2004) 
IAY11 yeast cells 
(empty vector) 
IAY11 cells transfected with pYES2.1/V5-His-
TOPO expression vector 
(Vacaru et 
al., 2009) 
IAY11 yeast cells 
(mSMSr-V5) 
IAY11 cells transfected with pYES2.1/V5-His-
TOPO expression vector harboring cDNA of 
murine SMSr 
Prof. Joost 
Holthuis 
(Osnabrück) 
IAY11 yeast cells 
(hSMSr-V5) 
IAY11 cells transfected with pYES2.1/V5-His-
TOPO expression vector harboring cDNA of 
human SMSr 
(Vacaru et 
al., 2009) 
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4∆.Lass5 yeast 
cells 
S. cerevisiae yeast strain expressing murine 
CerS5 cDNA instead of endogenous ceramide 
synthases 
(Cerantola 
et al., 2007) 
4∆.Lass5 yeast 
cells (mSMSr-V5) 
4∆.Lass5 yeast cells transfected with 
pYES2.1/V5-His-TOPO expression vector 
harboring cDNA of murine SMSr 
Prof. Joost 
Holthuis 
(Osnabrück) 
Brown adipocytes 
(wild type) 
immortalized mature brown adipocytes 
differentiated from iBAT preadipocytes of new 
born C57BL/6 mice   
this thesis 
Brown adipocytes 
(CerS4-/-) 
immortalized mature brown adipocytes 
differentiated from iBAT preadipocytes of new 
born CerS4-/- mice 
this thesis 
White adipocytes 
(wild type) 
mature white adipocytes differentiated from 
igWAT preadipocytes of 5 week old C57BL/6 
mice 
this thesis 
White adipocytes 
(CerS4-/-) 
mature white adipocytes differentiated from 
igWAT preadipocytes of 5 week old CerS4-/- 
mice 
this thesis 
 
2.8 Transgenic mouse lines 
Mouse line Description Reference 
SMSrD348E 
Insertion of point mutation D348E and 
NLS-lacZ reporter cDNA 
(Ginkel, 2013; Bickert 
et al., 2015; this study) 
SMSrflox 
Insertion of loxP sites flanking exon 5 and 
6 for conditional exchange by an 
exon 5-eGFP fusion sequence  
(Bickert, 2011; Bickert 
et al., 2015; this study) 
SMSrdelEx6 
Exchange of exon 5 and 6 by an 
exon 5-eGFP fusion sequence 
(Bickert, 2011; Bickert 
et al., 2015; this study) 
SMS2gt 
Exchange of exon 2 (including translation 
initiation codon) by neomycin cassette 
(Liu et al., 2009b) 
PEMT-/- 
Exchange of exon 2 (including translation 
initiation codon) by neomycin cassette 
(Walkey et al., 1997) 
Deleter-Flp 
Ubiquitous expression of Flp-recombinase 
under control of the human β-actin 
promoter 
(Rodríguez et al., 
2000) 
Pgk-Cre 
Ubiquitous expression of Cre-recombinase 
under control of the pgk  
promoter 
(Lallemand et al., 
1998) 
CerS4-/- 
Exchange of the whole coding region 
of the cers4 gene by NLS-lacZ cDNA 
(Imgrund, 2011; Ebel, 
2014; Ebel et al., 
2014) 
All mouse lines were in a C57BL/6 background (at least 87.5 %). 
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2.9 Lipid standards 
All lipid standards were ordered from Avanti polar lipids, except for NBD-GlcCer 
(Matreya) and NBD-CPE (generous gift of P. Devaux from Institut de Biologie 
Physico-Chimique, Paris).  
Lipid standard Chain length Application 
Ceramide (Cer) 
d18:1-12:0 MS (Dörmann) 
d18:1-h12:0 MS (Dörmann) 
d18:1-17:0 MS (Dörmann/Somerharju) 
Ceramide phosphoethanolamine 
(CPE) 
d18:1-17:0 MS (Somerharju) 
Sphingomyelin (SM) 
d18:1-12:0 MS (Dörmann) 
d18:1-17:0 MS (Dörmann) 
d18:1-15:0 MS (Somerharju) 
Hexosylceramide (HexCer) 
Glc-d18:1-12:0 MS (Dörmann) 
Gal-d18:1-24:1 MS (Dörmann) 
Gal-d18:1-15:0 MS (Somerharju) 
Long chain bases (LCBs) 
d17:1 MS (Dörmann) 
d16:0 MS (Dörmann) 
d20:0 MS (Dörmann) 
Phosphatidylcholine (PC) di20:1 MS (Somerharju) 
Phosphatidylethanolamine (PE) di22:1 MS (Somerharju) 
Phosphatidylinositol (PI) di16:0 MS (Somerharju) 
Phosphatidylserine (PS) di14:1 MS (Somerharju) 
NBD-Ceramide d18:1-6:0 TLC 
NBD-CPE d18:1-6:0 TLC 
NBD-GlcCer d18:1-6:0 TLC 
NBD-SM d18:1-6:0 TLC 
Cholesterol (Chol) 
 
TLC 
Diacylglycerol (DAG) 
 
TLC 
Triacylglycerol (TAG) 
 
TLC 
d refers to two hydroxy groups in the sphingoid backbone; h refers to a hydroxylated 
fatty acyl chain; Gal - galactose; Glc - glucose  
 
 
 
 
 
 
 
 
 
 
 
Material 
 
40 
 
2.10 Buffers 
Buffer R 20 mM  HEPES-KOH (pH 7.2) 
 15 mM  KCl 
 5 mM  NaCl 
 250 mM  Sucrose 
 1 mM  PMSF 
 0.1 % (v/v)  PIC 
PMSF (phenylmethanesulfonylfluoride; 200 x stock 34,8 mg/ml in isopropanol) and 
PIC (protease inhibitor cocktail; 1000 x stock in DMSO containing 1 mg/ml aprotinin, 
1 mg/ml leupeptin, 1 mg/ml pepstatin, 5 mg/ml antipain, 157 mg/ml benzamidine) 
were added right before use. 
 
Modified RIPA buffer 150 mM  NaCl 
(pH 7.4)     50 mM  Tris-HCl 
 1 mM  EDTA 
 1 mM  NaF 
     1 % (v/v)  NP-40 
 0.25 % (w/v)  Na-deoxycholate 
 1 mM  PMSF 
 1 tablet/ml  Complete® (Roche) 
Buffer was autoclaved and PMSF and Complete® protease inhibitor cocktail were 
added right before use. 
 
2.11 Cell culture media 
All media and supplements were cell culture grade or stock solutions were 
autoclaved/sterile filtered before use. 
 
DMEM(+)   DMEM (Dulbecco‟s Modified 
Eagle Medium)-GlutaMAX; 
4500 mg/L glucose; Gibco) 
 10 %  Fetal calf serum (FCS) 
 1 %  Penicillin/Streptomycin (P/S) 
For brown adipocytes (B) DMEM with pyruvate and for white adipocytes (W) DMEM 
without pyruvate was used. 
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Collagenase digestion buffer-B 123 mM  NaCl 
(pH 7.4)     5 mM  KCl 
 1.3 mM  CaCl 
 100 mM  HEPES 
     5 mM  Glucose 
 1.5 % (w/v)  BSA (Bovine serum albumin) 
 0.2 % (w/v)  Collagenase type II 
(Worthington) 
    
Culture medium-B   DMEM(+) 
 10 nM  HEPES 
 4 nM  Insulin (Sigma) 
 4 nM  Triiodothyronine (T3; Sigma) 
 25 µg/ml  L-Ascorbat (Sigma) 
    
Differentiation medium-B   DMEM(+) 
 20 nM  Insulin 
 1 nM  T3 
    
Induction medium-B   Differentiation medium-B 
 500 µM  Isobutylmethylxanthine (Sigma) 
 1 µM  Dexamethasone (Sigma) 
    
Collagenase digestion buffer-W   DMEM 
 0.5 % (w/v)  BSA 
 0.15 % (w/v)  Collagenase type II 
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Maintenance medium-W   DMEM 
 5 %  FCS 
 1 %  P/S 
 1 µg/ml  Insulin 
 1 nM  T3 
 0.1 %  ABP 
ABP: 50 mg/ml L-ascorbate, 1 mM d-biotin and 17 mM pantothenate (all Sigma) 
    
Induction medium-W   Maintenance medium-W 
 500 µM  Isobutylmethylxanthine 
 0.25 µM  Dexamethasone 
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3 Methods 
Applied methods that are not explicitly mentioned in this section were conducted as 
described before (Bickert, 2011; Ginkel, 2013; Ebel, 2014). 
 
3.1 Nucleic acid analysis 
3.1.1 Mouse genotyping 
Genotyping of transgenic mice was performed by PCR. Reaction mixtures and 
programs are listed in tables below. Concentrations were as follows: MgCl2 (25 mM), 
primer (0.1 mM), dNTPs (10 mM each), GoTaq-Polymerase (5 U/μl; Promega). 
Expected fragment sizes for the respective alleles are indicated below the 
corresponding tables. 
 
SMSrD348E genotyping PCR: 
 
 
 
 
 
Fragment sizes: SMSr wild type allele, 393 bp; SMSrD348E allele, 580 bp, 
SMSrD348ENeo allele, 493 bp. 
 
SMSrflox genotyping PCR: 
 
 
 
 
 
Fragment sizes: SMSr wild type allele, 386 bp; SMSrflox allele, 451 bp; SMSrdelEx6 
allele, 707 bp. 
 
 
Components Volume 
Go-Taq buffer (5x) 5 µl 
MgCl2 1 µl 
dNTPs 0.5 µl 
Primer: SMSr_1 0.2 µl 
Primer: SMSr_2b 0.2 µl 
Primer: SMSr_3b 0.2 µl 
H20 16.7 µl 
Go-Taq polymerase 0.2 µl 
DNA 1 µl 
Temperature Time Cycles 
95°C 5 min 1 
95°C 45 s 
35 65°C 45 s 
72°C 45 s 
72°C 10 min 1 
Temperature Time Cycles 
95°C 5 min 1 
95°C 45 s 
35 56°C 45 s 
72°C 60 s 
72°C 10 min 1 
Components Volume 
Go-Taq buffer (5x) 5 µl 
MgCl2 1 µl 
DMSO 0.5 µl 
dNTPs 0.5 µl 
Primer: SMSr_loxP_for 0.2 µl 
Primer: SMSr_loxP_rev 0.2 µl 
Primer: SMSr_eGFP_rev 0.2 µl 
H20 16.2 µl 
Go-Taq polymerase 0.2 µl 
DNA 1 µl 
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SMS2gt genotyping PCR: 
 
 
 
 
Fragment sizes: SMS2 wild type allele, 252 bp; SMSgt allele, 354 bp. 
 
CerS4 genotyping PCR: 
 
 
 
 
Fragment sizes: CerS4 wild type allele, 400 bp; CerS4-/- allele, 539 bp. 
 
Flp genotyping PCR: 
 
 
 
Fragment size: Flp recombinase allele, 1200 bp. 
 
 
 
 
 
Components Volume 
Go-Taq buffer (5x) 5 µl 
MgCl2 1.5 µl 
dNTPs 0.5 µl 
Primer: SMSr_loxP_for 0.2 µl 
Primer: SMSr_loxP_rev 0.2 µl 
Primer: SMSr_eGFP_rev 0.2 µl 
H20 16.2 µl 
Go-Taq polymerase 0.2 µl 
DNA 1 µl 
Temperature Time Cycles 
94°C 5 min 1 
94°C 60 s 
30 58°C 60 s 
72°C 60 s 
72°C 7 min 1 
Components Volume 
Go-Taq buffer (5x) 5 µl 
MgCl2 1 µl 
dNTPs 0.2 µl 
Primer: CerS4_E11_for 0.2 µl 
Primer: CerS4_LacZ_3‟HR_for 0.2 µl 
Primer: CerS4_3‟HR_rev 0.4 µl 
H20 16.8 µl 
Go-Taq polymerase 0.2 µl 
DNA 1 µl 
Temperature Time Cycles 
95°C 5 min 1 
95°C 60 s 
35 65°C 60 s 
72°C 60 s 
72°C 10 min 1 
Components Volume 
Go-Taq buffer (5x) 5 µl 
MgCl2 2 µl 
dNTPs 1 µl 
Primer: USP_Flp 0.2 µl 
Primer: DSP_Flp 0.2 µl 
H20 15.25 µl 
Go-Taq polymerase 0.25 µl 
DNA 1 µl 
Temperature Time Cycles 
96°C 5 min 1 
95°C 60 s 
34 58°C 60 s 
72°C 90 s 
72°C 10 min 1 
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Pgk-Cre genotyping PCR: 
 
 
 
Fragment size: Pgk-Cre recombinase allele, 500 bp. 
 
3.1.2 Southern blot analysis 
Southern blot analysis was performed as already described previously (Bickert, 
2011). For analysis of SMSrdelEx6 mice, genomic DNA from livers of homozygous, 
heterozygous and wild type mice was extracted and digested with XmnI. After 
electrophoretic separation DNA was transferred to Hybond-N+-membranes 
(Amersham Biosciences) and cross-linked by UV light exposure. External and 
internal probe (see chapter 2.3) were radioactively labeled with α-32P-dCTP 
(Hartmann Analytik) and incubated with the membrane in QuickHyb solution 
(Stratagene) at 68°C for 2 h. 
 
3.1.3 Real Time-PCR analysis 
For quantitative Real Time (RT)-PCR analysis, total RNA from cultured adipocytes 
was isolated using Trizol® (Invitrogen) according to the manufacturer‟s instructions. 
For reverse transcription of RNA to complementary DNA (cDNA) the Transcriptor 
First Strand Synthesis Kit (Roche) was used according to the manufacturer‟s 
instructions. PCR was done with SYBR-Green (Roche) using a HT7900 FAST Real 
Time-PCR system (Applied Biosystems). Fold changes were calculated using relative 
quantification methods (∆∆Ct algorithm). HPRT (hypoxanthine guanine 
phosphoribosyl transferase) served as internal control. Primer sequences are listed in 
chapter 2.2.1. 
 
3.2 Protein analysis 
3.2.1 Affinity chromatography of antisera 
For the generation of polyclonal antibodies targeting the SMSr protein, rabbits were 
immunized with an internal peptide (CWPFSKPAIMKRLIG) and a C-terminal peptide 
(CDGPIPDLSSDQYQY) of the mouse SMSr protein. Peptides were synthesized by 
Prof. Marten Egmond (Utrecht) and Pineda Antibody Service (Berlin) was responsible 
for immunization. For affinity chromatography of rabbit antisera two 
N-hydroxysuccinimide columns were loaded with the internal or the C-terminal 
Components Volume 
Go-Taq buffer (5x) 5 µl 
MgCl2 2 µl 
dNTPs 0.2 µl 
Primer: Pgk1_for 0.2 µl 
Primer: Int-Cre_rev 0.2 µl 
H20 16.3 µl 
Go-Taq polymerase 0.1 µl 
DNA 1 µl 
Temperature Time Cycles 
94°C 5 min 1 
94°C 30 s 
35 60°C 50 s 
72°C 90 s 
72°C 10 min 1 
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peptide, respectively (Ginkel, 2013). Antibody purification was essentially done as 
previously described (Ginkel, 2013), using either the column with the internal peptide 
or the column with the C-terminal peptide. Antibodies were eluted with 0.2 M glycine 
(pH 3) and collected in tubes with 0.5 ml 1 M Tris (pH 7.25) per 2 ml eluate. 
 
3.2.2 Immunoblot analysis 
For immunoblot analyses mouse tissues were homogenized in 1 ml/g wet weight of 
modified RIPA buffer using a Precellys® homogenizer (Peqlab Biotechnology). Cell 
debris was removed by centrifugation at 13,000g for 10-20 min at 4°C. For adipose 
tissue, supernatant centrifugation was repeated to avoid transferring excess lipids. 
For cell lysates, MEFs or BMDMs were grown on 10 cm plates and at 80-100 % 
confluence medium was removed and cells were washed with PBS. Subsequently, 
cells were scraped, diluted in 200 µl modified RIPA buffer and passed 10 times 
through a 27G needle. Protein concentration of tissue and cell lysates was 
determined using a BCA assay kit (Sigma-Aldrich). Depending on tissue or cell type 
25-50 µg of protein were mixed with urea buffer (40 mM Tris-HCl, 9 M urea, 1 mM 
EDTA, 5 % SDS, 5 % (v/v) ß-mercaptoethanol, 0.01 % (w/v) bromophenol blue, pH 
6–8) heated for 15 min at 65°C and separated by SDS-PAGE (12 %). Blotting onto 
nitrocellulose membranes (Hybond-ECL, GE Healthcare) was performed in transfer 
buffer (20 mM TrisBase, 150 mM glycine, 20 % methanol) for 1 h at 100 V. Transfer 
was checked by Ponceau S staining before membranes were incubated with blocking 
solution (5 % milk powder in TBS-T) for 1 h at RT to prevent unspecific binding. All 
antibodies were diluted to the appropriate concentrations (see chapter 2.1) in 
blocking solution. Incubation with primary antibody solution was done overnight at 
4°C, following three consecutive washing steps with TBS-T. Subsequently, 
membranes were incubated with secondary antibody solution for 1 h at RT. After 
repeated washing with TBS-T membranes were incubated with Amersham ECL 
Prime Western Blotting Detection Reagent (GE Healthcare) and developed using 
VersaDoc Imaging System (Bio-Rad). 
 
3.2.3 CPE/SM synthase activity assay 
Brain (0.4 g) and liver (0.6 g) tissue samples from 10 week old mice were 
homogenized in 800 µl ice cold buffer R using a Precellys® homogenizer (Peqlab 
Biotechnology). Cell debris was removed by centrifugation at 960 g for 10 min at 4°C 
and microsomal fractions were obtained by centrifugation of the supernatant at 
100,000 g for 1 h at 4°C. The microsomal pellet was resuspended in 0.5-1 ml 
buffer R and passed 20 times through a 27G needle, aliquots were frozen in liquid 
nitrogen and stored at -80°C. Protein concentration was determined using the BCA 
assay kit (Sigma-Aldrich). To ensure that microsomal fractions contained comparable 
amounts of ER membranes, protein expression of the ER marker calnexin was 
determined by immunoblot analysis as described in chapter 3.2.2. 
Methods 
47 
 
Microsomes were diluted in a total volume of 400 µl ice cold buffer R including 0.1 % 
v/v of 1000x PIC (final protein concentration: 2 mg/ml and 3.7 mg/ml for brain and 
liver microsomes, respectively) and kept on ice in 15 ml pyrex screw cap glass tubes 
(VWR). To this suspension N-ethylmaleimide (NEM) was added to a final 
concentration of 0.5 mM (100 mM stock solution in ethanol), to inhibit endogenous 
SMase activity. After this, C6-NBD-ceramide (NBD-Cer; (6-((N-(7-Nitrobenz-2-Oxa-
1,3-Diazol-4-yl)amino)hexanoyl) sphingosine; Molecular Probes); 2 mM stock in 
ethanol) was added to a final concentration of 2.5 µM. Samples were kept on ice for 
10 min, allowing incorporation of NBD-Cer into microsomal membranes. The reaction 
was started by shifting the samples to 37°C for 2 h under continuous shaking. 
Following incubation the reaction was stopped by addition of 1 ml methanol and 
0.5 ml chloroform, and vigorous vortexing. Lipids were extracted by further addition of 
0.5 ml chloroform and 0.5 ml 0.45 % NaCl, and vigorous vortexing. Following 
centrifugation at 3,000 g for 5 min at RT the lower organic phase was transferred to a 
fresh tube. The upper phase was re-extracted with 1 ml chloroform and after 
vortexing and another centrifugation step the lower phases were pooled. The 
combined organic phase was washed with 2 ml methanol/0.45 % NaCl (1:1 v/v) and 
following centrifugation the lower organic phase was transferred to a fresh tube and 
evaporated under a stream of nitrogen. 
 
For TLC (thin layer chromatography) analysis, lipids were redissolved in a suitable 
volume of chloroform/methanol (2:1 v/v). Samples together with NBD-Cer, NBD-CPE, 
NBD-GlcCer and NBD-SM lipid standards were applied to a TLC plate (NANO-
ADAMANT #821150; Macherey & Nagel) using the Linomat 5 (022.7808; CAMAG), 
operated at a dosage speed of 120 nl/s from a 100 µl syringe (Hamilton). The TLC 
plate was developed using an ADC2 TLC developer (CAMAG). The procedure 
comprised two consecutive 1D-runs. In the first run acetone was used to elute the 
excess NBD-Cer. In the second run chloroform/methanol/25 % ammonia (50:25:6 
v/v/v) was used in the same dimension to separate the reaction products NBD-SM 
and NBD-CPE. 
 
After drying the TLC plate, NBD-lipid species were visualized by scanning on a 
Typhoon FLA 9500 imager (laser 473 nm, filter setting BPB1, PMT 290 V; GE 
Healthcare) at a resolution of 50 µm pixel size. Using Imagequant software (GE 
Healthcare), images were contrast-adjusted and exported to TIFF format. 
 
3.3 Analysis of PEMT-mediated conversion of CPE in mouse liver 
For the construction of a recombinant adenovirus expressing 
phosphatidylethanolamine N-methyltransferase (PEMT) a cDNA encoding human 
PEMT was subcloned into a pADTrack-CMV shuttle vector. The vector was linearized 
with PmeI and inserted into an adenovirus using pADEasy-1 system for homologous 
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recombination in E. coli. The Ad.PEMT adenovirus expressed PEMT and GFP. An 
Ad.GFP adenovirus expressing only GFP was used as a control. 
 
Prior to infection, male wild type and PEMT deficient mice were given a standard diet 
ad libitum (#5001, LabDiet)(Jacobs et al., 2010). In 8 week old mice a single dose of 
Ad.GFP or Ad.PEMT (1.0 x 109 plaque-forming units) was injected into the tail vein. 
Seven days after injection mice were fasted and anesthetized with metofane 
(Pitmann-Moore Inc.) for tissue dissection. All procedures were approved by the 
University of Alberta‟s Institutional Animal Care Committee in accordance with 
guidelines of the Canadian Council on Animal Care. 
 
The influence of the adenoviral infection on liver CPE content was investigated by 
mass spectrometry as described in chapter 3.4.1. PEMT activity in the liver was 
determined as previously described (Ridgway & Vance, 1992). 
 
3.4 Lipid analysis 
3.4.1 Mass spectrometric analyses (Somerharju group) 
Tissues were homogenized in a small volume of water using a Precellys® 
homogenizer (Peqlab Biotechnology). Lipids were extracted according to Folch et al. 
(Folch et al., 1957) and lipid standards (see chapter 2.9) were added at the one-
phase stage of extraction. After evaporation of the solvents, the lipids were dissolved 
in methanol/chloroform (2:1 v/v) and for normalization the phosphate contents of the 
extracts were determined as described before (Bartlett & Lewis, 1970), samples were 
stored at -20°C. Glycerophospholipids, ceramides and hexosylceramides were 
quantified using direct infusion of the samples into the electrospray source of a 
Quattro Premier triple-quadrupole mass spectrometer (Waters Inc.) operated in the 
MS/MS mode. Analytes and internal standards were detected based on class-specific 
precursor ion (PC, PI, ceramide, hexosylceramide) or neutral loss (PE, PS) scanning 
as described previously (Kainu et al., 2010). Data were analyzed with Microsoft Excel 
using the LIMSA add-on (Haimi et al., 2006). 
 
For quantification of CPE and SM, a volume of the lipid extract corresponding to 
100 nmol of lipid phosphate was taken to dryness and dissolved in 1.5 ml methanol. 
Then 0.5 ml chloroform/methanol (9:1 v/v) containing C15:0-SM (1 nmol) and 
C17:0-CPE (0.25 nmol) standards (see chapter 2.9) and 0.5 ml NaOH (0.3 M) were 
added and samples were incubated overnight at RT. The solution was neutralized by 
addition of 0.3 ml HCl (0.3 M). Subsequently 3.5 ml chloroform and 1.2 ml water were 
added followed by vigorous vortexing. After centrifugation for 10 min at 3,000 rpm the 
upper phase was removed and the lower organic phase was washed twice with 
3.5 ml of theoretical Folch upper phase (Folch et al., 1957). After evaporating the 
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solvents under a stream of nitrogen, lipids from the lower phase were dissolved in 
0.2 ml methanol, transferred to conical MS vials, dried and dissolved in 40 µl LC-MS 
quality methanol and stored at -20°C. 
 
CPE and SM species were quantified using LC-MS. Chromatographic separation was 
carried out in the gradient mode using an Acquity Ultra Performance LC system 
equipped with an Acquity BEH-C18 1.0 × 150 mm column (Waters Inc.). The column 
temperature was 60°C and the flow rate 0.13 ml/min. Solvent A was 
acetonitrile/water (60:40 v/v) containing 10 mM ammonium formate and 1 % NH4OH, 
solvent B consisted of isopropanol/acetonitrile (90:10 v/v) containing 10 mM 
ammonium formate and 1 % NH4OH. The gradient started from 40 % B, changed 
linearly to 70 % B in 10 min and then to 100 % B in 4 min. After 2 min at 100 %, B 
changed to 40 % in 3 min and was kept there for 3 min prior to the next injection. For 
CPE and SM detection, the column eluent was infused to the ESI source of the 
Quattro Premier mass spectrometer operated in the positive ion mode using selective 
reaction monitoring (SRM). CPE species were detected based on neutral loss of m/z 
141 and SM species based on precursor ion scan/EIC of m/z 184. Peak areas of SM 
and CPE species and standards were obtained from the SRM chromatograms using 
QuanLynx software (Waters Inc.) and concentrations of molecular species and 
classes were determined with Microsoft Excel. 
 
3.4.2 Mass spectrometric analyses (Dörmann group) 
Tissues were homogenized in a small volume of water using a Precellys® 
homogenizer (Peqlab Biotechnology). Homogenates were transferred to Pyrex screw 
cap tubes and filled up with water to a final volume of 2 ml. The protein concentration 
for normalization was determined using BCA assay kit (Sigma-Aldrich). For lipid 
extraction 5 ml chloroform and 2.5 ml methanol, together with 50 µl lipid standard 
mixture (see chapter 2.9) were added and samples were vigorously vortexed. 
Samples were incubated overnight at 37°C under continuous shaking. Following 
incubation, samples were centrifuged at 5,300 rpm for 20-30 min at RT. Supernatants 
were transferred to fresh tubes and evaporated under a stream of nitrogen. For the 
second extraction step 5 ml chloroform/methanol 1:1 (v/v) were added to the 
remaining tissue pellet and samples were incubated as described above. For the 
third extraction step 5 ml chloroform/methanol 1:2 (v/v) were used. The supernatants 
resulting from each extraction step were pooled with the extracted lipids from the first 
step and solvents were evaporated under nitrogen. 
 
For alkaline hydrolysis, lipid extracts were dissolved in 2 ml chloroform/methanol 1:1 
(v/v) and mixed with 150 µl 1 M KOH in methanol. Following incubation for 2 h at 
40°C samples were neutralized with 6 µl acetic acid. Desalting of lipid extracts was 
performed essentially as described before (Brodesser, 2007). 
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Neutral sphingolipids were quantified by quantitative Time of Flight mass 
spectrometry (Q-TOF-MS). Lipid extracts were dissolved in Q-TOF solvent 
(methanol/chloroform/300 mM ammonium acetate (665:300:35, v/v/v)(Welti et al., 
2002)) and measured via direct infusion using an Agilent HPLC-Chip Cube MS 
interface coupled to an Agilent 6530 Accurate-Mass Q-TOF LC/MS instrument as 
previously described (Wewer et al., 2011; Ginkel et al., 2012). Sphingolipids were 
ionized in the positive mode and quantified after collision-induced dissociation by 
scanning for characteristic fragment ions (Ginkel et al., 2012). 
 
3.4.3 Thin layer chromatographic analysis of mouse feces 
Collected mouse feces were stored at –80°C. Prior to sample preparation feces and 
diet samples (control) were thawed and dried for 1 h at 37°C. Dried samples were 
grounded using mortar and pestle. Lipid extraction was performed according to the 
method of Bligh and Dyer (Bligh & Dyer, 1959). For that 100 mg of the grounded 
samples were suspended in 0.4 ml water in Pyrex screw cap tubes. To the 
suspension 1.5 ml chloroform/methanol 1:2 (v/v) were added, followed by vigorous 
vortexing. In the next step 0.5 ml chloroform were added and the mixture was 
vigorously vortexed. Then 0.5 ml water were added, followed by vigorous vortexing. 
Following extraction samples were centrifuged at 2,500 rpm for 10 min at RT. The 
lower organic phase was transferred to a fresh tube and solvents were evaporated 
under a stream of nitrogen. 
 
For TLC analysis lipid extracts were dissolved in 100 µl chloroform/methanol 1:1 (v/v) 
and 5 µl together with lipid standards for cholesterol, DAG and TAG (see chapter 2.9) 
were applied to a TLC plate (HPTLC Silica gel 60; Merck). TLC plates were 
developed in n-hexane/diethylether/acetic acid 70:30:1 (v/v/v) as previously 
described (Bauer et al., 2009). After thoroughly drying, TLC plates were incubated in 
a solution of 10 % CuSO4 and 8 % H2PO4 and heated to 180°C for 15 min to visualize 
lipids (Yao & Rastetter, 1985). 
 
3.5 Histological analysis 
3.5.1 β-galactosidase staining 
Cryostat sectioning of mouse tissues and β-galactosidase staining of tissue sections 
and cultured cells was essentially done as previously described (Degen, 2003). 
 
3.5.2 H&E staining 
Adipose tissue samples were fixed in 4 % paraformaldehyde in PBS for 24 h at 4°C 
and then embedded in paraffin. Paraffin embedding, microtome sectioning and H&E 
staining was essentially done as previously described (Schütz, 2011). 
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3.5.3 Electron microscopy 
Wild type and SMSrD348E mice were anesthetized with Florene® (AbbVie) and fixed 
by transcardial perfusion via the left ventricle with 2.5 % glutaraldehyde in 0.1 M 
cacodylate buffer. After fixation small pieces of liver, brain and kidney were incubated 
in 1 % (w/v) osmium tetroxide. After washing in cacodylate buffer samples were 
treated with 30 % and 50 % ethanol and subsequently incubated in 1 % uranyl 
acetate in 70 % ethanol for 6 min in the dark. Following incubation samples were 
dehydrated in a graded series of ethanol and propylenoxide and embedded in 
EPON® (Polysciences) according to the manufacturer‟s protocol. Ultrathin sections 
were obtained with an UltracutE® ultramicrotome (Reichert-Jung) and mounted on 
copper grids. Grids were incubated with 1 % uranyl acetate for 20 min and with 0.4 % 
lead citrate for 3 min. Samples were investigated using a transmission electron 
microscope (EM 902A; Zeiss). Digital image acquisition was performed using a 
MegaViewII slow-scan-CCD camera and ITEM® 5.0 software (Soft-imaging-systems). 
Images were stored as uncompressed TIFF files in 16 bits of gray and were 
processed with Photoshop® CS5 (Adobe). 
 
3.6 Isolation and culture of primary cells 
Isolation and culture of primary cells was performed as previously described: bone 
marrow derived macrophages (Ebel, 2014), mouse embryonic fibroblasts (ED 10.5) 
(Klahre, 2012), culture of embryonic stem (ES) cells (Bickert, 2011) and culture of 
yeast cells (Vacaru et al., 2009). 
 
3.6.1 Isolation and differentiation of brown preadipocytes 
For in vitro differentiation of brown preadipocytes, the stromal vascular fraction (SVF) 
containing preadipocytes was isolated from interscapular brown adipose tissue 
(iBAT) of newborn wild type and CerS4 deficient littermates (iBAT samples from 2-3 
animals per genotype were pooled). All steps were conducted under sterile 
conditions in a laminar flow hood. Adipose tissue samples were transferred into 
collagenase digestion buffer-B and cut into small pieces. The suspension was 
incubated for 30 min at 37°C and vortexed every 5 min. The suspension was filtered 
through a 100 µm nylon mesh to remove undigested tissue remnants, and incubated 
on ice for 30 min. The infranatant containing the SVF was filtered through a 30 µm 
nylon mesh, and SVF cells were pelleted by centrifugation at 700 g for 10 min at RT. 
Cells were resuspended in culture medium-B, seeded on 6-well plates (5.7 x 105 cells 
per well) and incubated at 37°C and 5 % CO2.  
 
One day following isolation (passage 0), brown preadipocytes were immortalized by 
infection with a lentivirus containing the SV40 T large antigen (rrl156-PGK-Tag), 
which elicits cellular transformation. For this purpose, medium was exchanged with 
DMEM(+) containing 0.25 ng/µl virus (800 µl per well). Cells were incubated 
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overnight and the next day, 3 ml DMEM(+) were added. Medium was replenished 
every second day and at 90 % confluence cells were splitted. 
 
For differentiation to mature brown adipocytes, 1.8 x 105 cells per well were seeded 
on 6-well plates. Two days after seeding, medium was exchanged with differentiation 
medium-B. Adipogenesis was induced by treating confluent cultures four days after 
seeding with induction medium-B for 48 hours. After this, cells were cultured in 
differentiation medium, which was replenished every second day until day 7 or 8 past 
induction. For stimulation, mature cells were incubated for 8 h in DMEM(+) containing 
200 µM cGMP (pCPT-cGMP; Biolog). 
 
3.6.2 Isolation and differentiation of white preadipocytes 
For in vitro differentiation of white preadipocytes, the SVF was isolated from inguinal 
white adipose tissue (igWAT) of 5 week old wild type and CerS4 deficient littermates 
(igWAT samples from 3 animals per genotype were pooled). After igWAT dissection, 
all steps were conducted under sterile conditions in a laminar flow hood. After 
removal of lymph nodes, igWAT samples were minced and suspended in 
collagenase digestion buffer-W (7 ml/g wet weight). The suspension was incubated 
for 30 min at 37°C and vortexed every 5 min. After this, DMEM(+) was added to a 
total volume of 14 ml. After 10 min at RT the infranatant was transferred to a fresh 
tube and SVF cells were pelleted by centrifugation at 700 g for 10 min at RT. The 
pellet was resuspended in DMEM(+) (2 ml/g adipose tissue) and the suspension was 
filtered through a 100 µm nylon mesh. Cells were seeded in T175 flasks and 
incubated at 37°C and 5 % CO2. At 70-80 % confluence, cells were splitted for 
differentiation.  
 
For differentiation to mature white adipocytes, cells were grown to confluence and 
after two days medium was exchanged by induction medium-W for seven days. 
Following this, cells were grown in maintenance medium-W for 5 days. Media were 
replenished every second day. For experiments, cells were splitted to 6-well plates 
(0.2 x 103 cells per well) and incubated for one day. For stimulation, mature cells 
were incubated for 8 h in DMEM(+) containing 200 µM cGMP or 1µM noradrenaline 
(Sigma), respectively. 
 
3.7 Physiological activation of energy expenditure in mice 
5 week old wild type or CerS4 deficient mice were fasted for 2 h and then put into 
Phenomaster cages (TSE Systems) at 4°C. Oxygen consumption was measured for 
100 s every 5 min for 1 h. Oxygen consumption, motility and food intake of wild type 
and CerS4 deficient animals was measured for 120 s every 18 min for 24 h at 23°C 
and 5 h at 30°C, respectively. 
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3.8 Feeding experiments 
Wild type (WT) and CerS4 deficient (KO) mice originated from homozygous WT and 
KO breedings, respectively. To retain comparability, littermates from heterozygous 
breedings were cross-bred (i.e. WT litter 1 X WT litter 2 and KO litter 1 X KO litter 2 
etc.) to obtain experimental animals. 
 
Experimental animals were exclusively male, started at the age of 7-8 weeks and 
were fed either a high fat diet (HFD; 60 % kcal from fat; C1090-60; Altromin) or a low 
fat diet (LFD; 10 % kcal from fat; C1090-10, Altromin) for 16 weeks. Each group (WT 
HFD, KO HFD, WT LFD and KO LFD) consisted of 20-25 mice. Mice were given 
access to food and water ad libitum and animal and food weight was determined 
once a week. Before and after the 16 week feeding period animals were subjected to 
glucose and insulin tolerance tests. After 5 weeks feces were collected for TLC 
analysis of excreted lipids. At the end of the experiment animals were anesthetized 
with Florene® (AbbVie) and transcardially perfused with PBS. Tissues were 
dissected, frozen on dry ice and stored at -80°C. 
 
3.8.1 Glucose tolerance test (GTT) 
Prior to starting GTTs mice were transferred to fresh cages and fasted for 6 h with 
free access to water during the whole procedure. After fasting, animals were weighed 
and the appropriate volume of 10 % glucose solution (Braun) for injection of 1 g 
glucose per kg mouse weight was determined. To measure basal glucose levels the 
tail vein was punctured 1-2 cm proximal of the tail tip with a sterile 20G Sterican® 
needle (0.9 x 60 mm; Braun), the first blood was wiped away and the next drop was 
measured using an Accu-Chek® Aviva glucometer (Roche) according to the 
manufacturer‟s instructions. Immediately after this, mice were intraperitoneally 
injected with the appropriate volume of glucose solution using a sterile 1 ml Inject® F 
syringe (Braun) equipped with a sterile 24G Sterican® needle (0.55 x 25 mm; Braun). 
Glucose levels were determined 15, 30, 60, 90 and 120 min after injection. For each 
measurement clotted blood was rubbed away and blood was obtained by gently 
pressing it towards the punctured site, the first drop was discarded before measuring 
as described above. After the last measurement animals were supplied with food. 
 
3.8.2 Insulin tolerance test (ITT) 
For ITTs mice were transferred to fresh cages and were not fasted to avoid potential 
hypoglycemia. Food was removed only before starting the measurements and free 
access to water was given during the whole procedure. Animals were weighed and 
the appropriate volume for injection of 0.75 U/kg insulin (Insuman; Sanofi Aventis; 
100 U/ml freshly diluted to 0.1 U/ml in sterile PBS before use) was determined. 
Glucose measurements and injections were conducted as described in the previous 
chapter. Glucose levels were determined 15, 30, 45 and 60 min after insulin injection. 
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In case of hypoglycemia mice were intraperitoneally injected with 150 µl 10 % 
glucose solution and were excluded from data analysis. After the last measurement 
animals were supplied with food.  
 
3.9 Mouse handling 
Animals were kept under standard conditions with a 12 h dark to light cycle with food 
and water ad libitum. Prior to dissection animals were anesthetized with Florene® 
(AbbVie) and transcardially perfused with PBS as previously described (Requardt et 
al., 2009). For serum analyses blood was collected by cardiac puncture from mice 
anesthetized with Florene® (Parasuraman et al., 2010), followed by immediate 
cervical dislocation. All housing and experimental conditions were in accordance to 
instructions of local and state authorities. 
 
3.10 Statistical analyses and image processing 
Data were processed using Microsoft Excel. For graphical presentation and statistical 
analyses Graph Pad Prism 5 software (Graph Pad Software) was used. Statistical 
significance for two group comparisons was determined by two-tailed Student’s t test. 
If not mentioned otherwise, multiple group comparisons were done using two-way 
analysis of variance (ANOVA) with Bonferroni post-hoc tests. Differences were 
considered statistically significant when p<0.05. Images were processed using 
Photoshop® CS5 (Adobe) and densitometric analysis was done using Fiji software.
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4 Results 
4.1 Characterization of transgenic mice lacking SMSr catalytic activity 
As SMSr catalytic activity proved to be essential for preventing ceramide 
accumulation and overall integrity in HeLa cells (Vacaru et al., 2009), it was aimed to 
deplete SMSr catalytic activity in mice to study the in vivo function of SMSr. 
 
The mouse smsr (or samd8) gene comprises six exons and is located on 
chromosome 14. The activity of the protein is depending on a catalytic triad of two 
histidine (H301 and H344) and one aspartate (D348) residues (Huitema et al., 2004; 
Tafesse et al., 2006), two of these residues are encoded by exon 6 (H344 and 
D348). In consequence of the results of (Vacaru et al., 2009), a very severe 
phenotype was expected for mice lacking SMSr catalytic activity, therefore it was 
decided to generate two different mouse lines. In the beginning, Dr. Christina Ginkel 
from our group generated SMSrD348E mice, these mice ubiquitously express the 
D348E point mutation, that was shown to lead to catalytic inactivity of SMSr in 
cultured HeLa cells (Vacaru et al., 2009). To circumvent possible embryonic lethality 
and to investigate SMSr function after tissue-specific depletion of SMSr catalytic 
activity, an additional mouse line for conditional deletion of exon 6 was generated 
during my diploma thesis (SMSrflox). For this Ph. D thesis these mice were 
crossbred with mice expressing Cre recombinase to generate SMSrdelEx6 mice. 
During this thesis, these mice were characterized and published (Bickert et al., 2015), 
the corresponding text is not further denoted. 
 
4.1.1 SMSrD348E mice 
The non-conditional SMSrD348E mouse line was generated by Dr. Christina Ginkel 
during her Ph. D thesis (Ginkel, 2013). Aside from the D348E point mutation these 
mice express a lacZ reporter gene encoding for β-galactosidase under transcriptional 
control of the endogenous SMSr promoter (Figure 4.1). 
 
The scheme for homologous recombination and generation of SMSrD348E mice is 
presented in Figure 4.1. Briefly, the SMSrD348E targeting vector included the 
genomic sequence of SMSr exons 4 and 5, a neomycin selection cassette (flanked 
by frt-sites) for selection of homologously recombined ES-cell clones in intron 5, and 
the mutated exon 6 encoding the D348E point mutation. After exon 6, NLS-lacZ 
reporter cDNA under control of an internal ribosomal entry site (IRES) was introduced 
followed by the SMSr 3‟ untranslated region (for details see (Ginkel, 2013)). 
 
For this thesis heterozygous animals (+/SMSrD348E) without neomycin selection 
cassette and backcrossed to 87.5 % C57BL/6 background were used to breed wild 
type and homozygous SMSrD348E littermates for investigation. Against our 
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expectations SMSrD348E mice were born according to the Mendelian ratio, 
indicating a non-essential role for SMSr during embryogenesis. Furthermore, adult 
animals showed normal morphology, behavior and fertility. 
 
 
Figure 4.1 - Generation of SMSrD348E mice. (A) Scheme of homologous recombination 
for generation of SMSrD348E mice. (adopted and modified from Bickert et al., 2015) 
 
4.1.2 SMSrdelEx6 mice 
The SMSrflox mouse line for conditional deletion of exon 6 and expression of a 
catalytically inactive SMSrNT-eGFP fusion protein was generated during my diploma 
thesis. Briefly, the approximately 19.5 kbp conditional SMSrflox targeting vector 
contained the genomic region of SMSr from exon 4 (5‟ homology region) to exon 6 
and the 3‟ untranslated region followed by a neomycin resistance cassette flanked by 
frt-sites. To deplete SMSr catalytic activity, two loxP-sites were introduced in intron 4 
and downstream of the neomycin selection cassette. Behind the 3‟ loxP-site a fusion 
sequence of exon 5 with an in-frame egfp, followed by the 3‟ homology region was 
introduced. In SMSrflox mice, Cre mediated recombination allowed the conditional 
deletion of exon 6 and the expression of an exon 5-egfp fusion sequence for 
translation of an SMSrNT-eGFP fusion protein in the resulting SMSrdelEx6 mice 
(Figure 4.2 A; for details see (Bickert, 2011)). 
 
For generation of SMSrflox mice, the targeting vector was transfected into HM1-ES 
cells. Transfected ES cell clones were analyzed for correct insertion of the targeting 
vector into the smsr locus by homologous recombination (Bickert, 2011). Positive 
clones were used for blastocyst injections (see chapter 1.4.1). Germ-line 
transmission chimeras resulting from blastocyst injections were available in the 
beginning of this Ph. D thesis, these mice were bred with C57BL/6 animals. Agouti-
colored offspring were genotyped and heterozygous animals were mated with 
deleter-Flp mice to remove the neomycin selection cassette (see chapter 1.4.2). 
Since SMSrD348E mice were vital and fertile, the conditional SMSrflox mice were 
crossbred with mice expressing the Cre recombinase under control of the 
phosphoglycerate kinase (pgk)-promoter for ubiquitous deletion of exon 6, generating 
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SMSrdelEx6 mice. These mice express an SMSrNT-eGFP fusion protein under 
control of the endogenous SMSr promoter. 
 
To verify the SMSrflox/SMSrdelEx6 mouse line, genotypes were analyzed by PCR 
analyses (Figure 4.2 B) and Southern blot hybridization (Figure 4.2 C, D). For 
Southern blot analyses liver DNA of wild type (+/+), heterozygous (+/SMSrdelEx6) 
and SMSrdelEx6 (SMSrdelEx6) mice was digested with XmnI. For hybridization an 
internal probe (969 bp part of the 3‟ homology region) was cut from the targeting 
vector by restriction digest with HincII and XbaI and a 5‟ external probe (513 bp 
sequence upstream of the 5‟ homology region), was amplified by PCR from a 
bacterial artificial chromosome (BAC) containing the genomic sequence of SMSr (see 
chapter 2.4). Southern blot hybridization using these probes confirmed correct 
insertion of the targeting vector by homologous recombination (Figure 4.2 C, D; for 
details see Bickert et al., 2015). The internal probe further confirmed that no multiple 
insertion of the targeting vector occurred. 
 
Heterozygous animals (+/SMSrdelEx6) were backcrossed to 87.5 % C57BL/6 
background and used to breed wild type and homozygous SMSrdelEx6 littermates for 
investigation. SMSrdelEx6 mice, like the SMSrD348E mice, were born in a Mendelian 
ratio and showed normal morphology, behavior and fertility. As a consequence, 
primarily SMSrD348E mice were used to investigate in vivo SMSr function in this 
thesis. 
 
The SMSrNT-eGFP fusion protein expressed in SMSrdelEx6 mice lacks the 
endogenous C-terminus of SMSr. Therefore, SMSrdelEx6 mice represented a 
valuable tool to verify the specificity of custom-made polyclonal antibodies targeting 
the C-terminus of SMSr and were used to investigate the tissue-specific expression 
pattern of SMSr. 
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Figure 4.2 - Generation of SMSrdelEx6 mice. (A) Schematic drawing for the generation of 
SMSrdelEx6 mice by homologous recombination (B) Genotyping PCR for wild type (+/+), 
heterozygous (+/SMSrdelEx6) and homozygous (SMSrdelEx6) mice; characteristic DNA 
fragments 386 bp (wild type), 707 bp (delEx6), 451 bp (floxed) (C, D) Southern blot analysis 
of SMSrdelEx6 mice. Expected fragment sizes: XmnI restriction: Internal probe (C): wild type 
11.5 kbp, delEx6 2.9 kbp. 5‟ external probe (D): wild type 11.5 kbp, delEx6 8.7 kbp. (Panels 
A-C were adopted and modified from Bickert et al., 2015) 
 
4.1.3 SMSr expression in mice 
The ceramide accumulation after acute down regulation of SMSr in HeLa cells, led to 
the hypothesis that SMSr functions as a ceramide sensor in the ER (Vacaru et al., 
2009). A sensor function would imply that SMSr is ubiquitously expressed. To test 
this hypothesis and to provide a basis for the functional analysis of SMSr in mice, 
transcript and protein expression were investigated in several mouse tissues and 
primary cells. 
 
4.1.3.1 ß-galactosidase staining in SMSrD348E mice 
As discussed in chapter 4.1.1, SMSrD348E mice express a ß-galactosidase-reporter 
protein with a nuclear localization signal (NLS). As the reporter protein is expressed 
under the control of the endogenous SMSr promoter, SMSrD348E mice were used to 
investigate the cell type specific expression of the SMSr protein. 
 
The first ß-galactosidase stainings were performed by Dr. Christina Ginkel during her 
Ph. D thesis. In these analyses cryo-sections from forebrain, cerebellum, kidney, 
heart and liver of SMSrD348E mice showed ß-galactosidase expression (Figure 4.3 
A-E; (Ginkel, 2013)). In the present thesis these stainings were complemented with 
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cryo-sections from testis and pancreas (Figure 4.3 F, G) and the original stainings 
were verified by repeated stainings (Figure 4.4 A-G). All stainings were evaluated in 
collaboration with the histologists Dr. Holger Jastrow and Prof. Elke Winterhager 
(University Hospital/University of Essen). 
 
In brain, neuronal areas like the forebrain cortex, the dentate gyrus and the 
hippocampal regions CA1, CA2, CA3 and CA4, as well as the cerebellar and the 
granular cell layer showed prominent ß-galactosidase staining (Figure 4.3/Figure 4.4 
A, B) In kidney, smsr promoter activity was mainly detected in the cortex (Figure 
4.3/Figure 4.4 C), whereas ß-galactosidase activity was not detectable in the medulla 
and papilla (data not shown; for details see Ginkel 2013). Moderate ß-galactosidase 
staining was detected in the AV-node of the heart, whereas cardiomyocytes in the 
myocard showed weaker staining (Figure 4.3/Figure 4.4 D). In liver, the whole tissue 
showed smsr promoter activity, but regions surrounding portal fields showed more 
prominent nuclear staining (Figure 4.3/Figure 4.4 E). In testis, ß-galactosidase 
signals were found adjacent to the basal epithelium of seminiferous tubules, probably 
resulting from nuclear staining of spermatogonia (Figure 4.3/Figure 4.4 F). In 
pancreas, ß-galactosidase staining was detected throughout the whole tissue, with 
strong staining of the exocrine portion and a somewhat weaker staining of the 
endocrine islets of Langerhans (Figure 4.3/Figure 4.4 G). For all investigated tissues, 
specificity of the ß-galactosidase staining was validated using cryo-sections of the 
corresponding wild type tissues (Figure 4.4 A-G). Importantly, no obvious alterations 
in cellular and tissue morphology were observed between wild type and SMSrD348E 
mice in any of the investigated tissues. 
 
Taken together, the analyses of smsr promoter activity in SMSrD348E mice show 
that smsr transcripts are nearly ubiquitously expressed in mice. A comprehensive 
microarray analysis of different mouse tissues already suggested a relatively even 
distribution of smsr transcripts in mice, especially when compared to sms1 and sms2 
transcripts (Figure 4.4 H). 
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Figure 4.3 - Mouse smsr is a widely expressed gene. (A-G) Analysis of smsr promoter 
activity by ß-galactosidase staining of cryo-sections (12 µm) from various SMSrD348E 
mouse tissues. Neuronal regions of allo- and neocortical brain areas (A) and cerebellum (B) 
show prominent ß-galactosidase staining mainly of nuclei and perinuclear areas of neurons. 
In kidney, prominent ß-galactosidase staining is displayed in the tubular system of the cortex 
(C). In heart, nuclei of all cardiomyocytes are ß-galactosidase positive, especially those of 
the AV-node (D). In liver, the distribution of ß-galactosidase activity is diffuse with areas of 
more and others of less intensive staining that cannot be clearly associated to special 
regions of the hepatic lobules (E). In testis, spermatogonia in the basal epithelium of the 
seminiferous tubules show similar nuclear ß-galactosidase staining (F). In pancreas, 
ß-galactosidase expression is displayed throughout the whole tissue, with a prominent 
staining of the exocrine portion and a somewhat weaker staining of the endocrine ß-islets 
(G). AV, atrioventricular node; Cx, cortex; DG, dentate gyrus; EC, exocrine cells; GC, 
granular cell layer; HC, hippocampus; L, islets of Langerhans; P, portal field; PC, Purkinje 
cell layer; S, seminiferous tubule (adopted and modified from Bickert et al., 2015; Panels A-E 
were taken from the Ph. D thesis of Dr. Christina Ginkel and are presented here for 
immediate comparison (Ginkel, 2013)). 
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Figure 4.4 – Repeated analysis of ß-galactosidase expression in SMSrD348E and wild 
type control mice. ß-galactosidase staining of cryo sections from SMSrD348E (D348E) and 
wild type (WT) animals proved to be specific in forebrain (A), cerebellum (B), kidney (C), 
heart (D), liver (E), testis (F) and pancreas (G), no staining was observed in wild type tissues. 
Images represent overviews and supplement images in Figure 4.3. (H) Transcript expression 
profiles from microarray analysis of SMSr (Samd8), SMS2 (Sgms2) and SMS1 (Sgms1), 
modified according to http://BioGPS.org (Wu et al., 2013), data set Mouse MOE430 Gene 
Atlas (Lattin et al., 2008). Microarray data were generated using an Affymetrix Mouse 
Genome 430 2.0 Array (GEO platform accession number GPL1261). cx, cortex, s., small. 
(Panel H was adopted and modified from Bickert et al., 2015) 
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4.1.3.2 Affinity purification of polyclonal antibodies targeting SMSr 
To analyze the tissue-specific expression pattern of SMSr in mice, new polyclonal 
antibodies targeting the mouse SMSr protein were generated. An internal peptide 
(CWPFSKPAIMKRLIG) between the SAM-domain and the first transmembrane 
domain and a C-terminal peptide (CDGPIPDLSSDQYQY) of the mouse SMSr protein 
(Figure 4.5 A) were synthesized by Prof. Marten Egmond (University of Utrecht). A 
mixture of these peptides was used to immunize different rabbits (Pineda Antibody 
Service, Berlin). For affinity chromatography of the rabbit sera two columns were 
loaded with the internal or the C-terminal peptide, respectively. 
 
The first antibodies were affinity purified by Dr. Christina Ginkel, using both columns 
connected in series. In immunoblot analysis of yeast cells (lack endogenous SMSr) 
overexpressing V5-tagged SMSr, these antibodies recognized a protein 
corresponding to SMSr-V5 (Ginkel, 2013). However, in immunoblot analyses of 
mouse tissue lysates these antibodies proved to be unspecific (data not shown). To 
improve quality of immunoblot signals, I repeated purification of three different rabbit 
sera (#1, #2 and #4) using either the column with the internal peptide or the column 
with the C-terminal peptide.  
 
The sequence of the peptides used for immunization is identical in the mouse 
(mSMSr) and the human (hSMSr) protein. For that reason, it was possible to use 
yeast cells overexpressing hSMSr-V5 to test the specificity of the newly generated 
antibodies in immunoblot analyses. The antibodies purified with the C-terminal 
peptide recognized a band at approximately 42-kDa, that was missing for lysates of 
yeast cells transfected with an empty vector (Figure 4.5 B, left panel). Incubation with 
an anti-V5 antibody revealed the same pattern (Figure 4.5 B, middle panel), 
demonstrating that the detected protein corresponds to hSMSr-V5. In contrast, 
antibodies purified with the internal peptide did not recognize hSMSr-V5 (data not 
shown), suggesting that the internal peptide had no immunogenic effect. Accordingly, 
only antibodies purified with the C-terminal peptide (derived from serum #4) were 
used for further analyses. 
 
4.1.3.3 SMSr tissue-specific expression 
Using total protein extracts of 19 different tissues of wild type mice, the tissue-specific 
distribution of SMSr was determined by immunoblot analyses using the newly 
generated anti-SMSr antibodies. The SMSrNT-eGFP fusion protein produced in 
SMSrdelEx6 mice lacks the endogenous C-terminus of SMSr (Figure 4.5 A), hence 
the antibodies which target the C-terminus do not recognize the truncated protein. 
Therefore, protein extracts from SMSrdelEx6 mice served as controls to ensure the 
specificity of the antibodies in each tissue. 
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For wild type protein extracts a protein migrating at approximately 42-kDa was 
detected in all of the investigated tissues. In tissues of SMSrdelEx6 mice this protein 
was consistently absent (Figure 4.5 C, D). The mouse and the human smsr gene 
each encode a 415-residue protein with a predicted molecular weight close to that of 
the detected protein. As the protein migrated approximately to the same height as the 
hSMSr-V5 protein (Figure 4.5 B) it is hereafter referred to as SMSr. 
 
The analyses confirmed a broad tissue distribution of the SMSr protein, in line with 
the ß-galactosidase expression and the microarray analyses discussed in chapter 
4.1.3.1. The strongest expression of all tissues was observed in testis, brain, kidney 
and pancreas (Figure 4.5 C, D). In comparison to these tissues expression was 
rather low in spleen, lung, heart and eye and moderate in liver and other investigated 
tissues. 
 
In several of the wild type tissues (forebrain, cerebellum, testis, stomach, small 
intestine, muscle, skin, eye, prostate and pancreas) the anti-SMSr antibodies 
recognized an additional protein migrating at approximately 48-kDa, which was 
absent in tissues of SMSrdelEx6 mice (Figure 4.5 C, D). Database analysis revealed 
two protein coding transcripts for the mouse SMSr, coding for a 415-residue protein 
and a 478-residue protein, respectively (http://www.ensembl.org; Gene ID: 
ENSMUSG00000021770). As already mentioned, the protein detected at 42-kDa 
corresponds to the 415-residue protein isoform (SMSr). Consequently, the protein 
detected at 48-kDa corresponds to the 478-residue protein isoform, hereafter referred 
to as SMSr-2. The protein is the predominant isoform only in testis (Figure 4.5 C). In 
a subset of tissues (large intestine, caecum, kidney, spleen, lung, heart and fat) 
unequivocal identification of SMSr-2 expression was not possible due to unspecific 
binding of the anti-SMSr antibodies at the corresponding height (Figure 4.5 C, D). 
 
Notably, the anti-SMSr antibodies did not recognize SMSr in immunofluorescence 
analyses of wild type cryo-sections from liver and brain under different experimental 
conditions (data not shown). 
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Figure 4.5 - Tissue-specific distribution of the SMSr protein in mice. (A) Putative 
membrane topology of native SMSr, SMSrD348E and SMSrNT-eGFP fusion protein 
(SMSrdelEx6 mice) predicted by TMHMM (http://www.cbs.dtu.dk/services/TMHMM/). The 
endogenous C-terminus in the SMSrNT-eGFP (SMSrdelEx6) fusion protein is replaced by an 
eGFP reporter which is predicted to be oriented towards the ER lumen. Lack of the 
C-terminus allowed verifying the specificity of the newly generated anti-SMSr antibodies in 
immunoblot analysis (B-D). Predicted molecular mass: wild type and SMSrD348E 48.2 kDa 
(415 aa), SMSrNT-eGFP (SMSrdelEx6) 63.5 kDa (559 aa). (B) Immunoblot analysis with 
lysates from yeast cells overexpressing an hSMSr-V5 construct. The anti-SMSr antibodies 
specifically recognized the 49.6 kDa hSMSr-V5 fusion protein, as well as an antibody 
targeting the V5-tag. Ponceau S staining was used as loading control. (C, D) Immunoblot 
analyses of wild type (WT) tissue lysates, lysates from SMSrdelEx6 mice (KO) served as 
negative controls. The anti-SMSr antibodies specifically recognized the predicted 48.2 kDa 
(SMSr) and 54.7 kDa (SMSr-2) protein isoforms. Both isoforms did not migrate to positions 
expected for their theoretical mass. Different protein standards revealed, SMSr and the 
corresponding SMSr-V5 migrate at about 42 kDa, SMSr-2 migrates at about 48 kDa. GAPDH 
was used as loading control. 25 µg of protein were applied for forebrain, cerebellum and 
testis, 50 µg for liver and other tissues. (Data are representative of at least 3 independent 
experiments; s. - small; l. - large). (adopted and modified from Bickert et al., 2015). 
 
4.1.3.4 SMSr expression in primary cells 
The analyses of SMSr expression in mice were supplemented by the investigation of 
different primary cells. In contrast to previous data (Ginkel, 2013), no ß-galactosidase 
staining was observed in embryonic stem cells from SMSrD348E mice (Figure 4.6 A). 
Nuclear ß-galactosidase staining was found in embryonic fibroblasts from 
SMSrD348E mice (Figure 4.6 B). Immunoblot analyses of cell lysates from wild type 
embryonic fibroblasts confirmed the expression of SMSr (Figure 4.6 C; left panel). 
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Additionally SMSr was found to be expressed in bone marrow derived macrophages 
from wild type mice (Figure 4.6 C; right panel). 
 
 
Figure 4.6 - Analyses of SMSr expression in primary cells (A) ß-galactosidase staining of 
embryonic stem (ES) cells from SMSrD348E mice revealed no nuclear staining. (B) 
ß-galactosidase staining of mouse embryonic fibroblasts (MEF; ED 10.5) revealed nuclear 
staining in SMSrD348E cells. Wild type (WT) cells served as negative controls. (C) SMSr 
was specifically detected by the anti-SMSr antibodies in cell lysates of MEF cells (left panel) 
and bone marrow derived macrophages (BMDM; right panel). MEFs and BMDMs from 
SMSrdelEx6 mice (KO) served as negative controls. GAPDH was used as loading control, 
20 µg of protein were applied. 
 
4.1.4 Activity and protein expression in SMSrD348E and SMSrdelEx6 mice 
As a prerequisite for the phenotypic analyses, functionality of the transgenic mouse 
lines was verified. For this purpose enzyme activity and protein expression of the 
point-mutated SMSrD348E and the truncated SMSrNT-eGFP protein were determined 
in CPE synthase activity assays and immunoblot analyses, respectively. 
 
4.1.4.1 CPE synthase activity of mouse SMSr 
Previously, it was shown that human SMSr (hSMSr) and Drosophila SMSr (dSMSr) 
exhibit CPE synthase activity (Vacaru et al., 2009). In collaboration with the group of 
Prof. Joost Holthuis (University of Osnabrück) it was investigated whether mSMSr is 
also capable of catalyzing the synthesis of CPE. Therefore, a construct carrying a 
V5-tagged version of mSMSr (mSMSr-V5) was transfected to budding yeast, an 
organism which lacks endogenous CPE synthase activity. In a CPE synthase activity 
assay lysates of these yeast cells supported conversion of C6-NBD-ceramide (NBD-
Cer) into NBD-CPE (Figure 4.7 A). In the next step, 4∆.Lass5 yeast cells which 
express ceramide synthase 5 instead of the endogenous enzymes for ceramide 
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production (Cerantola et al., 2007), were transfected with mSMSr-V5. LC-MS/MS 
analysis of these yeast cells in collaboration with Prof. Pentti Somerharju (University 
of Helsinki), revealed production of several species of CPE that were missing in 
mock-transfected cells (Figure 4.7 B). In addition, CPE synthase activity was 
determined in yeast cells transfected with hSMSr or hSMSrD348E (Figure 4.7 C). While 
NBD-CPE production was observed in cells transfected with hSMSr, activity was 
abrogated in cells transfected with hSMSrD348E. 
 
 
Figure 4.7 - Mouse SMSr catalyzes CPE production and point mutation D348E leads to 
catalytic inactivation of SMSr. (A) TLC (thin layer chromatography) analysis showing 
production of NBD-CPE and NBD-CPI after incubation of NBD-ceramide with lysates of yeast 
strains overexpressing hSMSr or mSMSr. CPI (ceramide phophoinositol) is a major 
constituent of cell membranes in yeast cells, which lack endogenous SM and CPE 
production (B) LC-MS/MS analysis (neutral loss m/z 141 scan) showing different molecular 
species of CPE after alkaline hydrolysis of glycerolipids in 4∆.Lass5 yeast cells (express 
ceramide synthase 5 instead of the endogenous ceramide synthases) transfected with 
mSMSr. (C) TLC analysis after incubation of NBD-ceramide with lysates of yeast strains 
overexpressing hSMSr or hSMSrD348E. In contrast to yeast cells transfected with hSMSr, 
conversion of NBD-ceramide to NBD-CPE was not supported by cells transfected with 
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hSMSrD348E, indicating that catalytic activity of the point-mutated protein is lost. Immunoblot 
analysis (below TLC) confirms that comparable amounts of protein were used. (adopted and 
modified from Bickert et al., 2015). 
 
4.1.4.2 CPE/SM synthase activity in SMSr and SMS2 mutant mice 
CPE synthase activity was readily detectable in lysates of yeast cells overexpressing 
mSMSr-V5 or hSMSr-V5 (Figure 4.7 A). Detection of endogenous CPE synthase 
activity of SMSr in mouse tissues is complicated, since SMSr produces only trace 
amounts of CPE and since sphingomyelin synthase 2 (SMS2) is known to have a 
dual activity towards the production of SM and CPE (Ternes et al., 2009). To prove 
that catalytic activity is indeed lost in SMSrD348E and SMSrdelEx6 mice, it was 
necessary to distinguish between CPE synthase activity exhibited by SMSr and 
SMS2. Therefore, double mutants of SMSr mutant and SMS2gt mice (Liu et al., 
2009b) were bred. SMS2gt mice were provided by Prof. Xian-Cheng Jiang (SUNY 
Downstate Medical Center, New York). CPE synthase activity was first described in 
microsomal preparations of rat brain and liver (Malgat et al., 1986). Therefore, 
microsomal preparations of brain and liver from wild type, SMSrD348E, SMSrdelEx6, 
SMS2gt single mutant and SMS2gt X SMSrD348E and SMS2gt X SMSrdelEx6 
double mutant mice were used for analyses of CPE (and SM) synthase activity. 
CPE/SM synthase activity measurements and subsequent TLC (thin layer 
chromatography) analyses were done in collaboration with Dr. Matthijs Kol from the 
group of Prof. Joost Holthuis (University of Osnabrück). 
 
Incubation of brain and liver microsomal fractions with NBD-Cer led to the formation 
of NBD-SM, NBD-CPE and NBD-GluCer (Figure 4.8 A and B). In brain, NBD-GluCer 
formation was not altered in microsomal fractions of any of the investigated 
genotypes compared to wild type (Figure 4.8 A). NBD-SM production was reduced 
approximately by half for SMS2gt and double mutant animals compared to wild type 
(Figure 4.8 A). No changes were detectable in SMSr single mutants. For SMS2gt 
mice the signal for NBD-CPE was only slightly decreased compared to wild type, but 
completely missing for all SMSr single and double mutants (Figure 4.8 A). 
 
As shown in Figure 4.8 B, in liver microsomal fractions no alterations in NBD-GluCer 
signals were observed between the investigated genotypes and the wild type control. 
In microsomal fractions from SMS2gt and double mutants, synthesis of NBD-SM was 
strongly decreased compared to wild type (Figure 4.8 B). Similar to brain, no change 
in NBD-SM production was observed for SMSr single mutants in the liver, showing 
that SMSr does not exhibit or influence SM synthase activity. NBD-CPE formation 
was only slightly decreased for all single mutants compared to wild type, but was 
completely missing for all double mutants (Figure 4.8 B). 
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Figure 4.8 - CPE and SM synthase activity in brain and liver microsomes of SMSr, 
SMS2 and double mutant mice. (A, B) TLC (thin layer chromatography) separation of 
reaction products NBD-SM, NBD-CPE and NBD-GluCer after incubation of NBD-ceramide 
with brain or liver microsomal fractions of wild type, SMSrD348E, SMSrdelEx6, SMS2gt 
single mutant or SMS2gt X SMSrD348E and SMS2gt X SMSrdelEx6 double mutant mice. (A) 
In brain microsomal fractions production of NBD-SM was strongly reduced only in SMS2gt 
and double mutant animals. NBD-CPE production was essentially abolished in SMSr single 
and double mutant microsomes and only slightly decreased for SMS2gt mice. (B) In liver 
microsomal fractions production of NBD-SM was strongly decreased for SMS2 single and 
double mutant mice. NBD-CPE production was reduced by half in single mutant microsomes 
and completely abolished for all double mutants. (C, D) Immunoblot analyses of microsomal 
fractions used in A and B (note that in A sample arrangement differs between TLC and 
immunoblot). Antibodies against the ER marker calnexin confirmed that equal amounts of ER 
membranes were used in the assay. Antibodies against SMSr recognized a protein in wild 
type and SMS2gt samples. As expected, no signal was detected in SMSrdelEx6 and 
SMS2gt X SMSrdelEx6 samples, but the point-mutated SMSrD348E protein was strongly 
reduced for all corresponding genotypes in both tissues. 25 µg of protein were applied per 
lane. (Panels A and B adopted and modified from Bickert et al., 2015). 
 
To ensure that equal amounts of ER membranes were used in the CPE/SM synthase 
assay, microsomal preparations were analyzed by immunoblot prior to the assay. An 
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antibody against the ER marker calnexin confirmed equal loading for both tissues 
(Figure 4.8 C, D). Moreover, anti-SMSr antibodies were used to determine 
expression of SMSr and SMSrD348E protein levels. In wild type and SMS2gt 
microsomal preparations of both tissues, the SMSr protein was readily detectable 
and as expected, no signal was detected for SMSrdelEx6 and 
SMS2gt X SMSrdelEx6 mice. Notably, compared to the wild type, the signal for the 
SMSrD348E protein was strongly reduced in both tissues (Figure 4.8 C, D). 
 
4.1.4.3 SMSrD348E and SMSrNT-eGFP protein expression 
To further investigate the expression of the SMSrD348E protein, total tissue lysates 
from wild type and SMSrD348E mice were investigated by immunoblot analyses 
using the anti-SMSr antibodies. In tissue lysates from forebrain small amounts of 
SMSrD348E protein were detectable, but the protein was virtually absent in liver, 
kidney, lung, spleen and cerebellum (Figure 4.9). 
 
 
Figure 4.9 – Immunoblot analysis of protein expression in SMSrD348E mice. (D) 
Immunoblot analyses of total protein lysates from different tissues of wild type (WT) and 
SMSrD348E (D348E) mice using anti-SMSr antibodies. 75 µg protein were applied per lane; 
GAPDH served as loading control. 
 
Similar to what was observed for the SMSrD348E mice, the SMSrNT-eGFP fusion 
protein in SMSrdelEx6 mice might also be degraded. On cryo-sections from kidney 
and liver of SMSrdelEx6 mice the fusion protein was neither detectable by 
endogenous fluorescence of eGFP, nor in immunofluorescence analyses using 
different antibodies against GFP (data not shown). In the same line, these antibodies 
did not detect the fusion protein in immunoblot analyses of total protein lysates from 
liver of SMSrdelEx6 mice (data not shown). 
 
4.1.5 Analysis of sphingolipid content in SMSr and SMS2 mutant mice 
As a basis for the functional analysis of SMSr in mice, the sphingolipid content in 
a variety of tissues from wild type and SMSrD348E mice was determined by mass 
spectrometric analyses in collaboration with Prof. Pentti Somerharju (University of 
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Helsinki). To get a more comprehensive overview of CPE metabolizing enzymes in 
mice, the analysis was extended by including tissues from the SMS2gt and 
SMS2gt X SMSrD348E mice that were already discussed in chapter 4.1.4.2. 
 
4.1.5.1 Distribution of CPE and SM in mouse tissues 
The analysis started with the quantification of CPE and SM levels in forebrain, 
cerebellum, liver, testis, kidney, spleen, lung, heart, muscle and small intestine of wild 
type mice. Since CPE could not be detected by direct infusion MS/MS, CPE and 
SM levels were quantified by LC-MS analysis (Figure 4.10 A, B). In all 
investigated tissues the steady-state levels of CPE were exceedingly low, in 
comparison the levels of SM were 300 to 1,500 fold higher depending on the 
tissue. While CPE levels were relatively high in testis and brain (~0.020 mol % of 
total phospholipid), they were particularly low in heart and liver (~0.002-0.005 mol % 
of total phospholipid). 
 
It was suggested that in liver low quantities of SM can be produced by the step-wise 
methylation of CPE (Muehlenberg et al., 1972; Malgat et al., 1986). This reaction is 
analogous to the S-adenosylmethionine-dependent conversion of PE to PC catalyzed 
by the liver-specific enzyme phosphatidylethanolamine N-methyltransferase 
(PEMT)(Ridgway & Vance, 1992; Jacobs et al., 2010). As CPE levels were 
particularly low in the liver, the impact of PEMT removal on liver CPE levels was 
investigated in collaboration with Dr. René Jacobs, Prof. Dennis Vance (University of 
Alberta) and Prof. Pentti Somerharju (University of Helsinki). In the liver of PEMT KO 
mice CPE levels were 20 times higher compared to wild type controls (Figure 4.10 
C). Moreover, CPE levels in PEMT KO mice were reduced by 50 % after 
adenovirus-mediated transduction with a functional PEMT construct (Figure 4.10 
C), which restored PEMT activity (Figure 4.10 D). 
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Figure 4.10 – Mass spectrometric quantification of CPE and SM levels in different 
mouse tissues. (A, B) LC-MS analysis of CPE and SM levels in forebrain, cerebellum, liver, 
testis, kidney, spleen, lung, heart, muscle and small intestine of wild type mice (n=4). (C) LC-
MS analysis for comparison of liver CPE content of wild type (WT) mice, PEMT KO mice 
transduced with GFP (KO Ad. GFP) and PEMT KO mice transduced with functional PEMT 
(KO Ad. PEMT)(n=2-3). (D) PEMT activity assay from liver lysates of wild type mice 
transduced with GFP (WT Ad. GFP), PEMT KO mice transduced with GFP (KO Ad. GFP) 
and PEMT KO mice transduced with PEMT (KO Ad. PEMT) proved functionality of the PEMT 
construct (n=3). Data are means ± SEM; *, p<0.05; **, p<0.005; ***; p<0.001. (adopted and 
modified from Bickert et al., 2015) 
 
4.1.5.2 Impact of SMSr and SMS2 inactivation on tissue CPE and SM levels 
The impact of disrupting SMSr and SMS2 catalytic activity on CPE and SM levels 
was investigated in a variety of tissues from wild type, SMSrD348E, SMS2gt and 
SMS2gt X SMSrD348E double mutant mice. The LC-MS analysis of forebrain and 
cerebellum revealed a 40-60 % reduction in short-chain CPE species (C18:0, C20:0) 
in SMSrD348E and double mutant mice relative to wild type mice (Figure 4.11 A, B). 
In contrast, inactivation of SMSr did not lead to significant changes in the levels of 
long-chain CPE species (C22:0, C24:0, C24:1). Depletion of SMSr decreased the 
total levels of CPE by about 30 % in forebrain and cerebellum (Figure 4.12 A, B). SM 
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levels in brain were not affected by depletion of SMSr (Figure 4.11 D, E). The 
depletion of SMS2 did not alter the levels of CPE in the brain, but caused a reduction 
in total SM levels by about 15 % (Figure 4.12 K, L). The loss of SMS2 affected all 
major species except for C16:0 SM in forebrain and C20:0 to C22:0 SM species in 
cerebellum (Figure 4.11 D, E). In liver, no significant differences in CPE levels 
between wild type and mutant mice were detectable (Figure 4.11 C and Figure 
4.12 C). Inactivation of SMS2 led to a decrease (~20%) in total SM levels in liver 
(Figure 4.12 M), the decrease affected all major species (Figure 4.11 F), but was only 
significant for SMS2gt mice. 
  
 
Figure 4.11 - LC-MS analyses of CPE, SM, ceramide and hexosylceramide species in 
forebrain, cerebellum and liver of wild type, SMSrD348E, SMS2gtXSMSrD348E and 
SMS2gt mice. (A-C) Analysis of main CPE species. (D-E) Analysis of main SM species. (F-
H) Analysis of main ceramide species. (I-K) Analysis of main hexosylceramide (Hex-Cer) 
species. Data are means ± SEM; two-tailed Student’s t test: *, p<0.05; **, p<0.005, ***, 
p<0.001; n=3-4. (adopted and modified from Bickert et al., 2015). 
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Figure 4.12 - LC-MS analysis of CPE and SM content in forebrain, cerebellum, liver, testis, 
kidney, spleen, lung, heart, muscle and small intestine of wild type, SMSrD348E, 
SMS2gtXSMSrD348E and SMS2gt mice. (A-J) Sum of main CPE species. (K-T) Sum of 
main SM species. Data are means ± SEM; two-tailed Student’s t test: *, p<0.05; **, p<0.005; 
***, p<0.001; n=3-4. (adopted and modified from Bickert et al., 2015) 
 
In addition to brain and liver, the CPE (and SM) content was also determined in other 
tissues. In testis and kidney total CPE levels were largely unaffected in mutant mice 
(Figure 4.12 D, E). However, a minor decrease in C16:0 and a significant decrease in 
C18:0 CPE species were observed compared to wild type mice (~10-20%), 
depending on depletion of SMSr in testis and of both CPE synthases in kidney 
(Figure 4.13 A, B). In spleen total CPE levels were decreased by about 30 % and in 
lung by about 50 % compared to wild type mice, but the difference was not significant 
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(Figure 4.12 F, G). This was characterized by a decrease in C16:0 to C20:0 CPE 
species, which only reached statistical significance for C20:0 species (Figure 4.13 C, 
D). In small intestine, the sum of the main CPE species was decreased by about 
70 % only in SMS2gt X SMSrD348E double mutant mice (Figure 4.12 J). This was 
characterized by a decrease C16:0 to C20:0 CPE species, which was only significant 
for C16:0 species (Figure 4.13 G). No significant differences in total CPE levels 
between wild type and mutant mice were observed in heart (Figure 4.12 H), but 
C16:0 CPE levels, although not significant, were decreased in SMS2 mutant mice 
(Figure 4.13 E). In muscle, total CPE levels were decreased by 40-50 % in SMS2 
and double mutant compared to wild type mice, but the differences were not 
significant (Figure 4.12 I). The loss of SMS2 affected C16:0, as well as C18:0 CPE 
species (Figure 4.13 F). Total SM levels were significantly decreased in kidney 
(~25 %) of SMS2 and double mutant mice (Figure 4.12 O), depletion of SMS2 
affected all major species except for C16:0 SM (Figure 4.14 B). 
 
The data on steady-state CPE levels in wild type and SMSr mutant mice show that 
SMSr is a major determinant for CPE levels in the brain. Furthermore, SMSr 
contributes to a minor extent to the CPE content in testis, kidney, spleen and lung. In 
none of the investigated tissues, combined inactivation of both known CPE 
synthases (i.e. SMSr and SMS2) did completely eliminate CPE. 
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Figure 4.13 - LC-MS analysis of main CPE species in testis (A), kidney (B), spleen (C), 
lung (D), heart (E), muscle (F) and small intestine (G) of wild type, SMSrD348E, 
SMS2gtXSMSrD348E and SMS2gt mice. Data are means ± SEM; two-tailed Student’s t test: 
*, p<0.05; **, p<0.005; n=3-4. (adopted and modified from Bickert et al., 2015) 
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Figure 4.14 - LC-MS analysis of main SM species in testis (A), kidney (B), spleen (C), lung 
(D), heart (E), muscle (F) and small intestine (G) of wild type, SMSrD348E, 
SMS2gtXSMSrD348E and SMS2gt mice. Data are means ± SEM; two-tailed Student’s t test:  
*, p<0.05; **, p<0.005; ***, p<0.001; n=3-4. (adopted and modified from Bickert et al., 2015) 
 
4.1.5.3 Determination of ceramide levels in SMSr and SMS2 mutant mice 
In human HeLa and Drosophila S2 cells, acute depletion or catalytic inactivation of 
SMSr led to a massive accumulation of ceramide and hexosylceramide in the ER 
(Vacaru et al., 2009). To investigate if inactivation of SMSr leads to a similar effect in 
mice, the ceramide and hexosylceramide levels in different tissues from wild type and 
SMSrD348E mice were determined by quantitative MS/MS analysis. Additionally, the 
analysis included SMS2gt and SMS2gt X SMSrD348E mice.  
 
In forebrain, cerebellum and liver of SMSrD348E mice none of the investigated main 
species of ceramide or hexosylceramide were increased compared to wild type mice 
(Figure 4.15). The same was true for ceramide species (Figure 4.16) and 
hexosylceramide species (Figure 4.17) in the other investigated tissues of 
SMSrD348E compared to wild type mice. Only in testis of SMSrD348E compared to 
wild type mice a slight increase in C24:0 ceramide (~50 %) was observed (Figure 
4.16 A), but the levels of C24:0 ceramide in testis are rather low (~0.5 % relative to 
the total level of main ceramide species Figure 4.18 D). Consistent with these 
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findings, total levels of ceramide and hexosylceramide species were unaltered in 
SMSrD348E compared to wild type mice in all of the investigated tissues (Figure 
4.18). 
 
A minor increase in C24:1 ceramide was observed in forebrain of SMS2gt compared 
to wild type mice and a similar increase was observed for C24:1 hexosylceramide 
(Figure 4.15 A, D). Moreover, C18:0 to C24:1 hexosylceramide species were 
increased in liver of SMS2 mutant compared to wild type mice (Figure 4.15 F). Total 
ceramide levels were not affected by SMS2 depletion in brain and liver (Figure 4.18 
A-C). Total hexosylceramide levels were increased by about 30 % in liver of SMS2gt 
compared to wild type mice, but the difference did not reach statistical significance 
(Figure 4.18 M). In kidney of SMS2gt and double mutant mice C16:0 and C24:0 
ceramide species were increased compared to wild type mice (Figure 4.16 B) and 
also C16:0, C22:0 and C24:0 hexosylceramide species were increased in these mice 
Figure 4.17 B). Consistent with these findings, total ceramide levels in kidney were 
increased by about 15 % in SMS2 mutant compared to wild type mice, and total 
hexosylceramide species were increased by about 25 % (Figure 4.18 E, O). In spleen 
of SMS2gt and double mutant mice C22:0, C24:0 and C24:1 ceramide (Figure 
4.16 C) and hexosylceramide (Figure 4.17 C) species were increased compared to 
wild type mice. Total ceramide and hexosylceramide levels in these mice were 
increased by about 15-20 % compared to wild type mice (Figure 4.18 F, P). Depletion 
of SMS2 increased C22:0 and C24:0 ceramide- (Figure 4.16 D, E) and 
hexosylceramide (Figure 4.17 D, E) species in lung and heart compared to mice 
expressing functional SMS2. The decrease significantly affected total ceramide levels 
in lung (~30 %; Figure 4.18 G) and total hexosylceramide levels in heart (~60 %; 
Figure 4.18 R) of SMS2 mutant mice. 
 
These results indicate that ceramide and hexosylceramide levels are not affected by 
loss of SMSr catalytic activity. In contrast, loss of SMS2 increased ceramide and 
hexosylceramide levels in liver, kidney, spleen, lung and heart and to a minor extent 
in forebrain, but the increases were not especially pronounced. 
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Figure 4.15 - MS analysis of ceramide and hexosylceramide species in forebrain, 
cerebellum and liver of wild type, SMSrD348E, SMS2gtXSMSrD348E and SMS2gt mice. (A-
C) Analysis of main ceramide species. (D-E) Analysis of main hexosylceramide (Hex-Cer) 
species. Data are means ± SEM; two-tailed Student‟s t test: *, p<0.05; **, p<0.005; n=3-4. 
(adopted and modified from Bickert et al., 2015). 
 
 
Figure 4.16 - MS analysis of main ceramide species in testis (A), kidney (B), spleen (C), 
lung (D), heart (E), muscle (F) and small intestine (G) of wild type, SMSrD348E, 
SMS2gtXSMSrD348E and SMS2gt mice. Data are means of two independent 
Results 
79 
 
measurements ± SEM; two-tailed Student’s t test: *, p<0.05; **, p<0.005; ***, p<0.001; n=3-4. 
(adopted and modified from Bickert et al., 2015) 
 
 
Figure 4.17 - MS analysis of main hexosylceramide species in testis (A), kidney (B), 
spleen (C), lung (D), heart (E), muscle (F) and small intestine (G) of wild type, SMSrD348E, 
SMS2gtXSMSrD348E and SMS2gt mice. Data are means of two independent 
measurements ± SEM; two-tailed Student’s t test: *, p<0.05; **, p<0.005; n=3-4. (adopted 
and modified from Bickert et al., 2015) 
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Figure 4.18 - MS analysis of ceramide and hexosylceramide content in forebrain, 
cerebellum, liver, testis, kidney, spleen, lung, heart, muscle and small intestine of wild type, 
SMSrD348E, SMS2gtXSMSrD348E and SMS2gt mice. (A-J) Sum of main ceramide species. 
(K-T) Sum of main hexosylceramide species. Data are means of two independent 
measurements ± SEM; two-tailed Student’s t test: *, p<0.05; **, p<0.005; n=3-4. (adopted 
and modified from Bickert et al., 2015) 
 
Besides measuring the sphingolipid levels in wild type and SMSr and SMS2 mutant 
mice, various glycerophospholipid classes were analyzed by quantitative MS/MS 
analysis (Figure 4.19). The analysis revealed no remarkable changes for most of the 
investigated tissues. The total levels of phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) were slightly increased in spleen and heart of the mutant 
mice (Figure 4.19 F, H). 
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Figure 4.19 - MS analysis of glycerophospholipid content in forebrain (A), cerebellum 
(B), liver (C), testis (D), kidney (E), spleen (F), lung (G), heart (H), muscle (I) and small 
intestine (J) of wild type, SMSrD348E, SMS2gtXSMSrD348E and SMS2gt mice. Data are 
means of two independent measurements ± SEM; two-tailed Student’s t test: *, p<0.05; **, 
p<0.005; n=3-4 (PC, phosphatidylcholine, PE, phosphatidylethanolamine, PS, 
phosphatidylserine, PI, phosphatidylinositol). (adopted and modified from Bickert et al., 2015) 
 
Liver and brain samples from wild type and SMSrD348E mice were also investigated 
in independent MS analyses in collaboration with Dr. Katharina vom Dorp from the 
group of Prof. Peter Dörmann (University of Bonn). These quantitative-time of flight 
(Q-TOF)-MS analyses confirmed the data presented on SM, ceramide and 
hexosylceramide content and additionally, revealed no significant alterations in the 
levels of species with hydroxylated and odd-numbered fatty acyl-chains or in free 
LCBs (d18:0, d18:1, d18:2; data not shown). 
 
4.1.6 Ultra-structural analysis of cellular integrity in SMSrD348E mice 
Acute depletion of SMSr in cultured HeLa cells was accompanied by fragmentation of 
ER exit sites, a structural collapse of the early secretory pathway and induction of a 
mitochondrial pathway of apoptosis (Vacaru et al., 2009; Tafesse et al., 2014). 
Therefore, liver and brain ultra-thin sections from SMSrD348E mice were screened 
for ultra-structural aberrations in collaboration with Dr. Holger Jastrow and Prof. Elke 
Winterhager (University Hospital/University of Essen). 
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A systematic analysis of brain sections from SMSrD348E mice revealed that the 
integrity of neuronal cells from different brain regions of SMSrD348E mice was not 
significantly altered compared to wild type littermates (Figure 4.20 A, B). In 
hepatocytes of SMSrD348E mice no obvious alteration in ER or Golgi morphology 
was observed compared to wild type littermates (Figure 4.20 C, D). Moreover, neither 
integrity of mitochondria, nor the number or appearance of lipid droplets or glycogen 
granules was altered. In conjunction with these findings, analysis of kidney sections 
also revealed no differences in cellular integrity between wild type and SMSrD348E 
mice (data not shown). 
 
 
Figure 4.20 - Electron micrographs of hepatocytes and hippocampal neurons of wild 
type and SMSrD348E mice. (A) Hippocampal neurons of wild type mice revealed the typical 
morphology with abundant free ribosomes, mitochondria and some Golgi-complexes. (B) No 
obvious alterations in the morphology of cell organelles were observed in comparable 
SMSrD348E neurons. (C) Wild type mice reveal the typical cellular equipment of liver cells 
with abundant rough endoplasmic reticulum (RER), numerous mitochondria (Mi), lipid 
droplets (L) and large glycogen stores (Gs). Higher magnification of a small Golgi-apparatus 
which is typical for liver cells shows big vesicles containing lipoprotein complexes (insert). (D) 
No obvious morphological differences are detectable in cell organelles of a SMSrD348E 
hepatocyte. Higher magnification of a comparable Golgi-complex does show the same 
appearance with large vesicles containing lipoproteins (insert). For analysis littermates were 
used (n=4). b, bile canaliculus; G, Golgi-apparatus, Gs, glycogen stores; GV, Golgi vesicle; 
L, lipid droplet; Mi, mitochondria; #, Nissl substance; NP, nuclear pores; Nc, nucleolus; N, 
nucleus; scale bar insert, 200 nm. (adopted and modified from Bickert et al., 2015) 
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To further investigate liver integrity in SMSrD348E mice, serum activities of liver 
transaminases (ALT/AST) and creatine phosphokinase (CPK) were measured in 
collaboration with Prof. Gunther Hartmann (University Hospital Bonn). No significant 
differences were found between wild type and SMSrD348E mice (Figure 4.21). 
 
 
Figure 4.21 - Analysis of serum activities of alanine transaminase (ALT), aspartate 
transaminase (AST) and creatine phosphokinase (CPK) in wild type (n=6) and 
SMSrD348E (n=3) mice. Data are means ± SEM. (adopted and modified from Bickert et al., 
2015) 
 
Taken together, disruption of SMSr catalytic activity has no impact on the structural 
integrity of mouse brain, liver and kidney cells. Therefore, in contrast to human HeLa 
and Drosophila S2 cells after acute depletion of SMSr, cells in SMSrD348E mice 
appear to lack phenotypic abnormalities associated with a deregulation of ER 
ceramide levels. 
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4.2 Diet-induced obesity in ceramide synthase 4 deficient mice 
As discussed in chapter 1.3.3.5 several CerS have been shown to be involved in diet-
induced obesity in mice. These studies suggested an essential function of C16 
ceramide in the development of obesity. Nevertheless, not much is known about the 
specific function of CerS4 and corresponding C18 to C22 ceramides in mice, except 
for an essential function in the skin (see chapter 1.3.2.4). To investigate possible 
implications of CerS4 and corresponding ceramide species in the development of 
obesity, CerS4 deficient mice were subjected to high fat diet feeding. 
 
CerS4 deficient mice were generated in our group by Dr. Silke Imgrund and the basic 
characterization was performed by Dr. Philipp Ebel (see chapter 1.3.2.4). In these 
mice the whole coding region, ranging from exon 2 to exon 11 was exchanged by an 
NLS-LacZ reporter gene for investigation of CerS4 expression (Figure 4.22). 
 
 
Figure 4.22 – Scheme of the CerS4 locus in wild type and CerS4 deficient mice. The 
CerS4 wild type (WT) locus is approximately 33 kb in size and consists of 11 exons of which 
the first encodes the 5‟ untranslated region. To generate CerS4 deficient (KO) mice, the 
whole coding region (exons 2-11) was exchanged by an NLS-LacZ reporter gene. Arrows 
indicate position of primers used for mouse genotyping. (adopted and modified from Ebel et 
al., 2014) 
 
4.2.1 High fat diet feeding of CerS4 deficient mice 
For analysis of CerS4 function in the development of obesity, male wild type (WT) 
and CerS4 deficient (KO) mice were either fed a high fat diet (HFD; 60 % kcal from 
fat) or a low fat diet (LFD; 10 % kcal from fat) for 16 weeks. Four different groups, 
each of approximately 20 mice were investigated, subsequently denoted as WT HFD, 
KO HFD, WT LFD and KO LFD. Prior to starting the experiment, animals were 7-8 
weeks old and weight matched. 
 
HFD feeding led to a strong, diet-dependent increase in weight gain within 
genotypes, the differences for WT mice were significant starting from week 4 
(week 4: WT HFD +1.6 g; week 16: WT HFD +6.6 g), those for KO mice starting from 
week 6 (week 6: KO HFD +2.0 g; week 16: KO HFD +3.0 g) (Figure 4.23 A). 
Strikingly, KO mice fed HFD showed significantly reduced weight gain compared to 
WT mice starting from week 10 (week 10: WT HFD +1.9 g; week 16: WT HFD 
+3.7 g), while no difference was observed between WT and KO mice on LFD 
(week 16: WT LFD +0.1 g). Remarkably, weight gain after HFD consumption was 
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reduced, although food intake was significantly increased in KO compared to WT 
mice (~3.2 g per week; Figure 4.23 B). This was also the case for intake of LFD 
(~3.8 g per week), but weight gain was not altered between WT and KO mice.   
 
 
Figure 4.23 – Weight gain and food intake during high fat diet feeding. 7-8 week old wild 
type (WT) and Cers4 deficient mice (KO) were fed either high fat diet (HFD) or low fat diet 
(LFD) for 16 weeks. (A) Growth curve illustrating genotype and diet-dependent weight gain 
differences. (B) Average food intake per week, depicted are means of three consecutive 
weeks. Intake of HFD and LFD strongly differed within genotypes, but for reasons of clarity 
significance is not depicted (A and B n=22; 16; 22; 17 mice for WT HFD; KO HFD; WT LFD; 
KO LFD, respectively). (C) TLC analysis of lipid extracts from feces collected after 5 weeks of 
HFD feeding (n=4 mice). Chol, cholesterol; DAG, diacylglycerol; FFA, free fatty acids; TAG, 
triacylglycerol. (D) Tissue weight after 16 week exposure to HFD or LFD (n=19; 13; 19; 
13 mice). g, gonadal; i, interscapular; r, renal; s, subcutaneous. Data are means ± SEM; 
significance indicators: 1x, p<0.05; 2x, p<0.01; 3x, p<0.001. 
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TLC analysis of lipid extracts from feces collected after 5 weeks of HFD feeding 
revealed no alterations in the levels of triacylglycerols, diacylglycerols or free fatty 
acids between WT and KO mice (Figure 4.23 C). In line with the observed body 
weight gain, analysis of tissue weights revealed a substantial increase in gonadal- 
(~160 %), subcutaneous- (~160 %) and renal- (~230 %) WAT weight in WT mice fed 
HFD compared to WT mice fed LFD (Figure 4.23 D). In comparison, consistent with 
the reduction in body weight gain, KO mice showed strongly reduced weights of 
gonadal- (~40 %), subcutaneous- (~40 %) and renal- (~50 %) WAT compared to WT 
mice after HFD consumption. Adipose tissue weights from KO mice fed HFD were 
slightly but not significantly increased compared to those of WT and KO mice fed 
LFD, which did not differ from each other. HFD feeding did not alter weights of 
interscapular BAT (iBAT) and liver. Moreover, the genotype had no effect on iBAT 
weight, but liver weight was significantly decreased in KO compared to WT mice after 
16 week exposure to LFD. 
 
4.2.2 Glucose tolerance and insulin sensitivity in CerS4 deficient mice 
Prior to starting the feeding experiment, animals were subjected to glucose tolerance 
tests (GTTs) and insulin tolerance tests (ITTs). Interestingly, at the age of 7-8 weeks 
KO mice displayed significantly increased glucose tolerance (Figure 4.24 A and E) 
and insulin sensitivity (Figure 4.24 B and G). Upon exposure to HFD, WT mice 
developed severe glucose intolerance (Figure 4.24 C and F) and moderate insulin 
insensitivity compared to WT mice fed LFD (Figure 4.24 D and H). Strikingly, KO 
mice were protected from diet-induced glucose intolerance and displayed an insulin 
sensitivity similar to that observed for KO mice after consumption of LFD. Moreover, 
comparable to the measurements from 7-8 week old animals, glucose tolerance and 
insulin sensitivity were still significantly increased in 23-24 week old KO compared to 
WT mice after consumption of LFD. 
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Figure 4.24 - Glucose and insulin tolerance in CerS4 deficient mice. (A and B) Glucose 
tolerance test (GTT) and insulin tolerance test (ITT) from 7-8 week old wild type (WT) and 
CerS4 deficient (KO) mice prior to starting feeding experiment (n=19 for WT, 18 for KO). (C 
and D) GTT and ITT from 23-24 week old WT and KO mice after 16 week exposure to HFD 
or LFD (n=22; 16; 22; 17 mice for WT HFD; KO HFD; WT LFD; KO LFD, respectively). (E-H) 
Area under the curve (AUC) of GTT and ITT prior and after feeding experiment. Data are 
means ± SEM; significance indicators: 1x, p<0.05; 2x, p<0.01; 3x, p<0.001. 
 
4.2.3 CerS expression after HFD feeding 
To investigate how HFD and depletion of CerS4 affect expression of CerS in mice, 
tissue lysates of liver and pancreas were investigated by immunoblot analyses 
(Figure 4.25). Antibodies against CerS4 revealed low expression in WT livers and 
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suggested an increase following HFD feeding, however due to unspecific binding of 
the antibodies protein expression was not quantifiable in the liver (Figure 4.25 A and 
C). Analysis of CerS2 expression revealed no diet-dependent alterations between 
WT groups, but a moderate increase in KO compared to WT mice on both diets 
(HFD ~15 %; LFD ~30 %). Expression of CerS6 was not altered between WT and KO 
mice on both diets. Since insulin receptor (IR)-dependent signaling in the liver was 
shown to be impaired in CerS2 deficient mice (Park et al., 2013a), expression of the 
IRβ subchain was investigated in the liver. Diet did not influence IRβ subchain 
expression in WT mice. However, expression was increased in KO compared to WT 
mice fed LFD (~30 %) and the difference was even stronger following exposure to 
HFD (~40 %). 
 
 
Figure 4.25 – Immunoblot analyses of CerS and insulin receptor expression in liver 
and pancreas. (A) Protein expression of CerS4, CerS2, CerS6 and insulin receptor β chain 
(IRβ) in the liver of wild type (WT) and CerS4 deficient mice (KO) after consumption of HFD 
or LFD. (B) Protein expression of CerS4, CerS2, CerS6 in the pancreas of WT and KO mice 
KO after consumption of HFD or LFD. (C and D) Densitometric quantification of protein 
expression relative to GAPDH in liver and pancreas. Due to background signals CerS4 
expression was not quantifiable in the liver. Values for pancreas CerS4 expression represent 
means after background subtraction. 50 µg protein were applied per lane. Data are means ± 
SEM; n=3-5. Significance indicators refer to genotype-dependent differences based on two-
way ANOVA (*, p<0.05), Bonferroni post hoc group comparisons revealed no significances. 
 
In pancreas, CerS4 expression was readily detectable and similar to liver, expression 
seemed to be increased after consumption of HFD (~25 %), but the difference did not 
reach statistical significance (Figure 4.25 B and D). While CerS2 expression was not 
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altered between WT and KO mice after HFD consumption, the expression was 
decreased in KO compared to WT mice following LFD feeding (~40 %), but the 
difference was not significant. Analysis of CerS6 expression revealed increases in 
KO compared to WT mice after consumption of both diets (~30-40 %). 
 
4.2.4 Analysis of sphingolipid content in CerS4 deficient mice 
To investigate the influence of CerS4 depletion and HFD on the sphingolipid content, 
lipids extracted from liver, iBAT and pancreas of WT and KO mice after 16 week 
exposure to HFD or LFD were analyzed. Following extraction the sphingolipid content 
was determined by quantitative-time of flight (Q-TOF) mass spectrometry in 
collaboration with Dr. Katharina vom Dorp from the group of Prof. Peter Dörmann 
(University of Bonn). 
 
In liver, the levels of C18:0, C20:0 and also C22:0 ceramide were decreased in KO 
compared to WT mice (~50-60 %), but the differences were not significant (Figure 
4.26 A). These species were slightly increased (~40-50 %) in HFD compared to LFD 
fed WT mice. The situation was similar for hexosylceramide species, but C22:0 
hexosylceramide was not altered between WT mice after HFD and LFD consumption 
(Figure 4.26 B). Analysis of liver SM content revealed significant increases in C18:0, 
C20:0 and C22:0 (~40-50 %) SM levels in HFD compared to LFD fed WT mice 
(Figure 4.26 C). Moreover, these species were decreased in KO compared to WT 
mice after exposure to HFD (C18:0 ~50 %; C20:0 ~40 %; C22:0 ~30 %), but the 
difference was not significant for C22:0 SM species. These data show that CerS4 
contributes to the levels of C18:0 and C20:0 sphingolipid species in liver and that 
C22:0 sphingolipid levels at least partially depend on CerS4. 
 
In iBAT, C16:0 and C24:1 ceramide species were significantly increased in HFD 
compared to LFD fed WT mice (~50 %; Figure 4.26 D). C18:0 and C20:0 ceramide 
species were decreased in KO compared to WT mice after HFD consumption 
(~35 %; ~50 %), but the difference was not significant. Analysis of hexosylceramide 
species revealed a decrease in C20:0 (~30 %) in KO compared to WT mice fed HFD 
(Figure 4.26 E). Consumption of HFD led to an increase in C16:0 and C18:0 SM 
species in WT mice compared to WT mice fed LFD (~40-50 %), but the difference 
was not significant for C16:0 SM (Figure 4.26 F). However, a similar, but significant 
increase in C16:0 SM (~40 %) was observed for KO mice fed HFD compared to KO 
mice fed LFD. Taken together, the data show that CerS4 is responsible for the 
generation of C18:0 and C20:0, but not C22:0 ceramide species in iBAT, as these 
species were rather increased in KO mice. 
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Figure 4.26 – MS analysis of sphingolipid content in liver, brown adipose tissue and 
pancreas after 16 week feeding. Quantification of main ceramide (Cer), hexosylceramide 
(Hex-Cer) and sphingomyelin (SM) species with incorporated sphingosine (d18:1) in wild 
type (WT) and CerS4 deficient (KO) mice after 16 week consumption of HFD or LFD. 
Investigation of the less abundant species with incorporated sphinganine (d18:0) and 
sphingadiene (d18:2) revealed similar tendencies. (A-C) Analysis of liver. (D-F) Analysis of 
interscapular brown adipose tissue (iBAT). (G-I) Analysis of pancreas (G-I). n=4-5; Data are 
means ± SEM; significance indicators: 1x, p<0.05; 2x, p<0.01; 3x, p<0.001. 
 
In the pancreas, exposure of WT mice to HFD led to a significant increase (~40-50%) 
in C18:0, C20:0 and C22:0 ceramide species compared to WT mice fed LFD (Figure 
4.26 G). In KO compared to WT mice C18:0 and C20:0 ceramide species were highly 
significantly decreased (~70 %; ~90 %) and C22:0 species were slightly, but not 
significantly decreased (~20 %). Interestingly, C16:0 and C24:1 ceramide levels were 
increased in KO compared to WT mice on HFD (~50 %; ~30 %) and LFD (~55 %; 
~45 %), but the differences were only significant for mice fed LFD. Analysis of 
hexosylceramide levels revealed slight increases in C16:0 and C24:1 species (~15-
20 %) and a significant increase in C20:0 hexosylceramide (~40 %) in KO compared 
to WT mice on both diets (Figure 4.26 H). HFD consumption increased the levels of 
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C18:0, C20:0 and C22:0 SM levels in WT mice fed HFD compared to WT mice fed 
LFD (~40 %; ~20 %; ~35 %; Figure 4.26 I). In KO mice C18:0, C20:0 and C22:0 SM 
species were decreased compared to WT mice (HFD: ~65 %; ~85 %; ~20 %; LFD: 
~50 %; ~90 %; ~30 %). The decrease was highly significant for C18:0 and C20:0 SM 
after HFD consumption, but after LFD consumption only the decrease in C20:0 SM 
was highly significant. Notably, C16:0 SM species were significantly increased in KO 
compared to WT mice after consumption of HFD and LFD (~30 %), and also C24:0 
and C24:1 ceramide levels were increased (~20-30 %). These data show that C18:0 
and C20:0, but also C22:0 sphingolipid levels in the pancreas strongly depend on 
CerS4 and that depletion of CerS4 leads to an increase in C16:0 ceramide 
production. 
 
4.2.5 Hair loss in CerS4 deficient mice 
It was expected that CerS4 deficient mice would progressively loose hair during the 
feeding experiment. Nevertheless, according to the findings of Ebel et al. 2014, it was 
assumed that heat loss up to the age of 23-24 weeks would be negligible at ambient 
temperatures of about 22°C. However, the thermoneutral temperature of mice is at 
about 30°C and it was suggested that even minor alterations in fur composition might 
lead to heat loss and hence compensatory increases in metabolic activity at lower 
ambient temperatures (Cannon & Nedergaard, 2011). Figure 4.27 presents an 
overview of the extent of hair loss in CerS4 deficient mice of different age. CerS4 
deficient mice are indistinguishable from WT mice till the age of 6-7 weeks, when hair 
loss becomes visible in the neck and the fur appears tousled. With increasing age, 
hair loss extends to the back and the decreased density is clearly visible in the back 
of 22-24 week old animals. 
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Figure 4.27 - Hair loss in CerS4 deficient mice. 5 week old CerS4 deficient (KO) mice 
show no obvious signs of hair loss compared to wild type (WT) mice. Hair loss becomes 
obvious in 6-7 week old animals, starting in the neck. In 12-14 week old animals hair loss 
starts to extend through the back. 20-22 week old animals show obvious hair loss, 
characterized by decreased density throughout the back. 
 
It was not possible to clearly distinguish between protective effects resulting from hair 
loss or from improved function of metabolically active tissues due to lack of CerS4. 
Therefore, the analysis was continued in 5 week old animals, which as previously 
discussed show no obvious signs of hair loss (Figure 4.27). 
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4.3 Energy expenditure and adipose tissue function in CerS4 deficient mice 
Protection from diet-induced obesity is often accompanied by increased energy 
expenditure. Increased energy expenditure can have different reasons. For instance, 
it can be a consequence of increased muscular activity or result from increased 
thermogenesis in BAT. To investigate energy expenditure and adipose tissue 
function in CerS4 deficient mice, a collaboration with Dr. Thorsten Gnad and Prof. 
Alexander Pfeifer from the Institute of Pharmacology and Toxicology (University of 
Bonn), who are experts on non-shivering thermogenesis, was initiated. 
 
4.3.1 Oxygen consumption in CerS4 deficient mice 
Energy expenditure is usually associated with oxygen consumption. Oxygen 
consumption of wild type (WT) and CerS4 deficient (KO) mice was determined at 
different ambient temperatures. Oxygen consumption at 23°C (housing temperature), 
was measured for 24 h. The analysis revealed significantly increased oxygen 
consumption in KO compared to WT mice (Figure 4.28 A and B). Mouse motility was 
not altered at this temperature (Figure 4.28 C). Measurement of food intake during 
the experiment revealed no differences between WT and KO mice (Figure 4.28 D). 
Cold exposure, the physiological stimulus for BAT activation, at 4°C for 1 h did also 
increase oxygen consumption in KO compared to WT mice, but the difference did not 
reach statistical significance (Figure 4.28 E and F). Oxygen consumption at 4°C was 
also not affected by increased motility (Figure 4.28 G). In contrast, analysis of mice 
exposed to 30°C (thermoneutral temperature) for 5 h suggested increased oxygen 
consumption in KO compared to WT mice, but the difference was only modest and 
not significant (Figure 4.28 H and I). 
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Figure 4.28 – Oxygen consumption in 5 week old mice. Wild type (WT) and CerS4 
deficient (KO) mice were subjected to oxygen consumption measurements at different 
ambient temperatures. (A and B) Oxygen consumption measured for 24 h at 23°C 
(measurement started at 6 am) and motility (C) and food intake (D) during this time (n=3 for 
WT; 4 for KO). (E and F) Oxygen consumption measured for 1 h at 4°C and motility (G) 
during this time (n=3 for WT; 5 for KO). (H and I) Oxygen consumption measured for 5 h at 
30°C (n=3). Data are means ± SEM; *, p<0.05. 
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4.3.2 CerS expression in adipose tissue 
As a basis for further analyses, different adipose tissue depots of 5 week old WT 
mice were investigated by immunoblot analysis to determine the protein expression 
of CerS4 and other CerS (Figure 4.29). The analysis revealed that CerS4 is only 
weakly expressed in interscapular BAT (iBAT). Expression in white adipose tissue 
was much stronger, with high levels in inguinal WAT (igWAT; subcutaneous WAT 
depot) and especially high levels in gonadal WAT (gWAT; visceral WAT depot). 
CerS2 was highly expressed in all investigated adipose tissue depots with 
comparable levels in iBAT, igWAT and gWAT. CerS5 showed a similar expression 
pattern to CerS4. It was virtually absent in iBAT, strongly expressed in igWAT and 
even stronger in gWAT. In contrast, CerS6 was virtually absent in gWAT and 
expressed to similar extents in iBAT and igWAT. 
 
Figure 4.29 – Protein expression of ceramide synthases in adipose tissue of 5 week 
old mice. Immunoblot analysis of CerS4, CerS2, CerS5 and CerS6 expression in 
interscapular BAT (iBAT), inguinal WAT (igWAT) and gonadal WAT (gWAT) of wild type 
(WT) mice (n=3). Tissues from CerS4 deficient (KO) mice served as control for the anti-
CerS4 antibodies; GAPDH served as loading control. 
 
4.3.3 Adipose tissue in CerS4 deficient mice 
Analysis of 5-6 week old KO mice revealed no differences in body size and body 
weight compared to WT mice (Figure 4.30 A and B). Similar to that, no differences 
were observed for iBAT, igWAT and gWAT weight (Figure 4.30 C). H&E (hematoxylin 
and eosin)-staining of paraffin sections from iBAT revealed slightly increased 
adipocyte size in KO compared to WT mice (Figure 4.30 D; upper panels). In igWAT, 
H&E-staining revealed a strong decrease in adipocyte size in KO compared to WT 
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mice (Figure 4.30 D; lower panels). Moreover, multiple, smaller multilocular 
adipocytes were interspersed in KO tissue, but absent in WT mice. 
 
 
 
Figure 4.30 – Adipose tissue weight and morphology in 5-6 week old mice. (A) Body 
length (measured from nose to tailtip and from nose to tailroot) and (B) body weight of wild 
type (WT) and CerS4 deficient (KO) mice (n=8). (C) Tissue weight of interscapular BAT 
(iBAT), inguinal WAT (igWAT) and gonadal WAT (gWAT) (n=11-12). (D) Representative 
H&E-stainings of iBAT and igWAT paraffin sections (5 µm); scale bar 100 µm. 
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4.3.4 Cultured brown and white adipocytes of CerS4 deficient mice 
The increased oxygen consumption and the altered adipose tissue morphology in 
CerS4 deficient mice point to increased browning of WAT. The fact that 5 week old 
mice show no signs of hair loss or altered food intake, indicates that these mice do 
not suffer from heat loss. Nevertheless, to completely exclude possible effects 
resulting from alterations of skin or fur, brown and white preadipocytes were isolated 
from new born and 5 week old mice, respectively, and differentiated in vitro. These 
cells were investigated by Real Time (RT)-PCR analysis of adipogenic and 
thermogenic markers. 
 
In cultured brown adipocytes from WT and KO mice, no differences were observed in 
the mRNA levels of the adipogenic marker PPARγ (peroxisome proliferator-activated 
receptor γ), the major transcription factor regulating adipocyte differentiation 
(Kajimura et al., 2010) (Figure 4.31 A). In the same line, the mRNA levels of aP2 
(adipocyte Protein 2, also known as FABP4, fatty acid binding protein 4), a target 
gene of PPARγ and a marker for differentiated adipocytes (Shan et al., 2012) were 
unaltered. No significant difference was also observed for the mRNA of UCP1, the 
characteristic marker of BAT. Stimulation of brown adipocytes with cGMP (cyclic 
guanosine monophosphate), which induces adipogenesis and activates BAT cells 
(Mitschke et al., 2013), increased mRNA levels of PPARγ, aP2 and UCP1 by about 
100 % compared to untreated cells. The mRNA levels of PPARγ and aP2 in cGMP-
treated WT and KO cells were not altered, but UCP1 levels were slightly, but 
significantly increased (~10 %) in treated KO compared to WT cells. 
 
In cultured white adipocytes, the mRNA level of PPARγ was significantly elevated by 
about 65 % in KO compared to WT cells (Figure 4.31 B). In contrast, aP2 levels were 
unaltered. Stimulation of cultured white adipocytes with cGMP increased mRNA 
levels of PPARγ and aP2 by about 100 % compared to untreated cells. Notably, 
cGMP treatment abrogated the increase in PPARγ mRNA levels observed for 
untreated KO cells and also aP2 levels were not altered between cGMP-treated WT 
and KO cells. 
 
Analysis of thermogenic markers in cultured white adipocytes revealed a substantial 
increase (~500 %) in UCP1 mRNA in KO compared to WT cells (Figure 4.31 C). In 
addition, mRNA levels of the BAT markers PGC1α (PPARγ coactivator 1α), PRDM16 
(PR domain containing 16) and CIDEA (cell death-inducing DFFA-like effector A) 
were determined. PGC1α regulates mitochondrial biogenesis and oxidative 
metabolism in BAT (Kajimura & Saito, 2014). PRDM16 (PR domain containing 16) is 
a major determining factor for BAT development (Lo & Sun, 2013). And CIDEA (cell 
death-inducing DFFA-like effector A) is a BAT specific marker involved in lipid droplet 
fusion and lipid storage in brown adipocytes (Wu et al., 2014). All of these 
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thermogenic markers were increased (PGC1α ~50 %; PRDM16 ~170 %; CIDEA 
~100 %) in KO compared to WT cells, but the differences did not reach statistical 
significance (Figure 4.31 C). Treatment with NE (norepinephrine), a well-known 
inducer of browning (Chen et al., 2013b), substantially increased the expression 
levels of all thermogenic markers compared to untreated cells (UCP1 ~500 %; 
PGC1α ~150 %; PRDM16 ~180 %; CIDEA ~200 %). The increase was even stronger 
in NE-treated KO compared to WT cells. The difference was highly significant for 
UCP1 mRNA levels (~30 %) and also significant for CIDEA mRNA (~40 %), but not 
for PGC1α (~20 %) and PRDM16 (~30 %). 
  
 
Figure 4.31 – RT-PCR analysis of adipogenic and thermogenic markers in brown and 
white adipocytes. (A) Relative mRNA levels of BAT markers in untreated or cGMP (cyclic 
guanosine monophosphate)-treated brown adipocytes isolated from iBAT of new born wild 
type (WT) and CerS4 deficient (KO) mice. (B) Relative mRNA levels of adipogenic markers in 
untreated or cGMP-treated white adipocytes isolated from igWAT of 5 week old WT and KO 
mice. (B) Relative mRNA levels of thermogenic markers in untreated or NE (norepinephrine)-
treated white adipocytes. Data are means ± SEM, n=4; significance indicators: 1x, p<0.05; 
3x, p<0.001. 
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5 Discussion 
5.1 SMSr 
SMSr is the best-conserved member of the SMS family and together with a second 
member, SMS2, catalyzes production of the SM analogue CPE. Previously it was 
shown that in cultured cells, SMSr function is critical for ceramide homeostasis and 
suppression of ceramide-induced mitochondrial apoptosis (Vacaru et al., 2009; 
Tafesse et al., 2014). These studies revealed that the regulatory function of SMSr is 
strongly dependent on its catalytic activity and it was shown that the point mutation 
D348E leads to catalytic inactivity of the human SMSr protein. To investigate the 
in vivo function of SMSr, we aimed to deplete SMSr catalytic activity in mice. 
Therefore, the transgenic mouse lines SMSrD348E and SMSrdelEx6 were 
established. As a prerequisite for this study it was shown that the point mutation 
D348E and depletion of exon 6, both lead to catalytic inactivity of SMSr in 
SMSrD348E and SMSrdelEx6 mice, respectively. However, ubiquitous catalytic 
inactivation of SMSr in both mouse lines did not affect embryonic development, 
survival, healthiness or fertility. Notably, a simultaneous study from the collaborating 
group of Prof. Xian-Cheng Jiang (New York) reported the same for SMSr null mice 
(Ding et al., 2015), pointing also to a discrepancy between the in vitro and in vivo 
function of SMSr. 
 
5.1.1 SMSr expression 
In this Ph. D thesis it was shown that the newly generated antibodies raised against 
SMSr specifically recognize the mouse and human protein in immunoblot analyses. 
In contrast, the antibodies did not recognize mouse SMSr in immunofluorescence 
analyses of liver and brain. Therefore, recognition of the epitope in the native protein 
might be prevented by protein folding. 
 
Northern Blot analyses of human and mouse tissues suggested ubiquitous 
expression of SMS1 and SMS2 in mammals (Huitema et al., 2004; Yang et al., 
2005). To investigate SMSr expression in mice, the newly generated, specific 
antibodies against SMSr and ß-galactosidase stainings in SMSrD348E mice were 
used. SMSr expression was found in every investigated mouse tissue, as well as in 
mouse embryonic fibroblasts and bone marrow derived macrophages, but not in 
embryonic stem cells, as was reported before (Ginkel, 2013). The positive signals in 
the original study probably resulted from staining of early differentiating cells such as 
embryonic fibroblasts, in which SMSr was found to be expressed in this Ph. D thesis. 
The strongest expression of SMSr was observed in brain and testis, which might 
indicate a fundamental role of the protein in these tissues. However, loss of catalytic 
activity in SMSr mutant mice did not obviously affect integrity of these tissues. 
Independent analyses of SMSr transcript levels also revealed a broad tissue 
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distribution and especially high levels in testis and bone marrow derived 
macrophages (Ding et al., 2015). Although immunoblot analyses showed that SMSr 
is widely expressed in mice, ß-galactosidase stainings e.g. of brain, liver or testis 
indicated that it is not expressed in every cell type. 
 
Interestingly, in immunoblot analyses the newly generated antibodies recognized two 
different protein isoforms, which according to their appearance were termed, SMSr 
and SMSr-2. Database analysis revealed two protein coding transcripts for the 
murine smsr (http://www.ensembl.org; Gene ID: ENSMUSG00000021770), indicating 
that mouse smsr is subject to alternative splicing. Alternative splicing was already 
described for mouse sms1, another homologue of the SMS family, with multiple 
transcripts in a variety of tissues e.g. brain, liver, kidney or testis (Yang et al., 2005). 
Nevertheless, alternative splicing of the murine smsr seems to be more specific, 
since the SMSr-2 protein isoform was not found in all investigated tissues and it was 
the main isoform only in testis, where alternative splicing is very frequent (Elliott & 
Grellscheid, 2006). 
 
5.1.2 Protein degradation in SMSrD348E and SMSrdelEx6 mice 
The analysis of SMSrD348E protein levels in microsomal fractions and total tissue 
lysates suggests that the protein gets degraded. The point-mutated protein is 
translated from a bicistronic transcript, which additionally harbors the sequence for 
the ß-galactosidase reporter protein. Since ß-galactosidase expression was readily 
detected in several mouse tissues and residual SMSrD348E protein was found in 
microsomal fractions of brain and liver, transcription of the bicistronic mRNA is 
probably not compromised. The substantial decrease in SMSrD348E protein levels 
rather implies that due to the D348E point mutation the protein gets misfolded and at 
least partially degraded. As low amounts of SMSrD348E protein were detectable in 
ER membrane-enriched microsomal fractions of brain and liver, it is probably not 
completely absent. Rather the amount in total tissue lysates is below detection level. 
The original intention when establishing the SMSrD348E mouse line was to generate 
mice with catalytically inactive SMSr. Since SMSrD348E mice do not exhibit CPE 
synthase activity, degradation of the point-mutated protein was negligible for the 
phenotypic analyses of these mice. 
 
The SMSrdelEx6 mice used in this thesis exclusively served as negative controls to 
verify the specificity of the newly generated antibodies against SMSr. A possible 
degradation of the truncated protein did not influence this, because loss of the protein 
due to degradation serves the same function as lack of the endogenous C-terminus 
in the SMSrNT-eGFP fusion protein, in both cases the anti-SMSr antibodies should 
not detect any signal for SMSr. Even if the analyses in this thesis were not influenced 
by the fact that the mutated proteins in SMSrD348E and SMSrdelEx6 mice are 
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probably degraded, these circumstances have to be taken into account in future 
investigations. 
 
5.1.3 SMSr catalytic activity 
The results from the CPE synthase activity assay indicate that due to the point 
mutation D348E, or respectively deletion of exon 6, catalytic activity is lost in 
SMSrD348E and SMSrdelEx6 mice. However, the observed decrease in 
SMSrD348E protein levels in microsomal fractions would lead to a per se decrease in 
CPE synthase activity, even if catalytic activity is not affected by the D348E point 
mutation. Nevertheless, NBD-CPE production was completely abolished in brain and 
liver microsomal fractions of SMSrD348E mice, despite residual protein. Therefore, it 
can be concluded that the D348E point mutation and hence also deletion of exon 6, 
indeed lead to catalytic inactivity of SMSr. 
 
The enzyme assay data on SMSr single and SMSr X SMS2 double mutant mice 
revealed that SMSr is the predominant CPE synthase in brain. In contrast, 
contribution of SMS2 to brain CPE synthase activity was only minor, although SMS2 
deficiency markedly reduced SMS activity. However, SMS activity was found to be 
rather low, indicating that both SMSs exhibit only weak activity in brain. Contrary to 
this, SMS activity was very high in liver and the results indicated that SMS2 is the 
predominant contributor to this activity. The results are in line with previous 
measurements, where SMS activity was reduced by 80 % in the liver of SMS2gt 
animals and only by 15 % in the liver of SMS1 KO mice (Li et al., 2012). The total 
CPE synthase activity in liver was shown to result from equal contributions of SMSr 
and SMS2, as NBD-CPE production was similarly decreased in all single mutants 
and only completely abolished in double mutants. This is in line with the observed 
CPE synthase activity in the liver of SMSr null mice, which was decreased by 
approximately 50 % (Ding et al., 2015). The study further reported that CPE synthase 
activity in kidney and bone marrow derived macrophages from SMSr null mice is 
decreased to about 20-30 %. The analyses of enzyme activities in brain and liver of 
SMS mutant mice performed in the course of this Ph. D thesis complemented 
previous heterologous expression studies (Ternes et al., 2009; Vacaru et al., 2009), 
confirming that SMSr acts as monofunctional CPE synthase and that SMS2 acts as a 
bifunctional enzyme with both SM and CPE synthase activity. The data on CPE- and 
SM synthase activity in liver and brain correlate well with the protein expression of 
SMSr, as well as with the microarray analysis of SMS expression from BioGPS 
(Lattin et al., 2008). Taken together, SMSr in contrast to SMS1 and SMS2 is strongly 
expressed in brain, whereas in liver SMSr and SMS2 are moderately expressed and 
SMS1 seems to be nearly absent. 
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5.1.4 Masspectrometric analyses of CPE and SM content 
In line with previous findings in cultured mammalian cells (Vacaru et al., 2009), it was 
shown that SMSr and SMS2 produce only trace amounts of CPE in mouse tissues. 
Steady-state levels of CPE, determined by mass spectrometry, were exceedingly low 
in all investigated tissues, i.e. ~300 to 1,500-fold below those of SM. The influence of 
SMSr on CPE levels was clearly pronounced only in brain. The decrease in 
SMSrD348E mice was in line the high expression level of SMSr and the significant 
contribution to total CPE synthase activity in this tissue. Decreased CPE levels in 
kidney were also in correlation with high expression levels of SMSr. In contrast, 
despite low expression of SMSr, CPE levels were also slightly decreased in spleen 
and lung of SMSrD348E mice, indicating that independent of protein expression 
other mechanisms might come into play to adjust SMSr catalytic activity. In 
conjunction with the expression levels of sms2 a significant decrease in kidney CPE 
levels was also observed for SMS2gt mice. Since SMSrD348E mice displayed a 
similar decrease, it is surprising that kidney CPE levels were not further decreased in 
double mutants. This indicates that cells might be able to maintain CPE levels by 
adjusting the activity of enzymes involved in CPE synthesis or degradation. This 
question should be addressed by extended analyses of tissues in which the 
expression of SMSr and SMS2 cannot exclusively explain changes in CPE levels. In 
small intestine only combinatorial depletion of SMSr and SMS2 activity led to a 
significant decrease in CPE levels. This indicates that both enzymes equally 
contribute to CPE synthesis, in conjunction with comparable expression levels in this 
tissue. The MS analysis of liver suggests that CPE levels primarily depend on SMS2. 
This is in contrast to the low expression of sms2 and the high expression of SMSr in 
this tissue. Surprisingly, CPE levels were particularly low in liver and no decrease 
was detectable in single and double mutant mice, although CPE synthase activity 
was completely abolished in double mutants. Metabolic labeling experiments in 
cultured HeLa cells indicated that CPE is not a short-lived metabolic intermediate 
(Vacaru et al., 2009), which is supported by the fact that CPE was readily detectable 
in all tissues apart from liver. The present data suggest that in liver cells the liver-
specific methyl-transferase PEMT (Ridgway & Vance, 1992) may use CPE as 
precursor in a methylation-dependent pathway of SM production. Despite expression 
of SMSr and SMS2, this could explain the particularly low steady-state levels of CPE 
in liver compared to other tissues. The results indicate that the contribution of the 
PEMT-dependent pathway to total SM levels in the liver is very small and the 
physiological relevance is unclear. To further verify that PEMT-catalyzed methylation 
of CPE occurs in the liver, enzyme activity assays are necessary. 
 
An interesting finding is that primarily the shorter chain CPE species C18:0 and 
C20:0 (and to a lower extent C16:0) were affected in SMSrD348E mice. The 
preference for specific molecular species is well-established in sphingolipid 
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biosynthetic pathways, for instance the use of specific acyl-CoA species by CerS 
(see chapter 1.3.2.1). Notably, SMS2 depletion did also not affect C22:0, C24:0 and 
C24:1 CPE species, but all major SM species. This raises the question, whether 
molecular remodeling by a yet unknown mechanism could be responsible for 
production of longer chain CPE species. Remodeling of shorter chain CPE species 
could involve a mechanism analog to the elongation of fatty acids by the ELOVL 
(elongation of very long chain fatty acids) family (Jakobsson et al., 2006). 
Alternatively, longer CPE species could originate from corresponding SM species via 
an unidentified mechanism of SM demethylation or produced by a yet unknown CPE 
synthase with different or broader substrate specificity. 
 
Analysis of SM levels revealed remarkable decreases in forebrain, cerebellum and 
kidney of SMS2gt and double mutant mice. In case of kidney this clearly correlated 
with the expression of sms2. Interestingly, despite the decrease in SM levels, CPE 
levels were not affected in forebrain and cerebellum of SMS2gt mice. CPE levels are 
most likely not maintained by SMSr in this case, as the levels were similarly 
decreased in double mutant and SMSrD348E mice. The data on CPE and SM 
content in liver are comparable with findings from SMSr null and SMS2gt X SMSr null 
mice (Ding et al., 2015). Additionally, this study reported a similar discrepancy for 
bone marrow derived macrophages (BMDMs) from SMS2gt X SMSr null mice. These 
BMDMs displayed no decrease in CPE levels, although SM levels were significantly 
decreased, and CPE synthase activity in macrophages of SMSr null mice was 
reduced by approximately 70 % (Ding et al., 2015). 
 
SM production by SMS2 is obviously predominant over CPE production, but the 
question remains why SMSr and SMS2 are intrinsically unable to produce bulk 
amounts of CPE. The lipid phosphate phosphatase-type reaction mechanism utilized 
by members of the SMS enzyme family involves a single lipid binding site and 
includes transfer of the headgroup from PC or PE to a conserved histidine residue in 
the active site of the enzymes (Tafesse et al., 2006). Subsequently DAG is replaced 
by ceramide and the headgroup gets transferred onto ceramide generating SM or 
CPE, respectively. The ability of SMS2 to produce bulk amounts of SM suggests a 
higher affinity towards the head group donor PC in comparison to PE. The analysis of 
glycerophospholipid content suggests that the preferred use of PC instead of PE 
cannot be explained by the general PC/PE ratio, but it could be that the PC/PE ratio 
is especially high in the exoplasmic leaflet of the plasma membrane where the active 
site of SMS2 resides (Huitema et al., 2004; Tafesse et al., 2007). Moreover, as 
already suggested before, catalytic activity of SMSr and SMS2 may be under 
negative control by their product, CPE (see chapter 1.3.4.2). In any case, the fact that 
bulk production of CPE in insects is catalyzed by an unrelated enzyme from an 
insect-specific branch of the CDP-alcohol transferase superfamily (Vacaru et al., 
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2013) implies that the reaction mechanism used by enzymes of the SMS family is 
unsuited for efficient production of CPE. 
 
5.1.5 Determinants of CPE content 
The inability of SMSr and SMS2 to produce large amounts of CPE might explain the 
generally low levels in tissue CPE, but unexpectedly even in double mutant mice 
substantial amounts of residual CPE were still detectable in any of the investigated 
tissues. This suggests alternative sources of CPE and probably includes enzymes 
different from SMSr and SMS2. A virtually inexhaustible source for CPE production 
would be SM, similar to its synthesis by head group transfer from PC to ceramide, 
SM could be converted to CPE by head group exchange with PE. However, nothing 
is known about the identity of proteins that catalyze such a reaction. An alternative 
pathway for SM synthesis involves methylation of CPE (Muehlenberg et al., 1972). 
While on the one hand this pathway could contribute to the low CPE levels in mice, 
the reverse reaction i.e. demethylation of SM, could be an efficient way to keep CPE 
levels constant. However, the actual contribution and physiological relevance of this 
pathway is poorly understood. 
 
Since SMS2 exhibits CPE synthase activity and SMS1 and SMS2 show high 
sequence similarity (Huitema et al., 2004), it seems plausible that SMS1 might also 
be capable of catalyzing CPE production. Experiments with yeast cells 
overexpressing human SMS1 indicated that the enzyme is indeed capable of 
producing trace amounts of CPE and specific substitutions adjacent to the active site 
convert the enzyme into a monofunctional CPE synthase (Kol et al., 2016). The 
ability of SMS1 to produce CPE was also suggested based on observations in SMS1 
deficient mice, in which plasma CPE levels were significantly reduced (Ding et al., 
2015). Moreover, overexpression of SMS1 in SF9 insect cells increased CPE 
production (Ding et al., 2015). In consequence depending on the tissue and the 
respective expression levels of sms1, remaining CPE levels could at least partially be 
explained by SMS1-mediated production. By upregulation of sms1 expression cells 
could adapt to depleted CPE levels to alleviate deleterious effects resulting from that 
depletion. However, sms1 mRNA levels were not altered in the liver of SMSr null and 
SMSr null X SMS2gt mice (Ding et al., 2015). Nevertheless, no protein expression 
data is available and it could be that even in tissues where sms1 wild type levels are 
relatively low e. g. forebrain and cerebellum, a slight increase in SMS1 protein levels 
or activity might be sufficient to adjust steady-state CPE levels according to cellular 
needs. On the other hand SMS1-driven CPE synthesis could explain why CPE levels, 
despite high expression levels of SMSr, are not decreased in some tissues of 
SMSrD348E mice. This may occur in testis, where combinatorial loss of SMSr and 
SMS2 had no impact on CPE levels, since expression levels of sms1 are particularly 
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high and depletion in mice led to a substantial decrease in SMS activity (Li et al., 
2012). 
 
Another important factor for determination of CPE levels might be the largely 
unexplored degradation of CPE. Conversion of CPE to SM (for instance by 
methylation, as was shown for PEMT in the liver) might be sufficient with respect to 
the exceedingly low levels, but the existence of a specific enzyme cannot be 
excluded. A possibility could be a dual activity of SMases in analogy to dual activity of 
SMS1 and SMS2 in the production of CPE. However, it was shown that a bacterial 
SMase is not capable of degrading CPE (Sergelius et al., 2012). Nevertheless, the 
situation could be different in mammals, which express different isoforms of SMase. 
Alternatively, in line with the fact that usually every anabolic enzyme in the 
sphingolipid metabolic pathway has a catabolic counterpart (see chapter 1.3.1.4), 
mammals might express a specific CPEase. However, the identity of such a protein 
remains to be established. 
 
Furthermore, it cannot be excluded that tissue CPE at least partially originates from 
dietary intake. The liver as a central metabolic organ could play a decisive role in 
distributing CPE (as well as SM) or precursors originating from food, but also from de 
novo synthesis. In addition to the presence of PEMT, the latter could explain why 
CPE levels are exceedingly low in the liver. In line with this assumption a study 
focusing on regulation of plasma ceramide levels reported that the liver detects and 
secretes de novo synthesized ceramides (Watt et al., 2012). Such a release could be 
a general mechanism to ensure sphingolipid supply in various tissues or alternatively 
a way to protect the liver from accumulating intermediates of the sphingolipid 
metabolism. 
 
5.1.6 CPE function 
In insects, which lack SM synthases, CPE is a major plasma membrane constituent 
and produced in bulk amounts by a unique CPE synthase independent of SMSr 
(Vacaru et al., 2013). In Drosophila it was shown that CPE fulfills an essential 
function in glial ensheathment of axons (Ghosh et al., 2013). However, the role in 
mammals appears to be different as CPE levels are exceedingly low. This is 
supported by the fact that no morphological abnormalities were found in the brain 
and other tissues of SMSrD348E mice and even depletion of two different CPE 
synthases in mice did not compromise viability and healthiness. A recent study 
reported decreased expression of the drug transporter protein Pgp (Mdr1/P-
Glycoprotein) in the brain of SMS2 deficient mice (Zhang et al., 2011). The fact that 
CPE levels are not altered in forebrain and cerebellum of SMS2gt animals suggests 
that these effects are most likely not due to missing CPE production and rather are a 
consequence of missing SM synthesis. This is supported by the fact that despite a 
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significant decrease in CPE levels, integrity of brain cells was not affected in 
SMSrD348E mice. As CPE levels were not even completely wiped out in mice 
lacking two CPE synthases, the function of CPE in mice remains uncertain. 
 
As discussed for sphingolipids in general, CPE might affect biophysical properties of 
mammalian membranes. The head group of CPE, in contrast to that of SM, requires 
less space and should allow denser packing. However, it was shown that in contrast 
to SM, which preferentially interacts with cholesterol to form highly-ordered 
membrane lipid microdomains, CPE did not interact with cholesterol in artificial 
membranes (Térová et al., 2005). Moreover, as CPE levels in mammalian cells are 
exceedingly low it appears unlikely that CPE dramatically affects overall membrane 
properties. In contrast, CPE could exhibit specific functions e.g. in disturbing 
establishment or maintenance of lipid microdomains. Alternatively, as was suggested 
for the ganglioside GM3 (Kabayama et al., 2007), it could act as a co-factor that 
either modulates function or complex formation of membrane proteins. It was already 
speculated that CPE may inhibit SMSr function by blocking the active site after its 
production (see chapter 1.3.4.2), which could also be valid for SMS2. CPE liberated 
from the active site of SMSr (or SMS2) could also act as inhibitor of other enzymes 
with comparable substrate binding sites. 
 
5.1.7 SMSr is dispensable for ceramide homeostasis and cellular integrity 
in mice 
Previously it was reported that acute disruption of SMSr catalytic activity in cultured 
human HeLa and Drosophila S2 cells results in accumulation of ceramides in the ER, 
a structural collapse of ER exit sites, fragmentation of the Golgi and induction of a 
mitochondrial pathway of apoptosis (Vacaru et al., 2009; Tafesse et al., 2014). 
Contrary to these findings, no alterations in ceramide and hexosylceramide levels 
were observed in ten different tissues of SMSrD348E mice in this Ph. D thesis. 
Moreover, histological analysis (β-galactosidase stainings) revealed no 
morphological abnormalities in brain, liver, kidney, heart, pancreas or testis, and 
ultra-structural analysis of brain, liver and kidney showed no alterations in the 
morphology of ER, Golgi or other organelles. The analysis of serum activities of liver 
transaminases and creatine phosphokinase further confirmed that liver integrity is not 
affected after disruption of SMSr catalytic activity. In line with the unaffected vitality of 
SMSrD348E mice this indicates that cellular integrity is not compromised when SMSr 
catalytic activity is lost in vivo. 
 
While siRNA experiments in contrast to genetic approaches represent a convenient 
and less time consuming way to disturb gene expression, the observed 
consequences often result from off-target effects. However, the studies focusing on 
SMSr function in cultured cells reported similar effects for different siRNAs targeting 
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SMSr (Vacaru et al., 2009; Tafesse et al., 2014). Moreover, phenotypes could be 
rescued by transfection with an siRNA-resistant construct for wild type SMSr and in 
contrast, transfection with an siRNA-resistant construct for catalytically inactive 
SMSrD348E failed to rescue the phenotype. Therefore, it appears unlikely that the 
severely compromised cellular integrity in these studies resulted from off-target 
effects. 
 
An independent study reported that the elevation in ceramide levels after siRNA-
mediated knock-down of smsr in HeLa cells is not due to an increase in ceramide de 
novo synthesis (Siow & Wattenberg, 2012). Nevertheless, a block in de novo 
ceramide synthesis, a stimulated export of ceramides from the ER or consumption of 
excess ceramides by targeting SMS1 to the ER suppressed the compromised 
structural integrity and viability of cultured cells after acute depletion of SMSr (Vacaru 
et al., 2009; Tafesse et al., 2014). This indicates that the deregulation of ER 
ceramides is primarily responsible for these phenotypes. Therefore, it is surprising 
that catalytic inactivation of SMSr in mice did not alter ceramide levels, cell survival or 
integrity in any of the investigated tissues. The comparable findings in SMSr null mice 
(Ding et al., 2015) further emphasize the discrepancy between the in vitro and the in 
vivo system and the question how these contradictory results can be explained 
remains unanswered. 
 
The experiments with cultured HeLa and Drosophila S2 cells focused on the short-
term effects after siRNA-mediated depletion of endogenous SMSr and subsequent 
transfection with an siRNA-resistant, catalytically inactive SMSrD348E protein 
(Vacaru et al., 2009; Tafesse et al., 2014). In these studies, the consequences of 
SMSr inactivation were investigated within 3 days. For some cells this time span 
might be too short to adapt sphingolipid metabolism and prevent ceramide 
accumulation and subsequent perturbation of cellular integrity and viability. Since the 
study in this Ph. D thesis focused on adult mice, it cannot be excluded that depletion 
of SMSr catalytic activity leads to a transient deregulation of ER ceramides already 
during early embryonic development, which individual embryonic cells may be able to 
overcome. In order to ensure proper development and function, these and 
descendant cells might permanently adjust sphingolipid metabolism to compensate 
jeopardizing effects resulting from missing SMSr function. 
 
Similar to downregulation of smsr, acute depletion of sms1 or sms2 in HeLa cells led 
to a substantial increase in ceramide levels and was accompanied by a block in cell 
growth (Tafesse et al., 2007). Since SMS1 and SMS2 are capable of producing bulk 
amounts of SM, ceramide accumulation is likely in this case. While no alterations in 
SM levels were observed in SMSrD348E compared to wild type mice, SM levels were 
reduced by about 15-25 % in forebrain, cerebellum, kidney and liver of SMS2gt mice. 
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Notably, no significant increase in ceramide or hexosylceramide levels was observed 
in forebrain and cerebellum and the increases in ceramide levels in kidney and in 
hexosylceramide levels in liver were rather small with respect to the high 
SM/(hexosyl)ceramide ratio in these tissues (~10:1 for SM/ceramide in kidney and for 
SM/hexosylceramide in liver). The data are in line with previous findings in SMS2gt 
mice (Liu et al., 2009b), and also genetic ablation of SMS1 did not dramatically 
increase ceramide levels in different tissues (Yano et al., 2011; Li et al., 2012). This 
raises the question, whether mammals have evolved compensatory mechanisms to 
prevent ceramide accumulation. One possibility to prevent ceramide accumulation in 
SMSrD348E mice could be a reduction in ceramide synthesis. However, this should 
be accompanied by accumulation of the corresponding substrates (i.e. LCBs and 
acyl-CoAs) and the levels of LCBs were not altered in SMSrD348E mice. The 
unaltered LCB levels also exclude inhibited sphingolipid de novo synthesis. In the 
same line it is unlikely that steady-state ceramide levels in these mice are adjusted 
by an increased conversion to hexosylceramide or SM, as the levels of these 
sphingolipids were also unaffected. Moreover, the fact that sphingosine levels are not 
increased in SMSrD348E mice also argues against increased ceramide degradation 
by the action of ceramidases. Actually, sphingosine resulting from this degradation 
could be immediately converted to S1P, but substantially increased levels of S1P 
would probably severely affect cellular integrity (Mendelson et al., 2014), and S1P 
levels were unaltered in the plasma of SMSr null mice (Ding et al., 2015). To avoid 
toxic accumulation of ceramides mammals may have co-evolved different proteins 
with redundant function. In case of SMSr depletion such a protein could cope with 
missing function. The loss of such a protein in a genetically unstable cancer cell line 
such as HeLa might explain the inability to prevent ceramide accumulation after 
siRNA-mediated knock-down of smsr. 
 
In the follow-up publication on SMSr function in cultured HeLa cells it was reported 
that the observed ceramide accumulation after acute knock-down of SMSr results in 
mislocalisation of ceramide to mitochondria and thereby induces a mitochondrial 
pathway of apoptosis (Tafesse et al., 2014). Interestingly, similar to the SMSrD348E 
point mutation, a SAM domain deletion construct was not able to rescue this 
phenotype after transfection into these HeLa cells, although catalytic activity was 
restored (Vacaru et al., 2009; Tafesse et al., 2014). Since SMSrD348E and 
SMSrdelEx6 mice are supposed to express mutated proteins with functional SAM 
domain, a protective function of the SAM domain in these mice cannot be excluded. 
However, similar to SMSrD348E mice the previously mentioned SMSr Null mice, 
which completely lack SMSr, did not show any obvious phenotypic alterations (Ding 
et al., 2015). This indicates that presence of the SAM domain does not prevent 
negative effects in SMSrD348E mice. 
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In conclusion, the study in this Ph. D thesis implies that SMSr is not a critical 
regulator of ceramide levels and that SMSr-mediated CPE production is dispensable 
for development, survival, healthiness and fertility in mice kept under standardized 
conditions. Nevertheless, as SMSr is highly conserved in the animal kingdom 
(Vacaru et al., 2013) and ubiquitously expressed in mice, it cannot be excluded that it 
fulfills a role different from the ceramide regulatory function or only under stressed 
metabolic conditions. 
 
5.1.8 Future perspectives for investigation of SMSr function 
Analysis of SMSr and CPE function in mice is complicated by the fact that residual 
CPE was found in all investigated tissues even after depletion of two known CPE 
synthases. Therefore, knowing the origin of the SMSr/SMS2-independent CPE pool 
would facilitate future studies on the biological function of SMSr and CPE in 
mammals. In line with the idea that all members of the SMS family are capable of 
producing CPE, combinatorial depletion of these members in mice might shed further 
light on the origin of residual CPE in mammals, generation of these mice is already in 
progress in the group of Prof. Xian-Cheng Jiang (New York) (Ding et al., 2015). 
 
To investigate possible compensatory mechanisms and short-term consequences of 
SMSr inactivation in vivo, conditional SMSrdelEx6 mice could be crossbred with mice 
expressing an inducible Cre recombinase (Feil et al., 2009). Such acute depletion of 
SMSr catalytic activity could help understanding the contradictory results of the in 
vitro and the in vivo system. 
 
Ceramide accumulation, disruption of the early secretory pathway and induction of 
mitochondrial apoptosis so far were only described for depletion of SMSr catalytic 
activity in cultured HeLa and Drosophila S2 cell lines. Acute depletion of SMSr in 
different primary cells and further cell lines could help to identify particular cell types 
or specialized metabolic conditions that require proper function of SMSr. One of 
these approaches could focus on embryonic fibroblasts isolated from SMSr mutant 
mice, in which the already mentioned compensatory mechanisms could be 
evaluated. However, the earliest time point to isolate such cells is embryonic day 9.5 
to 10.5 and a possible compensation might already occur at earlier developmental 
stages. 
 
In line with the original findings in HeLa cells, SMSr might specifically influence 
cancer cell metabolism. By preventing ceramide accumulation and subsequent 
apoptosis in cancer cells, SMSr could significantly promote cancer growth. Therefore, 
depletion of SMSr in additional cancer cell lines and especially induced 
tumorigenesis in SMSr mutant mice could help unraveling SMSr function in mice. 
SMSr could also be involved in radiation-induced apoptosis, which in HeLa cells was 
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shown to be associated with an increase in ceramide de novo synthesis (Mesicek et 
al., 2010). Following preliminary studies in different cell lines, SMSr mutant mice 
could be exposed to radiation to see whether loss of SMSr catalytic activity affects 
the resulting consequences. 
 
SMS1 and SMS2, besides several other enzymes of the sphingolipid metabolic 
pathway have been shown to be involved in the development of diet-induced obesity 
and obesity-associated comorbidities e.g. atherosclerosis (see chapters 1.3.3.4 and 
1.3.4). Therefore, it might be interesting to challenge SMSr mutant mice by exposure 
to high fat diet. A more drastical way to investigate SMSr function in mice would be 
drug-induced interference with ceramide metabolism. As ceramide accumulation was 
shown to be the cause of the severely compromised integrity of acutely 
SMSr-depleted HeLa cells, it would be interesting to see whether an increase in 
ceramide production differentially affects SMSr mutant compared to wild type mice. 
For this purpose several drugs are available that have been shown to increase 
ceramide generation via different pathways (Senchenkov et al., 2001). Ceramide 
accumulation in SMSr mutant mice could also be induced by retroviral transduction 
with functional SMase. Another approach would be a block in CERT function. CERT 
deficient mice display dramatic increases in ER ceramide levels and would represent 
a promising system to investigate SMSr function (Wang et al., 2009). Unfortunately, 
these mice die due to developmental heart defects already at embryonic day 11.5 
and no conditional mice are available so far. However, a recent study identified 
several CERT ligands that could be used to acutely interfere with CERT function in 
SMSr mutant mice (Santos et al., 2014). In contrast, it might also be revealing to 
investigate whether a block in sphingolipid de novo synthesis by myriocin or inhibition 
of ceramide synthesis by fumonisin B1 differentially affect vitality in SMSr mutant 
compared to wild type mice. 
 
It was shown that SMSr is highly expressed in bone marrow derived macrophages, 
but genetic ablation of SMSr in mice did not alter CPE levels in these cells, although 
CPE synthase activity was decreased to 30 % compared to wild type controls (Ding 
et al., 2015). According to a broad microarray analysis, SMSr expression in bone 
marrow derived macrophages was substantially increased following LPS treatment 
(Lattin et al., 2008). This implies that SMSr might have a function in or after activation 
of macrophages. In the same line it was shown that depletion of SMS1 and SMS2 
attenuated activation of macrophages after LPS treatment (Gowda et al., 2011; Li et 
al., 2012). Moreover, LPS treatment of RAW264.7 macrophages and mouse 
peritoneal macrophages moderately increased sphingolipid de novo synthesis 
(Chang et al., 2011) and substantial increases in this case may be prevented by 
SMSr. Therefore, challenging SMSr mutant mice with LPS or other inflammatory 
stimuli could be a promising approach. 
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5.1.9 Regulation of ceramide homeostasis 
The involvement of ceramides in essential cellular processes including proliferation or 
apoptosis necessitates tight regulation of ceramide homeostasis and mammals have 
probably evolved mechanisms to circumvent problems resulting from an imbalance in 
ceramide generation. While it was shown that the activity of CerS and other enzymes 
of the sphingolipid metabolic pathway can be modulated by post-transcriptional 
modification (see chapter 1.3.2.5), the intrinsic mechanisms underlying these 
modifications are largely unexplored. Similar to what was observed for other 
metabolic pathways, particular sphingolipid species could be monitored by proteins 
that are able to adjust synthesis and/or degradation in response to deviations from a 
specific threshold. The sensing of sterols is a well-understood mechanism of that 
type (Goldstein et al., 2006). In case of high cholesterol levels in the ER, cholesterol 
specifically binds to a Scap/SREBP complex, leading to retention of SREBP in the 
ER. When cholesterol levels are low, the sequestration of SREBP is abrogated, 
allowing export and subsequent transcriptional activation of cholesterol synthesis. It 
was postulated that SMSr is the elusive protein that monitors ceramide levels and 
regulates ceramide homeostasis (Vacaru et al., 2009; Tafesse et al., 2014). 
However, the data presented in this thesis clearly demonstrate that SMSr is 
dispensable for ceramide homeostasis and cellular integrity in mice and the question 
how mammalian cells regulate ceramide levels to avoid jeopardizing overall integrity 
remains unanswered. 
 
Aside from proteins that monitor concentrations of ceramide or possibly other 
intermediate or terminal products of the sphingolipid metabolic pathway, additional 
mechanisms might exist to ensure proper sphingolipid metabolism. These 
mechanisms could involve regulation of enzyme expression, activity or localization, 
as well as adjustment of substrate availability through altered uptake, export, 
synthesis or subcellular localization. 
 
An interesting mechanism was shown in yeast, in which TORC2 (target of rapamycin 
kinase complex 2) is responsible for the adjustment of ceramide synthesis to regulate 
the levels of LCBs, LCB-phosphates and ceramides (Aronova et al., 2008). Activation 
of ceramide synthesis was shown to be mediated by yeast protein kinase 2 (Ypk2) 
and counteracted by calcineurin phosphatase. Strikingly, the activation involves a 
feedback mechanism, which is characterized by direct activation of Ypk2 by 
increased levels of LCBs (Liu et al., 2005). However, the mechanism is not 
completely understood and it is not yet established whether this mode of regulation is 
conserved in higher organisms (Breslow & Weissman, 2010). 
 
Another mechanism that was discovered in yeast depends on the action of the ER-
resident transmembrane proteins ORM1 and ORM2. These proteins negatively 
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regulate the first and rate-limiting step in the de novo ceramide synthesis by 
associating with SPT (Gururaj et al., 2013). While overexpression of ORM1 and 
ORM2 in yeast cells decreased sphingolipid levels, the opposite effect was observed 
after depletion of ORMs (Breslow et al., 2010). Interestingly, the inhibitory action of 
the yeast ORM proteins was relieved by phosphorylation of an N-terminal serine 
motif in response to disruption of sphingolipid de novo synthesis by myriocin, pointing 
to a feedback mechanism (Breslow & Weissman, 2010). Phosphorylation of ORM1 
was shown to be dependent on TORC1 and mediated by Npr1 kinase in response to 
decreased nitrogen supply and sphingolipid content (Gururaj et al., 2013). In 
contrast, ORM2 phosphorylation is mediated by the previously mentioned TORC2 
complex through the action of Ypk1 in response to altered plasma membrane status 
and decreased sphingolipid content (Gururaj et al., 2013). In cultured HeLa cells it 
was shown that the mammalian homologs ORMDL1-3 negatively regulate SPT 
activity (Siow & Wattenberg, 2012). However, the mammalian proteins lack the 
N-terminal phosphorylation motif and regulation of SPT activity rather depends on the 
coordinated expression of the individual ORMDLs (Kiefer et al., 2015). In human 
embryonic kidney (HEK) cells exposed to palmitate, only overexpression of all 
ORMDLs completely inhibited SPT (Kiefer et al., 2015). It was shown that this 
depends on the formation of oligomeric ORMDL complexes which associate with 
SPT and change conformation in response to alterations in sphingolipid content 
(Kiefer et al., 2015). Currently, the identity of the sphingolipid species that regulate 
ORMDL expression is not known. However, inhibition of ceramide synthesis with 
fumonisin B1 increased SPT activity in HeLa cells, pointing to a role of ceramides or 
higher order sphingolipids (Siow & Wattenberg, 2012) and it was also reported that 
SK1-mediated production of S1P negatively regulates sphingolipid synthesis (Siow et 
al., 2015). While ORMDL-dependent regulation of SPT activity was already 
investigated in several mammalian cell lines, the in vivo situation is largely 
unexplored due to the lack of appropriate systems, including ORMDL deficient mice 
(Paulenda & Draber, 2016). 
 
As indicated by the above mentioned studies, it appears likely that regulation of 
ceramide metabolism is strongly dependent on feedback mechanisms similar to what 
was observed for the sterol and glycerophospholipid metabolism (Breslow & 
Weissman, 2010). A good example is the regulation of CERT-mediated ceramide 
transport. As part of a negative feedback loop, the directed transport from the ER to 
the trans-Golgi depends on the activation of protein kinase D (PKD) in acceptor 
membranes (Olayioye & Hausser, 2012). By providing ceramide for SM production, 
CERT indirectly contributes to the production of diacylglycerol (DAG), a side product 
of SM synthesis at the trans-Golgi. In a concentration dependent manner, DAG 
recruits and activates PKD, which in turn leads to phosphorylation of CERT. 
Subsequent hyperphosphorylation of a serine repeat motif leads to dissociation from 
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the trans-Golgi and inactivation of the ceramide transfer activity due to 
conformational changes. Binding to the ER allows dephosphorylation by the action of 
phosphatase PP2Cε, which reactivates ceramide transfer activity. In HeLa cells such 
regulation was observed after depletion of SM levels by SMase treatment, which led 
to phosphorylation of CERT, and in turn increased ceramide delivery for SM 
synthesis at the Golgi (Kumagai et al., 2014). 
 
Data on the identity and function of regulatory mechanisms in mammalian cells are 
scarce and further investigations are necessary to understand how ceramide 
homeostasis is controlled. In the context of this study it is especially interesting how 
mammalian cells might overcome harmful increases in ceramides or higher order 
sphingolipids. 
 
One possibility would be adjustment of sphingolipid synthesis and/or degradation via 
feedback mechanisms, depending on the concentration of specific sphingolipid 
species. For instance, monitoring of ceramide levels in the ER would allow an 
immediate adjustment of de novo synthesis, as SPT is also located here. 
Alternatively, ceramide or SM levels could be sensed in the Golgi or the plasma 
membrane. A hypothetical model could include a protein with low affinity to ceramide 
or SM that binds only at particularly high concentrations. Binding could induce a 
conformational change and subsequent recruitment of co-factors for retrograde 
trafficking. Via a yet unidentified pathway this could signal abundance of ceramide or 
SM and therefore inhibit SPT or CerS activity, or alternatively activate SMases and 
ceramidases. In line with that notion it was reported that the p24 protein, a 
component of the COPI (coat protein complex I)-retrograde trafficking machinery, has 
a binding pocket that specifically binds to C18 SM (Contreras et al., 2012). A 
bioinformatic analysis in this study identified another 50 proteins with putative 
sphingolipid binding domain and most of the identified proteins locate to the plasma 
membrane. Whether one of these proteins qualifies for a sphingolipid sensor and 
how such sensors adjust sphingolipid metabolic pathways remains to be established. 
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5.2 Diet-induced obesity in CerS4 deficient mice 
Prior to starting this study, different groups already investigated CerS function in the 
development of diet-induced obesity in mice. CerS5 and CerS6 deficient mice were 
shown to be protected from diet-induced obesity. In CerS5 deficient mice this was 
probably a result of decreased lipid accumulation in WAT, which was accompanied 
by reduced adipose tissue inflammation and improved glucose tolerance (Gosejacob 
et al., 2016). Protection of CerS6 deficient mice was characterized by improved 
glucose tolerance and higher energy expenditure associated with increased 
β-oxidation in BAT and liver (Turpin et al., 2014). In contrast, mice heterozygous for 
CerS2 were more prone to diet-induced obesity, with increased susceptibility to 
steatohepatitis and insulin resistance probably due to impaired β-oxidation in liver 
(Raichur et al., 2014). Interestingly, these studies consistently suggested that C16:0 
ceramide is a major player in the development of obesity, as the levels were 
decreased in the respective tissues of CerS5 and CerS6 deficient mice and 
increased in the liver of heterozygous CerS2 mice (Raichur et al., 2014; Turpin et al., 
2014; Gosejacob et al., 2016). 
 
5.2.1 CerS4 deficient mice are protected from diet-induced obesity 
To investigate the function of CerS4 and corresponding ceramide species in the 
development of diet-induced obesity, wild type and CerS4 deficient mice were fed a 
high fat diet (HFD) for 16 weeks. Interestingly, CerS4 deficient mice were protected 
from diet-induced obesity, characterized by strongly decreased weight gain, reduced 
adipose tissue weight and improved glucose and insulin tolerance. The feces 
analysis revealed no alterations in the levels of triacylglycerols, diacylglycerols or free 
fatty acids between wild type and CerS4 deficient mice. This indicates that the 
reduced weight gain, despite increased food intake did most likely not result from 
altered intestinal lipid resorption. It cannot be excluded that some of the protective 
effects are a consequence of the observed hair loss in older mice (Cannon & 
Nedergaard, 2011), which starts to become obvious in 6-7 week old animals. 
Nevertheless, glucose and insulin tolerance were already significantly improved in 7-
8 week old animals, when hair loss was not especially pronounced, indicating that 
CerS4 might affect these parameters independent of hair loss. 
 
As discussed in chapter 1.3.3.2, overall glucose tolerance and insulin sensitivity is 
dependent on glucose and insulin homeostasis in different peripheral tissues. For 
instance, ubiquitous depletion of CerS6 in mice, significantly improved overall 
glucose tolerance and insulin sensitivity, whereas the effect was weaker after 
conditional depletion in either liver or BAT (Turpin et al., 2014). In the same line, 
overall glucose tolerance and insulin sensitivity might be improved through 
independent CerS4 action in peripheral tissues. 
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A central organ in this context is the pancreas. The pancreas is responsible for 
insulin production and release in response to food intake to facilitate glucose uptake 
and energy storage in peripheral tissues. It could be shown that CerS4 is highly 
expressed in pancreas. In line with that finding, C18:0 and C20:0 (and to a minor 
extent C22:0) sphingolipid levels were decreased in pancreas of CerS4 deficient 
mice. Interestingly, C16:0 ceramide levels in pancreas of CerS4 deficient mice were 
increased, which could be explained by the concomitant increase in CerS6 protein 
levels. Given the strong impact of CerS4 deficiency on sphingolipid levels in 
pancreas, protection from diet-induced obesity and insulin resistance in CerS4 
deficient mice might at least partially result from improved pancreas function. In line 
with that notion, a previous study reported increased rates of glucolipotoxicity-
induced apoptosis in the pancreatic β-cell line INS-1 after overexpression of CerS4 
and the concomitant increase in C18:0 and C22:0 ceramides (C20:0 ceramide levels 
were not determined)(Véret et al., 2011). Glucolipotoxicity might also compromise 
pancreatic β-cell function in mice following exposure to HFD. Depletion of CerS4 in 
this context could result in decreased rates of β-cell apoptosis and hence maintain 
insulin secretion from the pancreas, leading to an overall improvement in glucose 
tolerance. The increase in C16:0 sphingolipid species in the pancreas of CerS4 
deficient mice, might argue against improved pancreas function, since C16:0 
ceramide was suggested to be a negative regulator of iBAT, liver and WAT function 
(Raichur et al., 2014; Turpin et al., 2014; Gosejacob et al., 2016). However, the 
increase in C16:0 ceramide, as well as the decrease in C18:0 and C20:0 ceramides 
was comparable in CerS4 deficient mice fed either HFD or LFD. And both groups 
showed significantly improved glucose tolerance and insulin sensitivity compared to 
the corresponding wild type groups. Therefore, despite the increase in C16:0 
ceramide, it appears unlikely that pancreas function is impaired in CerS4 deficient 
mice. A possible explanation might be that the increase in C16:0 ceramide is rather 
negligible due to the high levels in pancreas (3-4 fold higher compared to iBAT or 
liver). This could be the case, if C16:0 ceramides exert their negative actions by 
altering membrane biophysical properties and thereby affect membrane-associated 
cellular signaling, as was discussed for ceramides in general (Grösch et al., 2012; 
Silva et al., 2012). A detailed discussion of the influence of altered ceramide levels on 
membrane biophysical properties and cellular signaling is presented in chapter 5.2.6. 
 
The mass spectrometric analyses of liver revealed that despite low expression levels 
of CerS4, liver C18:0 and C20:0 sphingolipid levels were decreased in CerS4 
deficient compared to wild type mice fed HFD. The increased levels of these species 
in wild type mice following HFD feeding could be due to increased protein expression 
of CerS4, as indicated by the immunoblot analysis. Moreover, the data indicate that 
the levels of C22:0 sphingolipids in liver do not solely depend on CerS2, but also on 
CerS4, since C22:0 sphingolipid levels were lower in CerS4 deficient mice, despite a 
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slight increase in CerS2 protein expression. The data suggest that aside from 
pancreas, the overall improvement in glucose and insulin tolerance in CerS4 deficient 
mice could partially originate from liver. Interestingly, C18:0 and C20:0 ceramide 
levels in CerS4 deficient mice fed HFD were similar to those observed in wild type 
mice fed LFD and glucose tolerance in these groups was comparable. Protection of 
CerS4 deficient mice from insulin resistance could be due to the increased 
expression of the IRβ subchain in CerS4 deficient compared to wild type mice, which 
was especially pronounced after exposure to HFD. It was suggested that hepatic 
insulin resistance in CerS2 deficient mice is a consequence of impaired IR clustering 
in the plasma membrane (Park et al., 2013a). This was concluded from the finding 
that IRs did not localize to detergent-resistant membranes, probably due to depletion 
of C22 and C24 ceramides. Interestingly, CerS2 protein levels were increased in 
CerS4 deficient compared to wild type mice. However, the increase was rather small 
and not accompanied by an increase in the corresponding sphingolipid species. In 
contrast to C22 and C24 ceramides, C18 and C20 ceramides generated by CerS4 
might have a destabilizing effect on IRs and depletion in CerS4 deficient mice could 
contribute to the establishment of a membrane environment that stabilizes IRs, for 
instance by increasing the ratio of ceramides generated by CerS2. Improved cluster 
formation could in turn protect IRs from degradation, which might explain the 
increased levels of IRβ-subchain in CerS4 deficient mice. 
 
The fact that HFD-induced weight gain and white adipose tissue weight were 
significantly reduced in CerS4 deficient compared to wild type mice, despite 
increased food intake, points to increased energy expenditure. A tissue specialized in 
energy expenditure is BAT. The mass spectrometric analysis of iBAT revealed that 
C18:0 and C20:0 sphingolipid species were decreased, despite low expression of 
CerS4 in this tissue. In contrast to liver and pancreas, depletion of CerS4 did not 
affect C22 sphingolipid levels. These levels were rather increased, probably resulting 
from alternative use of the accumulating substrates by CerS2. Whether protein 
expression of CerS2 is increased in 22-24 week old CerS4 deficient mice remains to 
be established. The immunoblot analysis of 5 week old mice revealed high 
expression of CerS2 in iBAT, but expression was not altered in the CerS4 deficient 
control. It remains to be established why CerS4 does not affect C22:0 sphingolipid 
levels in iBAT. A possible explanation could be specific modifications or interactions 
that affect substrate specificity of CerS4 in iBAT or alternative sources for C22:0 
ceramides that cover the effect of CerS4 depletion. Notably, C16:0 (and C18:0) 
sphingolipid levels were increased in mice fed HFD and probably due to the before 
mentioned alternative use of substrates the increase in C16:0 species was even 
stronger in CerS4 deficient mice. It was suggested that increased levels of C16:0 
ceramide compromise iBAT function and promote development of diet-induced 
obesity (Turpin et al., 2014). This might indicate that protection from diet-induced 
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obesity in CerS4 deficient mice is not a result of improved iBAT function. However, as 
was already discussed for pancreas, iBAT function could also depend on the 
biophysical constitution of cellular membranes. In this context it could also be that the 
altered sphingolipid content in iBAT of CerS4 deficient mice allows the establishment 
of a membrane environment that improves iBAT function. 
 
5.2.2 Hair loss and protection from diet-induced obesity 
The hair loss in 23-24 week old CerS4 deficient mice is very obvious and with respect 
to the fact that the thermoneutral temperature for mice is 30°C, it is likely that heat 
loss occurs in these mice (Cannon & Nedergaard, 2011). Moreover, as CerS4 
deficient mice can be distinguished according to fur appearance at the age of 6-7 
weeks, it cannot be excluded that heat loss already occurs in these mice. The 
increased food intake indicates that insulation is already affected in these mice 
(Cannon & Nedergaard, 2011). However, in contrast to the hair loss, the food intake 
did not progressively increase and remained similar starting from week 7 of the 16 
week experiment. 
 
Extensive review of present literature revealed several examples for mouse mutants 
that are protected from diet-induced obesity due to alterations of skin or fur 
composition. For instance, ELOVL3 (elongation of very long chain fatty acids 
3)(Zadravec et al., 2010) or DGAT1 (diacylglycerol acyltransferase 1)(Smith et al., 
2000) deficient mice. DGAT1 deficient mice, display a hair loss phenotype even more 
severe than that observed in CerS4 deficient mice (Chen et al., 2002). These mice 
also showed increased food intake at normal housing temperature (23°C) and the 
food intake was even higher at 4°C, but approximately the same at thermoneutral 
temperature (Chen et al., 2003). Notably, at thermoneutral temperature HFD-induced 
adiposity was still less pronounced compared to wild type animals, probably as a 
result of increased thermogenesis in adipose tissue (Chen et al., 2003). Therefore, it 
is possible that also protection from diet-induced obesity in CerS4 deficient mice not 
solely depends on hair loss. 
 
To circumvent possible effects resulting from hair loss and to investigate the 
putatively beneficial effects of CerS4 deficiency, energy expenditure and adipose 
tissue function were investigated in 5 week old mice. 5 week old CerS4 deficient mice 
show no obvious alterations in fur appearance. This is supported by the finding that 
hair follicles of CerS4 deficient mice regularly enter anagen at postnatal day 33 (P33) 
and catagen at P47 (Peters et al., 2015). The hair follicles remain in an anagen-like 
state and do not enter telogen only at P51. Together this suggests that 5 week old 
animals do not suffer from heat loss due to impaired insulation. 
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5.2.3 Energy expenditure in 5 week old mice 
The reduced weight gain of CerS4 deficient compared to wild type mice after 16 
week exposure to HFD clearly indicates increased energy expenditure in these mice. 
However, analysis of energy expenditure in these mice could be misleading due to 
the progressive hair loss. Therefore, oxygen consumption was investigated in 5 week 
old wild type and CerS4 deficient mice. Despite similar body size, body weight and 
adipose tissue weights (iBAT, igWAT and gWAT) compared to wild type mice, CerS4 
deficient mice exhibited significantly increased oxygen consumption compared to wild 
type mice at 23°C. The same effect was observed at 4°C and to a lower extent at 
thermoneutral temperature (30° C), but the differences did not reach statistical 
significance. However, energy expenditure appeared to be increased due to loss of 
CerS4 independent of hair loss. This is supported by the finding that food intake was 
not altered at 23°C, which further indicated that 5 week old CerS4 deficient mice do 
not suffer from heat loss. As motility was unaltered in CerS4 deficient compared to 
wild type mice at 23°C and 4°C, it is likely that the increased energy expenditure is 
independent of muscular activity. 
 
5.2.4 CerS expression in 5 week old mice 
As increased energy expenditure can be the result of stimulated development and 
activity of BAT, further analyses focused on adipose tissue. Interestingly, CerS4 
expression in iBAT was only weak, arguing against activation of iBAT due to loss of 
CerS4 in CerS4 deficient mice. In contrast, CerS4 was strongly expressed in igWAT 
and the levels were even higher in gWAT, pointing to a specific role in these tissues. 
The expression pattern of CerS5 was similar to that of CerS4, with low levels in iBAT, 
high levels in igWAT and even higher levels in gWAT, consistent with the previous 
expression analysis and the observed WAT phenotype in CerS5 deficient mice after 
HFD feeding (Gosejacob et al., 2016). In a similar fashion, the high levels of CerS6 in 
iBAT are in line with the improved BAT function in CerS6 deficient mice after HFD 
feeding (Turpin et al., 2014). The low expression levels of CerS6 in gWAT and of 
CerS5 in iBAT could explain why altered gWAT function in CerS5 deficient mice and 
altered iBAT function in CerS6 deficient mice cannot be compensated after exposure 
to HFD (Turpin et al., 2014; Gosejacob et al., 2016). Whether CerS5 and CerS6, 
consistent with their preference for C16 acyl-CoAs, can compensate each other‟s 
loss is not known. None of the previously mentioned studies focused on igWAT, in 
which both are expressed to a similar extent. Therefore, it would be interesting to see 
whether depletion of one or both of these CerS affects igWAT function after HFD 
feeding. 
 
5.2.5 Browning in CerS4 deficient mice 
Surprisingly, analysis of iBAT morphology revealed slightly increased adipocyte size 
in KO compared to wild type mice, despite low expression levels of CerS4. Usually, 
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brown adipocytes accumulate lipid droplets to store energy, which can be used for 
non-shivering thermogenesis e.g. in response to adrenergic stimulation following cold 
exposure (Westerberg et al., 2006). Therefore, the increased adipocyte size might 
point to enhanced thermogenic capacity of iBAT in CerS4 deficient mice. Contrary to 
this assumption, mRNA levels of the adipogenic markers PPARγ and aP2 were not 
altered in in vitro differentiated brown adipocytes from iBAT of new born mice. This 
could indicate that CerS4 affects iBAT thermogenic capacity only at later 
developmental stages. The finding that mRNA levels of UCP1 were also unaffected is 
in line with that notion. Despite this, UCP1 mRNA levels were increased in CerS4 
deficient cells after stimulation of adipogenesis and BAT function by cGMP, but the 
difference was rather small and probably without physiological consequences. 
Therefore, consistent with the low expression levels of CerS4, it appears unlikely that 
CerS4 deficiency affects adipocyte differentiation in iBAT or increases oxygen 
consumption by stimulating iBAT activity. 
 
The morphology of igWAT, in which CerS4 is highly expressed, was severely 
affected in CerS4 deficient mice. The reduced adipocyte size in CerS4 deficient 
compared to wild type mice could be a direct consequence of the observed increase 
in energy expenditure. The numerous smaller, multilocular adipocytes interspersed in 
CerS4 deficient tissue might represent thermogenic beige adipocytes, indicating 
increased browning (Chen et al., 2013b; Gnad et al., 2014). The RT-PCR analysis of 
in vitro differentiated white adipocytes from igWAT of 5 week old mice revealed a 
slight increase in PPARγ mRNA levels in CerS4 deficient compared to wild type cells. 
Since the mRNA levels of aP2, an adipogenic target gene of PPARγ were unaltered, 
this could indicate increased differentiation of adipocyte precursor cells to 
thermogenic beige adipocytes. This is in line with the finding that ectopic expression 
of PPARγ in fibroblasts and mesenchymal cells induces white adipocyte 
differentiation, but together with other transcriptional regulators is also required for 
brown adipocyte differentiation (Kajimura et al., 2010). Genetic ablation of PPARγ 
completely disrupts adipocyte differentiation in WAT and BAT (Kajimura & Saito, 
2014). Interestingly, it was shown that PPARγ in adipose tissue is also an essential 
regulator of whole body insulin sensitivity, as it regulates production and secretion of 
the adipokines adiponectin and leptin, important mediators of insulin action in 
peripheral tissues (Kintscher & Law, 2005). Therefore, the improved insulin sensitivity 
in CerS4 deficient mice could also be a consequence of increased PPARγ levels in 
WAT. However, it remains to be investigated if PPARγ levels are also elevated in 
WAT of CerS4 deficient mice. 
 
Notably, the levels of PPARγ mRNA in cultured white adipocytes were not increased 
in CerS4 deficient compared to wild type cells after stimulation of adipogenesis and 
browning by cGMP. In contrast, mRNA levels of thermogenic markers were 
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increased in CerS4 deficient compared to wild type cells and comparable increases 
were observed after stimulation with the browning inducer norepinephrine (NE). 
Especially the levels of UCP1, which uncouples the electron transport chain from 
ATP production to dissipate energy as heat, were significantly elevated in CerS4 
deficient cells. In addition, the mRNA levels of PRDM16 and PGC1α were increased. 
Both are involved in the regulation of mitochondrial biogenesis, oxidative metabolism 
and expression of BAT-selective genes (Lo & Sun, 2013; Kajimura & Saito, 2014). 
The mRNA levels of CIDEA were especially increased in CerS4 deficient compared 
to wild type cells following NE treatment. CIDEA is involved in lipid droplet fusion and 
lipid storage in brown adipocytes (Wu et al., 2014). Taken together, these results 
indicate that thermogenic capacity in CerS4 deficient mice is increased due to 
increased browning of igWAT. 
 
A study focusing on the farnesoid X receptor (FXR) reported protection from diet-
induced obesity and insulin resistance due to increased browning of igWAT following 
treatment of mice with glycine-β-muricholic acid (Gly-MCA), a specific inhibitor of 
FXR signaling in intestine (Jiang et al., 2015). This was characterized by decreased 
expression of several genes involved in ceramide synthesis in ileum, the distal part of 
the small intestine. For instance, expression of genes for subunits of serine 
palmitoyltransferase, for dihydroceramide desaturase or for CerS2 (decreased by 
~25 %) and CerS4 (decreased by ~50 %) was decreased. Notably, expression of 
ceramide synthesis-related genes was unaltered in WAT and liver. The altered 
expression in ileum resulted in a decrease in all major ceramide species (C16 to 
C24) and the decrease in C18 to C22 ceramides was especially pronounced. The 
mass spectrometric analysis of serum ceramides revealed a similar pattern and the 
authors conclude that the increase in thermogenic beige fat was likely a result of 
decreased ceramide generation in ileum (Jiang et al., 2015). Strikingly, administration 
of C16 ceramide restored the levels of all major ceramide species and reversed the 
beneficial effects of Gly-MCA in mice. Moreover, C16 ceramide treatment of cultured 
beige adipocytes markedly reduced expression of thermogenic markers. Taken 
together, these data support the assumption that depletion of CerS4 and the 
associated decrease in C18 to C22 ceramides promotes browning of igWAT. 
Notably, Gly-MCA treatment did not affect expression of thermogenic markers in 
iBAT (Jiang et al., 2015). In the same line, thermogenic markers were not affected in 
cultured brown adipocytes from iBAT of CerS4 deficient mice, further indicating that 
CerS4 and the corresponding ceramides affect development of beige adipocytes, 
rather than thermogenic activity in general. 
 
5.2.6 CerS4-mediated attenuation of browning 
The morphological analysis of adipose tissue and the RT-PCR analysis of cultured 
white adipocytes from CerS4 deficient mice suggest that CerS4 is a negative 
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regulator of browning in WAT. This raises the question, how this could be 
accomplished and which signaling pathways may be involved? 
 
PPARγ mRNA levels were increased in cultured white adipocytes from CerS4 
deficient compared to wild type mice, but the difference was abrogated after cGMP 
treatment. Endogenous cGMP is produced by the action of guanylyl cyclases in 
response to stimulation by nitric oxide (NO) or natriuretic peptides and the cGMP-
dependent effects on brown fat cell differentiation and thermogenesis are mediated 
by PKGI (Protein kinase G I)(Haas et al., 2009). The finding that no difference in the 
expression of adipogenic markers was observed in CerS4 deficient compared to wild 
type cells after cGMP treatment might argue against an involvement of CerS4 in this 
signaling pathway. In contrast, expression of thermogenic markers in CerS4 deficient 
compared to wild type cells was also increased after NE treatment. NE, which is 
endogenously released from the sympathetic nervous system, induces a thermogenic 
program in WAT by activating β-adrenoceptors (β-ARs)(Mottillo & Granneman, 
2011). The subsequent signaling cascade is characterized by activation of adenylyl 
cyclases, and the resulting increase in cAMP activates PKA (Protein kinase A), which 
mediates for instance, increased lipolysis, lipid oxidation or transcription of PPARγ, 
PGC1α and UCP1 (Mottillo & Granneman, 2011). It could be that CerS4 attenuates 
browning by affecting β-adrenergic signaling. Pharmacological activation of β3-ARs in 
mice reduced body fat and improved insulin sensitivity at least partially by increasing 
lipid oxidation in adipose tissue (Grujic et al., 1997). In line with that, CerS4 deficient 
mice fed with a HFD also displayed reduced body fat and higher insulin sensitivity 
and the latter was already higher in 7-8 week old animals prior to starting the 
experiment. Due to hair loss, browning and increased lipid oxidation is likely to occur 
in these mice (Cannon & Nedergaard, 2011). However, as indicated by the 
investigation of younger mice and cultured cells, CerS4 deficiency might contribute to 
these phenotypes independent of hair loss. 
 
Identification of the signaling pathways modulated by CerS4 is a prerequisite to 
determine the mechanism by which CerS4 affects browning. With respect to the 
analysis of ELOVL3 deficient mice, CerS4 deficiency might affect adipose tissue 
development by altering intracellular fatty acid levels. ELOVL3 is a fatty acid 
elongase responsible for production of fatty acids ranging from C20 to C24 and 
ELOVL3 deficient mice suffer from a hair phenotype characterized by tousled fur, 
similar to that observed in 6-7 week old CerS4 deficient mice (Westerberg et al., 
2004). It was shown that ELOVL3 deficient mice are unable to hyperrecruit BAT 
following cold exposure and at thermoneutral temperature, number and size of lipid 
droplets, and metabolic capacity within BAT cells was reduced (Westerberg et al., 
2006). These effects were accompanied by a decrease in C20:0 and C22:0 fatty 
acids and it could be that the impaired BAT function is a consequence of this 
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decrease. In a similar fashion, differentiation or function of thermogenic cells could be 
affected by lower levels of these fatty acids due to consumption of the corresponding 
fatty acyl-CoAs by CerS4. Notably, it was shown that a diet enriched in C20:1 and 
C22:1 fatty acids ameliorates metabolic dysfunction by increasing PPARγ expression 
in WAT (Yang et al., 2013). In line with this finding the increase in PPARγ mRNA 
levels observed in cultured white adipocytes of CerS4 deficient mice may be a result 
of increased C20 and C22 fatty acids. This is especially interesting with respect to the 
fact that fatty acids can act as ligands for PPARs, which are major transcriptional 
regulators of adipocyte differentiation and function (Georgiadi & Kersten, 2012). 
However, so far only interactions of PPARs with polyunsaturated fatty acids have 
been shown, and the question remains open whether mono-unsaturated or saturated 
fatty acids (especially C18 to C22 species) can bind to PPARs and affect their 
transcriptional activity. 
 
As previously discussed, increased browning in response to inhibition of FXR 
signaling is probably a consequence of decreased ceramide levels (Jiang et al., 
2015). Since CerS4 expression and the levels of the corresponding ceramide species 
were markedly reduced in this study, it is more likely that increased browning in 
CerS4 deficient mice is a direct consequence of altered ceramide levels. As already 
mentioned before, it has been suggested that altered ceramide levels can affect 
cellular signaling by altering membrane biophysical properties (Grösch et al., 2012; 
Silva et al., 2012). For instance, in giant unilamellar vesicles (GUVs) prepared from 
liver and brain microsomal fractions of CerS2 deficient mice, it was shown that the 
decrease in C22 to C24 ceramides increases membrane fluidity and order (Silva et 
al., 2012). This was accompanied by an overall alteration of membrane morphology. 
Such alterations have been shown to influence activation or inhibition of specific 
signaling molecules, for instance through curvature-dependent conformational 
changes (Reynwar et al., 2007). Especially interesting in this context are sphingolipid 
and cholesterol-enriched membrane lipid microdomains (Lingwood & Simons, 2010). 
It is assumed that such highly-ordered domains are rather small (10-200 nm), 
heterogeneous and highly dynamic, and that they can be stabilized to larger 
platforms (Pike, 2009). The temporary establishment of such microdomains probably 
facilitates local clustering of proteins involved in the execution and control of cellular 
signaling (Pike, 2009; van Meer & Hoetzl, 2010). Interestingly, C16 ceramide 
preferentially interacts with cholesterol, whereas C24 ceramide does not (ten 
Grotenhuis et al., 1996). Moreover, the existence of highly-ordered C16 
ceramide/cholesterol domains was already demonstrated in membranes of cultured 
cells (Goldschmidt-Arzi et al., 2011). With biophysical properties ranging between 
those of C16 and C24 ceramides, ceramides generated by CerS4 (C18, C20 and 
depending on the tissue maybe C22) could facilitate establishment of microdomains 
in which C16 and C24 ceramides exist together. A decrease in CerS4-generated 
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ceramides might in contrast favor the establishment of C16 ceramide-enriched 
platforms. The favored establishment of C16 ceramide-enriched microdomains and 
the possible consequences for cellular signaling could also explain the positive 
correlation between increased levels of C16 ceramide and the development of 
obesity and comorbidities observed after HFD feeding of CerS2, CerS5 and CerS6 
deficient mice (Raichur et al., 2014; Turpin et al., 2014; Gosejacob et al., 2016). 
 
It was already suggested that ceramides with different acyl-chain length differentially 
affect membrane biophysical properties and establishment of membrane lipid 
microdomains (Pinto et al., 2014). Together with the distinct expression pattern this 
could explain why depletion of different CerS leads to completely different 
phenotypes in mice. However, despite high expression levels and significantly altered 
sphingolipid content, CerS depletion does not necessarily alter the function of a given 
tissue. For instance, in the heart of CerS4 deficient mice C18 to C22-containing 
sphingolipids were strongly decreased and shorter (C16) and longer (C24) chain 
species were elevated, without affecting heart function (Ebel, 2014). This implies that 
a change in membrane biophysical properties due to altered sphingolipid content 
does not inevitably affect cellular signaling. Instead it presumably depends on cell 
type-specific components. For instance, it was shown that due to altered membrane 
biophysical properties in the liver of CerS2 deficient mice, TNFR1 (tumor necrosis 
factor α receptor 1) internalization in response to LPS (lipopolysaccharide) treatment 
is disrupted (Ali et al., 2013). The altered membrane biophysical properties in 
hepatocytes of CerS2 deficient mice are probably also responsible for mislocalisation 
of connexin 32 (Cx32), a major constituent of gap junction channels in the liver (Park 
et al., 2013b). 
 
Assuming that CerS4 attenuates browning of WAT by affecting β-adrenergic 
signaling, the depletion of C18 and C20-containing sphingolipids in CerS4 deficient 
mice may allow to establish a membrane environment that attracts or stabilizes 
β3-adrenoceptors, which are specifically expressed in adipose tissue (Mottillo & 
Granneman, 2011). The finding that iBAT function was not significantly affected in 
CerS4 deficient mice could then be explained by the low expression levels of CerS4. 
Changes in membrane biophysical properties in CerS4 deficient mice could also 
affect ligand attraction or stabilization of other receptors and membrane-bound 
components of specific signaling pathways. 
 
While the above mentioned mechanisms would affect the membrane constitution in 
general, it cannot be excluded that ceramides act as specific co-factors for proteins 
involved in cellular signaling. As discussed in chapter 5.1.9, several proteins with 
putative sphingolipid binding domain were already identified and most of them 
localize to the plasma membrane (Contreras et al., 2012). Specific ceramide/protein 
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interactions have already been suggested (Grösch et al., 2012). For instance, the 
activity of protein phosphatase 2 A (PP2A), a major phosphatase involved in insulin-
dependent signaling pathways, was stimulated in a stereospecific manner by the 
naturally occurring D-erythro-C18-ceramide, but not by the enantiomeric L-erythro-
C18-ceramide or diastereoisomeres (Chalfant et al., 1999). Hyperactivation of PP2A 
following treatment with free fatty acids decreased hepatic insulin sensitivity (Galbo et 
al., 2011). This suggests that the increased insulin sensitivity in CerS4 deficient mice 
could be a consequence of decreased PP2A activity due to the decrease in activating 
C18 ceramides. While data on specific interactions between ceramides and proteins 
are rather scarce, several interactions have been shown for gangliosides. For 
instance, the ganglioside GM3 modulates activity of the insulin receptor (IR) 
(Kabayama et al., 2007) and inhibits the epidermal growth factor (EGF) receptor in 
absence of the appropriate ligand (Coskun et al., 2011). However, these interactions 
probably depend on the head group, rather than the chain length of the ceramide 
backbone. Whether endogenous ceramides generated by CerS4 specifically interact 
with proteins involved in cellular signaling remains to be established. A prerequisite 
for such investigations is the already mentioned identification of signaling pathways 
that are affected by CerS4 function. 
 
Taken together, the study in this Ph. D thesis revealed that CerS4 deficient mice are 
protected from diet-induced obesity and insulin resistance. As indicated by the 
increased food intake in these mice, it cannot be excluded that the beneficial effects 
are caused by the progressive hair loss. However, glucose and insulin tolerance were 
already significantly improved in 7-8 week old animals, which exhibit only modest 
alterations in their fur appearance. The hair loss-independent analyses of younger 
mice and cultured adipocytes suggested increased browning in igWAT of CerS4 
deficient mice. Therefore, independent of hair loss, increased browning may lead to 
higher energy expenditure and alleviate diet-induced obesity in CerS4 deficient mice. 
Stimulation of browning is a potential strategy for the treatment of obesity and type 2 
diabetes in humans. Given the fact that CerS4 deficiency, apart from the hair loss 
phenotype, does not severely impact survival, vitality or fertility of mice (Ebel et al., 
2014; Peters et al., 2015), CerS4 could be a potential therapeutical target for the 
treatment of obesity and associated diseases. 
 
5.2.7 Future perspectives for investigation of CerS4 function in the 
development of obesity 
Further analyses of 5 week old animals and cultured adipocytes are necessary to 
verify the hypothesis that CerS4 is a negative regulator of browning in WAT. For 
instance, it needs to be verified whether the smaller cells interspersed in igWAT of 
CerS4 deficient mice actually represent thermogenic beige adipocytes. This could be 
verified by immunohistochemistry using antibodies against UCP1. Stainings with Oil 
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Red O, which stains neutral triacylglycerols (TAGs) and lipids, could be used to 
determine the general lipid storage capacity of igWAT adipocytes and to distinguish 
between white adipocytes (usually containing one large lipid droplet) and brown 
adipocytes (usually containing multiple small lipid droplets). Expression of adipogenic 
and thermogenic markers in adipose tissue depots needs to be investigated by 
RT-PCR and immunoblot analyses. Determination of cAMP or cGMP levels could 
help to identify the involved signaling pathways. RT-PCR analyses could also include 
genes involved in lipogenesis, lipolysis or β-oxidation, as well as transcriptional 
regulators of these processes. Lipolysis (TAG hydrolysis) is usually increased 
following activation of thermogenic adipose tissue (Mottillo & Granneman, 2011) and 
β-oxidation of the provided fatty acids is indispensable for thermogenesis in 
mitochondria of brown and beige adipocytes (Lee et al., 2015). Increased β-oxidation 
in iBAT (and liver) of CerS6 deficient mice probably contributed to protection from 
diet-induced obesity (Turpin et al., 2014). In contrast, β-oxidation was decreased in 
the liver of heterozygous CerS2gt mice and these mice were more susceptible to 
diet-induced obesity (Raichur et al., 2014). These studies suggested that high levels 
of C16 ceramide positively correlate with the development of diet-induced obesity 
and impaired mitochondrial β-oxidation. As a basis for further investigations, it is 
necessary to determine the sphingolipid profile in iBAT, igWAT and gWAT of CerS4 
deficient mice by mass spectrometry. 
 
In addition to the analyses of igWAT, further analyses could also focus on gWAT, in 
which CerS4 expression is even stronger. In contrast to the subcutaneous igWAT, 
gWAT represents a visceral adipose tissue depot. Subcutaneous and visceral 
adipose tissue depots strongly differ in their metabolic profile and it was suggested 
that visceral adipose tissue depots have a more negative impact on health 
(Sackmann-Sala et al., 2012). Therefore, it would be interesting to see whether 
depletion of CerS4 also affects browning in gWAT. 
 
The browning of WAT depots and the general capacity for non-shivering 
thermogenesis in CerS4 deficient mice could be further investigated by injecting mice 
with the β3-adrenoceptor agonist CL 316,243, which induces browning and stimulates 
thermogenesis (Gnad et al., 2014). Increased browning in CerS4 deficient mice could 
also be the result of altered release of catecholamines (e.g. NE) from the sympathetic 
nervous system. Therefore, it could be revealing to determine serum levels of NE in 
CerS4 deficient mice. The function of the sympathetic nervous system is controlled 
by the hypothalamus. It was shown that the hypothalamus is an important regulator 
of cold- and diet-induced thermogenesis and browning (Zhang & Bi, 2015). This may 
be relevant, since CerS4 is widely expressed in the brain (Brach, 2012). 
Morphological and mass spectrometric analyses of the hypothalamus in CerS4 
deficient mice could provide a basis for the investigation of CerS4 function in this 
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tissue. Further analyses could then focus on the signaling pathways involved in 
hypothalamic regulation of adipose tissue function (Zhang & Bi, 2015). 
 
The thermogenic potential of in vitro differentiated brown and white adipocytes from 
CerS4 deficient mice could be assessed by determining the in vitro oxygen 
consumption rate following NE treatment. To identify the signaling pathways that 
mediate increased browning in CerS4 deficient mice, cAMP and cGMP levels could 
be determined. In addition, further RT-PCR and immunoblot analyses of potentially 
involved receptors, protein kinases or target genes are necessary. Another 
interesting target of investigation are phosphodiesterases (PDEs), which mediate 
conversion of cAMP or cGMP to AMP or GMP, respectively (Mitschke et al., 2013). 
Decreased expression or activity of these enzymes in WAT of CerS4 deficient mice 
could increase intracellular cAMP or cGMP levels and thereby promote browning. 
 
In order to identify the mechanism by which CerS4 affects browning in WAT it is 
necessary to determine the sphingolipid profile of cultured brown and white 
adipocytes from CerS4 deficient mice by mass spectrometry. Cultured adipocytes 
could be treated with ceramides of different chain length (C16-C24) to assess the 
influence on adipogenic and thermogenic marker expression. In addition, CerS4 
could be overexpressed in CerS4 deficient cells in order to restore C18 to C22 
ceramide levels. If ceramides generated by CerS4 actually compromise browning of 
WAT, elevated levels of C18 to C22 ceramides should affect the browning capacity of 
CerS4 deficient cells. 
 
Due to the progressive hair loss it is difficult to pinpoint beneficial effects in the 
development of diet-induced obesity that actually result from CerS4 deficiency in 
peripheral tissues. A suitable system to circumvent possible effects resulting from 
hair loss would be mice which allow conditional depletion of CerS4 in a specific 
tissue. As previously described, such mice were already generated and used for the 
investigation of the hair loss phenotype (Peters et al., 2015). Based on the 
assumption that CerS4 might attenuate browning in WAT, a promising approach 
would be crossbreeding of conditional mice with mice expressing the Cre 
recombinase under control of an adipose tissue specific promoter (Lee et al., 2013). 
The mass spectrometric and immunoblot analyses of pancreas and liver suggest that 
these tissues might also contribute to protection from diet-induced obesity and insulin 
resistance in CerS4 deficient mice. Therefore, CerS4 could also be conditionally 
depleted in these tissues. Adipose tissue-, pancreas- and liver-specific CerS4 
mutants should be subjected to repeated feeding experiments to unequivocally 
determine the contribution of these tissues to protection from diet-induced obesity. 
Alternatively, CerS4 deficient mice could be exposed to HFD at thermoneutral 
temperature (30°C) to minimize effects resulting from heat loss. The identification of 
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the involved tissues is a prerequisite to unravel the mechanisms by which CerS4 
might affect the development of obesity. 
 
Aside from the investigation of adipose tissue depots, further analyses could also 
focus on pancreas function. CerS4 is strongly expressed in this tissue and depletion 
significantly affected the sphingolipid profile. It was suggested that CerS4 mediates 
glucolipotoxicity-induced apoptosis of INS1 β-cells (Véret et al., 2011). Therefore, the 
improved glucose and insulin tolerance observed in CerS4 deficient mice could be a 
consequence of improved pancreas function. Pancreas function could be 
investigated in pancreas-specific CerS4 mutants after HFD feeding. Such analyses 
could focus on apoptosis in pancreas or isolated β-cells, to see if insulin release is 
improved in CerS4 mutants due to decreased β-cell apoptosis. 
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6 Summary 
The first project of this Ph. D thesis focused on the biological function of the 
sphingomyelin synthase related protein (SMSr). Previously, it was reported that SMSr 
catalytic activity is essential to prevent ceramide accumulation and disruption of the 
early secretory pathway in cultured HeLa cells. The enzymatic product of SMSr is the 
sphingomyelin analog ceramide phosphoethanolamine (CPE), which can also be 
generated by the bifunctional sphingomyelin synthase 2 (SMS2). In this Ph. D thesis 
SMSr function was investigated in two mouse lines lacking SMSr catalytic activity. 
Conditional SMSrflox mice were generated during my diploma thesis and crossbred 
with pgk-Cre expressing mice for ubiquitous depletion of SMSr catalytic activity in the 
resulting SMSrdelEx6 mice. Point-mutated SMSrD348E mice were generated in our 
group already before. Mice from both mouse lines were born according to Mendelian 
ratio with no obvious phenotypic abnormalities. CPE synthase activity assays 
confirmed that SMSr catalytic activity is lost in both mouse lines and revealed that 
CPE synthase activity in brain primarily depends on SMSr and in liver to similar 
extent each on SMSr and SMS2. Immunoblot analyses with newly generated 
antibodies against SMSr revealed ubiquitous expression of SMSr with high levels in 
testis, brain and pancreas, but stainings of the ß-galactosidase reporter protein in 
tissues from SMSrD348E mice indicated that SMSr is not expressed in every cell 
type. Ultra-structural analysis of brain and liver cells from SMSrD348E mice showed 
no morphological abnormalities and analysis of serum activities of liver 
transaminases indicated that liver integrity is not affected. Mass spectrometric 
analysis revealed no alterations in ceramide levels in ten different tissues of 
SMSrD348E mice. Wild type levels of CPE were exceedingly low in all investigated 
tissues. In SMSrD348E mice CPE levels were largely decreased in brain and to a 
minor extent in testis, kidney, spleen and lung. Surprisingly, combined inactivation of 
SMSr and SMS2 reduced, but did not eliminate tissue-specific CPE pools. Besides 
providing a comprehensive inventory of CPE and metabolizing enzymes, the study in 
this Ph. D thesis shows that SMSr is not a critical regulator of ceramide homeostasis 
in mice, as was suggested for cultured HeLa cells. SMSr-mediated CPE biosynthesis 
is dispensable for mouse development, vitality, fertility and survival. 
 
The second project was directed on the function of ceramide synthase 4 (CerS4) in 
the development of diet-induced obesity. Previously, it was shown that loss of CerS5 
or CerS6 protects mice from high fat diet-induced obesity due to a decrease in C16 
ceramide in WAT, liver or BAT, and mice heterozygous for CerS2 were more 
susceptible to high fat diet-induced hepatosteatosis and insulin resistance due to an 
increase in C16 ceramide. The study in this Ph. D thesis showed that CerS4 deficient 
mice are protected from diet-induced obesity after 16 week exposure to high fat diet. 
This was characterized by reduced weight gain and adipose tissue weight compared 
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to wild type mice. In addition, glucose and insulin tolerance were improved, which 
was already observed in 7-8 week old animals prior to starting the feeding 
experiment. Mass spectrometric analysis revealed decreased levels of C18 to C22 
sphingolipid species in pancreas, liver and interscapular brown adipose tissue (iBAT) 
of CerS4 deficient mice, indicating that these tissues could contribute to the 
protection from diet-induced obesity. Since CerS4 deficient mice suffer from a 
progressive hair loss, which starts at the age of 6-7 weeks, it cannot be excluded that 
beneficial effects result from increased energy expenditure initiated to compensate 
heat loss. This is likely to occur, as these mice showed increased food intake. 
However, 5 week old CerS4 deficient mice, showed no obvious signs of hair loss and 
unaltered food intake, but exhibited already increased oxygen consumption and 
hence energy expenditure. Analysis of adipose tissue morphology in these mice 
suggested increased browning of inguinal white adipose tissue (igWAT), i.e. 
increased development of brown-like adipocytes, which similar to classical brown 
adipocytes are specialized in energy combustion for thermogenesis. In line with that, 
expression of PPARγ, a major transcriptional regulator of adipogenesis, and of 
thermogenic markers was increased in in vitro differentiated adipocytes from igWAT 
of CerS4 deficient mice. The results indicate that CerS4 might be an attenuator of 
browning in WAT. Increased browning independent of hair loss could contribute to 
the beneficial effects of CerS4 deficiency in the development of diet-induced obesity 
in mice. 
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8 List of abbreviations
AC Acid ceramidase 
ALT Alanine transaminase 
ANOVA Analysis of variance 
aP2 Adipocyte Protein 2 
AR Adrenoceptor 
aSMase Acid Sphingomyelinase 
AST Aspartate transaminase 
ATP Adenosine triphosphate 
AUC Area under the curve 
BAC Bacterial artificial chromosome 
BAT Brown adipose tissue 
BCA Bicinchoninic acid 
BMDM Bone marrow derived 
macrophages 
bp base pairs 
BSA Bovine serum albumin 
C1P Ceramide-1-phosphate 
cAMP cyclic adenosine 
monophosphate 
cDNA complementary DNA 
CDP Cytidine diphosphate 
Cer Ceramide 
CERK Ceramide kinase 
CerS Ceramide synthase 
CERT Ceramide transfer protein 
cGMP cyclic guanosine 
monophosphate 
CIDEA Cell death-inducing DFFA-like 
effector A 
CoA Coenzyme A 
CPE Ceramide phosphoethanolamine 
CPK Creatine phosphokinase 
Cre Causes recombination 
CT Carboxy terminus 
CTP Cytidine triphosphate 
DAG Diacylglycerol 
dCTP Deoxycytidine triphosphate 
DGAT Diacylglycerol acyltransferase 
DMEM Dulbecco's modified Eagle 
medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
e.g.  exempli gratia 
ECL Enhanced chemiluminiscence 
EDTA Ethylenediaminetetraacetic acid 
eGFP enhanced green fluorescent 
protein 
ELOVL Elongation of very long chain 
fatty acids 
ER Endoplasmic reticulum 
ES cells Embryonic stem cells 
FCS Fetal calf serum 
FFA Free fatty acid 
Flp Flippase 
frt Flippase recognition target 
FXR Farnesoid X receptor 
GalNAc N-acetylgalactosamine 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
GCS Glucosylceramide synthase 
GFP Green fluorescent protein 
GluCer Glucosylceramide 
Gly-MCA Glycine-β-muricholic acid 
GPI Glycosylphosphatidylinositol 
GSL Glycosphingolipid 
gt Gene trap 
GTT Glucose tolerance test 
gWAT gonadal WAT 
H&E Hematoxylin and eosin staining 
HEK Human embryonic kidney cells 
HexCer Hexosylceramide 
HF Hair follicle 
HFD High fat diet 
His Histidine 
HNSCC Human head and neck 
squamous cell carcinomas 
Hox Homeobox 
HRP Horse radish peroxidase 
hSMSr human SMSr 
i.e. id est 
iBAT interscapular BAT 
IR Insulin receptor 
IRES Internal ribosomal entry site 
ITT Insulin tolerance test 
igWAT inguinal WAT 
kbp kilo base pairs 
kDa kilo Dalton 
KO Knock out 
LacZ β-galactosidase 
Lag Longevity assurance gene 
LCB Long chain base 
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LC-MS Liquid chromatography-MS 
LDL Low density lipoprotein 
LFD Low fat diet 
loxP locus of crossing over in P1 
LPS Lipopolysaccharide 
MEF Mouse embryonic fibroblasts 
min Minute 
mRNA messenger RNA 
MS Mass spectrometry 
mSMSr mouse SMSr 
Myf5 Myogenic factor 5 
NBD Nitrobenz-2-Oxa-1,3-Diazol-4-yl 
NE Norepinephrine 
NLS Nuclear localisation signal 
nSMase Neutral Sphingomyelinase 
NT Amino terminus 
ORM Orosomucoid 
P Postnatal day 
P/S Penicillin/Streptomycin 
PARP Poly ADP ribose polymerase 
PBS Phosphate buffered saline 
PC Phosphatidylcholine 
PCR Polymerase chain reaction 
PE Phosphatidylethanolamine 
PEMT Phosphatidylethanolamine N-
methyltransferase 
PGC1α PPARγ coactivator 1α 
PGK Phosphoglycerate kinase 
PH Pleckstrin homology 
PI Phosphatidylinositol 
PIC Proteinase inhibitor cocktail 
PKA Protein kinase A (B, C, D, G) 
PMSF Phenylmethanesulfonylfluoride 
PP2A Protein phosphatase 2 A 
PPAR peroxisome proliferator- 
activated receptor 
PRDM16 PR domain containing 16 
PS Phosphatidylserine 
Q-TOF Quantitative Time of Flight-MS 
RNA Ribonucleic acid 
  
  
  
  
  
  
  
  
RT Room temperature 
RT-PCR Real Time-PCR 
rWAT renal WAT 
S1P Sphingosin-1-phosphate 
SAM Sterile alpha motif 
Samd8 SAM domain-containing  
protein 8 
SAP Sphingolipid activator protein 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
Ser Serine 
siRNA small interfering RNA 
SK1/2 Sphingosine kinase 1/2 
SM Sphingomyelin 
SMase Sphingomyelinase 
SMS Sphingomyelin synthase 
SMSr Sphingomyelin synthase related 
protein 
Sph Sphingosine 
SPT Serine palmitoyltransferase 
SREBP Sterol-responsive element 
binding protein 
SRM  Selective reaction monitoring 
SV40 Simian Virus 40 
SVF Stromal vascular fraction 
sWAT subcutaneous WAT 
T3 Triiodothyronine 
TAG Triacylglycerol 
TBST Tris-buffered saline-Tween 
Thr Threonine 
TLC Thin layer chromatography 
TNFα Tumor necrosis factor α 
TORC2 Target of rapamycin kinase 
complex 2 
Tyr Tyrosine 
UCP1 Uncoupling protein 1 
UV Ultraviolet light 
WAT White adipose tissue 
WT Wild type 
Ypk2 Yeast protein kinase 2 
  
  
  
  
  
  
  
